Pyrrolobenzodiazepine derivative and ligand-linker conjugate thereof
Patent Information
- Application Number
- IN202247043228
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-12-31
- Filing Date
- 2022-07-28
- Publication Date
- 2026-10-28
- Estimated Expiration
- 2040-12-30
AI Technical Summary
Conventional pyrrolobenzodiazepine compounds face challenges in scalability due to low yield during synthesis, stability issues in the bloodstream after administration, and toxicity, limiting their clinical application despite their anticancer efficacy.
Development of a novel pyrrolobenzodiazepine derivative with specific chemical modifications and a ligand-linker conjugate that enhances stability and reduces toxicity, allowing for targeted delivery and increased efficacy in treating proliferative diseases like cancer.
The modified pyrrolobenzodiazepine derivative exhibits improved stability and reduced toxicity, enabling effective treatment of proliferative diseases with minimized side effects and enhanced drug delivery to cancer cells.
Abstract
Description
[Technical Field]The present invention relates to apyrrolobenzodiazepine derivative and a ligand-linkerconjugate compound of the same, pharmaceuticallyacceptable salts thereof, or solvates thereof. Thepresent invention also relates to a pharmaceuticalcomposition for prevention or treatment of proliferativedisease comprising the same.[Background Art]DNA refers to a high molecular compound with adouble helix structure in which two long strands, whichare polymers of nucleotides, wind around each other, andis formed through the polymerization of nucleotidesdivided into unique nucleobases of cytosine (C), guanine(G), adenine (A), and thymine (T). Such DNA may formchromatin, and the condensed structure of chromatinlimits the cell's mechanical access to DNA, and thisinhibits essential processes such as transcription,replication, repair and recombination.Pyrrolobenzodiazepines (PBDs) are natural substanceshaving antibiotic or antitumor properties, and refers tosequence-selective DNA alkylating compounds.Pyrrolobenzodiazepines exhibit biological activity bybinding in the minor groove of DNA through selectivity tothe 5'-purine-guanine-purine sequence and formingcovalent bonds with exocyclic amino groups of guaninebases 3 and 4. It is known that this makespyrrolobenzodiazepines stronger than systemicchemotherapeutic drugs and block the division of cancercells without distorting the DNA helix, therebyexhibiting anticancer effects without the generalphenomenon of drug resistance. The first PBD, anthramycin,was discovered in 1965. Since then, a number of naturallyoccurring PBDs have been reported, and over 10 synthesisroutes have been developed for a variety of analogues (HuY, et al., Benzodiazepine biosynthesis in Streptomycesrefuineus. Chem Biol. 2007 Jun;14(6):691-701).Other agents belonging to the discoveredpyrrolobenzodiazepine antibiotic group include abbeymycin,chicamycin, DC-81, mazethramycin, neothramycin A,porothramycin, prothracarcin and the like, and analogs ofpyrrolobenzodiazepines have been steadily studied.Pyrrolobenzodiazepines have the following generalformula.The pyrrolobenzodiazepines differ from one anotherin the number, type and position of substituents on thearomatic ring A and the pyrrolo C ring, and the degree ofsaturation of the C ring. An imine (N=C), carbinolamine(NH-CH(OH)) or carbinolamine methyl ether (NH-CH(OMe))exists at the N10-C11 position, the electrophilic centerresponsible for the alkylation of DNA, of the B ring.It has been known through recent studies thatpyrrolobenzodiazepines may be linked with other monomersthrough the C8 position to form dimers and the dimers maybe used as antibody-drug conjugates (ADCs). For example,there are SG3249 (tesirine) with SG3199 as a payload andSGD-1910 (talirine) with dimer SGD-1882 having endo-exounsaturation as a payload. Recently, ADCT-301, ADCT-402,ADCT-601 and ADCT-602 including tesirine have also beenin clinical trials.In this regard, there are a registered patent for apyrrolobenzodiazepine (Medimmune, KR 10-1960130), aregistered patent for a pyrrolobenzodiazepine and aconjugate of the same (Medimmune, KR 10-1891859), aregistered patent for a pyrrolobenzodiazepine (Spirogen,KR 10-1059183), a registered patent for apyrrolobenzodiazepine-anti-CD22-antibody conjugate (ADCTherapeutics SA, KR 10-1995620), a published patent for apyrrolobenzodiazepine-antibody conjugate (ADCTherapeutics SA, KR 10-2019-0100413), a published patentfor a pyrrolobenzodiazepine and a conjugate of the same(Mersana Therapeutics, US 2017-0369453), a publishedpatent for pyrrolobenzodiazepine prodrug (ENDOCYTE, WO2016-148674), and the like.Meanwhile, there are a paper, which discloses thatmonomeric pyrrolobenzodiazepine compounds used as aprecursor are stable and exhibit little cytotoxicity(Masterson, Luke A. et al., Synthesis and biologicalevaluation of novel pyrrolo[2,1-c][1,4]benzodiazepineprodrugs for use in antibody directed enzyme prodrugtherapy, Bioorganic & Medicinal Chemistry Letters, 16(2),252-256 (2006)), a technology related to an antibody-drugconjugate having a form linked to the form of apyrrolobenzodiazepine dimer as a carbamate (Zhang, Dongluet al, Linker Immolation Determines Cell Killing Activityof Disulfide-Linked Pyrrolobenzodiazepine Antibody-DrugConjugates, ACS Medicinal Chemistry Letters, 7(11), 988-993 (2016)), and the like.However, in the case of the above technologies,there are limitations in that it is not easy to scale upthe compounds because of a low yield at the time ofpyrrolobenzodiazepine synthesis, it is difficult tosatisfactorily solve the problem of poor stability inblood after administration, and the compounds cannot beapplied clinically because of the toxicity even if thedrug efficacy is excellent.DNA minor groove binders are family compounds oflexitropsins, the first discovered compounds aredistamycin A and netropsin, and distamycin A wasidentified as an antibiotic isolated from a culture ofStrptomyces distallicus in 1962. In addition, there areanthracycline-based anticancer drugs such as actinomycinA and daunorubicin, and these anticancer drugs have amechanism of inhibiting the synthesis of DNA and RNA byintervening in the G-C base pairing site or by binding tothe DNA minor groove to form hydrogen bonds with the basepairs.Studies on the anticancer effect of these agents arebeing conducted, but these agents have the side effect incommon that they are highly toxic to the heart and causelife-threatening heart damage.Therefore, there is a demand for the development ofmore selective and effective drugs with greatly few sideeffects.Accordingly, the inventors of the present inventionhave prepared new compounds by conjugating varioussubstituents to the conventional pyrrolobenzodiazepineparent nucleus structures, and confirmed that thesynthesized compounds have significantly reduced sideeffects such as toxicity while exhibiting an equivalentlevel of efficacy compared to conventionally knownpyrrolobenzodiazepine compounds, thereby completing thepresent invention.[Summary of Invention][Technical Problem]An object of the present invention is to provide anovel pyrrolobenzodiazepine derivative compound withsignificantly reduced side effects such as toxicity whileexhibiting an equivalent level of efficacy compared to aconventional pyrrolobenzodiazepine compound, and aconjugate of the same with a ligand.Another object of the present invention is toprovide a pharmaceutical composition for prevention ortreatment of proliferative disease comprising thecompound or a conjugate of the compound with a ligand asan active ingredient.Another object of the present invention is toprovide a method for preventing or treating proliferativedisease by administering the compound or a conjugate ofthe compound with a ligand to an individual.[Solution to Problem]The present invention relates to apyrrolobenzodiazepine derivative, a pharmaceuticallyacceptable salt or solvate thereof.In the present invention, the pyrrolobenzodiazepinederivative is represented by the following ChemicalFormula I, and a pharmaceutically acceptable salt orsolvate thereof is provided:P-(B)a-(B')b-D (I)where,P is represented by the following Chemical FormulaII, where P is bonded or not bonded to Linker I;(II)where,a dotted line indicates arbitrary presence of adouble bond between C1 and C2 or C2 and C3 and arbitrarypresence of a double bond between N10 and C11;Q1 is selected from the group consisting of H, OH, O,CH2, CN, Rm, ORm, CH-Rm', C(Rm')2, O-SO2-Rm, CO2Rm, CORm, haloand dihalo,where Rm' is selected from the group consisting of Rm,CO2Rm, CORm, CHO, CO2H, and halo,where Rm is selected from the group consisting ofsubstituted or unsubstituted C1-12 alkyl, substituted orunsubstituted C2-12 alkenyl, substituted or unsubstitutedC2-12 alkynyl, substituted or unsubstituted C5-20 aryl,substituted or unsubstituted C5-20 heteroaryl, substitutedor unsubstituted C3-6 cycloalkyl, substituted orunsubstituted 3- to 7-membered heterocyclyl, substitutedor unsubstituted 3- to 7-membered heterocycloalkyl, andsubstituted or unsubstituted 5- to 7-membered heteroaryl,wherein, when substituted, respective hydrogen atomsof C1-12 alkyl, C1-12 alkoxy
[11] , C2-12 alkenyl, C2-12 alkynyl,C5-20 aryl, C5-20 heteroaryl, C3-6 cycloalkyl, 3- to 7-membered heterocyclyl, 3- to 7-membered heterocycloalkyl,or 5- to 7-membered heteroaryl are each independentlysubstituted with any one or more selected from the groupconsisting of C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C5-20aryl, C5-20 heteroaryl, C3-6 cycloalkyl, 3- to 7-memberedheterocyclyl, 3- to 7-membered heterocycloalkyl, and 5-to 7-membered heteroaryl;Q2, Q3, Q5, and Q7 are each independently selectedfrom the group consisting of -H, -Rm, -OH, -ORm, -SH, -SRm,-NH2, -NHRm, -NRmRm', -NO2, and halo,where Rm and Rm' are as defined above;Q4 is selected from the group consisting of -H, -Rm,-OH, -ORm, -SH, -SRm, -NH2, -NHRm, -NRmRm', -NO2, halo,substituted or unsubstituted C1-6 alkyl, substituted orunsubstituted C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl,substituted or unsubstituted C3-6 cycloalkyl, substitutedor unsubstituted 3- to 7-membered heterocycloalkyl,substituted or unsubstituted C5-12 aryl, substituted orunsubstituted 5- to 7-membered heteroaryl, -CN, -NCO, -ORn,-OC(=O)Rn, -OC(=O)NRnRn', -OS(=O)Rn, -OS(=O)2Rn, -SRn, -S(=O)Rn, -S(=O)2Rn, -S(=O)NRnRn', -S(=O)2NRnRn', -OS(=O)NRnRn',-OS(=O)2NRnRn', -NRnRn', -NRnC(=O)Ro, -NRnC(=O)ORo, -NRnC(=O)NRoRo', -NRnS(=O)Ro, -NRnS(=O)2Ro, -NRnS(=O)NRoRo', -NRnS(=O)2NRoRo', -C(=O)Rn, -C(=O)ORn and -C(=O)NRnRn',wherein, when substituted, one or more hydrogenatoms may be each independently
[12] substituted with C1-6alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-6cycloalkyl, 3- to 7-membered heterocycloalkyl, C5-10 aryl,5- to 7-membered heteroaryl, -ORp, -OC(=O)Rp, -OC(=O)NRpRp',-OS(=O)Rp, -OS(=O)2Rp, -SRp, -S(=O)Rp, -S(=O)2Rp, -S(=O)NRpRp', -S(=O)2NRpRp', -OS(=O)NRpRp', -OS(=O)2NRpRp', -NRpRp', -NRpC(=O)Rq, -NRpC(=O)ORq, -NRpC(=O)NRqRq', -NRpS(=O)Rq, -NRpS(=O)2Rq, -NRpS(=O)NRqRq', -NRpS(=O)2NRqRq', -C(=O)Rp, -C(=O)ORp or -C(=O)NRpRp,where, Rn, Rn', Ro, Ro', Rp, Rp', Rq and Rq' are eachindependently selected from the group consisting ofhydrogen, C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, C3-13cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-10 aryl,and 5- to 7-membered heteroaryl;X is a moiety bonded to Linker I, and is absent whennot bonded to Linker I,Y is selected from the group consisting of -O-, -S-,and -NH-; andQ6 is absent, or is a substituted or unsubstitutedand saturated or unsaturated C3-12 hydrocarbon chain,B and B' are each independently a bond, -O-, -NH-, -S-, -C(=O)-, -S(=O)-, -O-(CH2)n-, -(CH2)n-, -(CH2)n(C=O)-,-(CH2)n(C=O)NH-, -C6-10 arylene-, -O-(-C6-10 arylene)-, -(CH2)n-C6-10 arylene-, 5- to 20-membered heteroarylenecontaining a heteroatom independently selected from N, Oor S, -O-(5- to 20-membered heteroarylene containing aheteroatom independently selected from N, O or S)- or -(CH2CH2O)n-,where n is each independently an integer of 1 ormore and 10 or less, anda and b are each independently an integer of 0 or 1,andD is represented by the following Chemical FormulaIII,(III)where,means a site bonded to P, B or B',A1 and A2 are each independently a bond, -NH-, -O-,-C(=O)-, -C(=O)NH-, -NHC(=O)-, C6-10 arylene or 6- to 10-membered heteroarylene containing a heteroatomindependently selected from N, O or S;A-1 and A-2 are each independently selected from 5-to 20-membered heterocycloalkylene, 5- to 20-memberedheterocycloalkenylene, or 5- to 20-membered heteroarylene,in which one or more ring atoms are heteroatomsindependently selected from N, O or S,Z1, Z2, Z3, Z1', Z2' and Z3' are each independently C,N or S,R1 and R1' are each independently C1-10 heteroalkyl inwhich one or more atoms include heteroatoms independentlyselected from N, O or S, C1-10 alkyl, -(CH2)mOH, -(CH2)mNH2,-(CH2)mNHCH3, hydrogen, halo, or -C(=O)OH,m is an integer from 0 to 10,B1 and B2 are each independently a bond, -NH-, -O-,-C(=O)-, or -S-,a1 and a2 are each independently an integer from 0to 2; wherein a1 + a2 is an integer of 2 or less,E1 is a bond, -NH-, -C(=O)-, -C(=O)O-, -O-, -S-, -OCH2-, C1-20 alkylene, or -((CH2)p(CH2E11))q-, and e1 is aninteger from 0 to 10;E2 is a bond, C1-20 alkylene, or -((CH2)p(CH2E11))q-,and e2 is an integer from 0 to 20,where E11 is a bond, O, or S, p is an integer from 0to 10, and q is an integer from 1 to 20; andF1 is hydrogen, -OH, -OCH3, -SH, -SCH3, ,, or ,where,F11, F12, F13, F14, F15, F16, F17, and F18 are eachindependently C, N, O or S,a dotted line means a double bond or a single bond,F21, F22 and F22' are each independently selected from-H, -NH2, -CH3, -(CH2)rCH3, -(CH2)rOH, -(CH2)rNH2, -F33(CH2)rCH3, -F33(CH2)rOH, -F33(CH2)rNH2, or Linker II, whereF33 is selected from -O-, -S-, -CH2-, -C(=O)-, -NH-, -C(NH2)- or -C(=NH)-, andF21' is selected from =CH2, =NH, =F33'(CH2)rCH3,=F33'(CH2)rOH, or =F33'(CH2)rNH2, where F33' is selected from=N-, =CH-, =C(OH)- or =C(NH2)- and r is an integer from 0to 10;wherein, Linker I and Linker II are represented bythe following Chemical Formula IV, and are eachindependently selected,(IV)where,G is a glucuronic acid) moiety or ;where Rc is hydrogen or a carboxyl protecting group,each Rd is independently hydrogen or a hydroxylprotecting group;Ra and Rb are each independently hydrogen, C1-8 alkylor C3-8 cycloalkyl;W is -C(=O)-, -C(=O)NR'-, -C(=O)O-, -S(=O)2NR'-, -P(=O)R"NR'-, -S(=O)NR'- or -P(=O)2NR'-, and C, S or P isdirectly bonded to a phenyl ring,where R' and R" are each independently hydrogen, C1-8alkyl, C3-8-membered cycloalkyl, C1-8 alkoxy, C1-8 alkylthio,mono- or di- C1-8 alkylamino, 3- to 20-membered heteroarylor a compound of C6-20-membered aryl;T is independently C1-8 alkyl, halogen, cyano ornitro;s is an integer from 0 to 3;L is one or more units selected from the groupconsisting of a connection unit and a branching unit, ora combination of these units,wherein the connection unit connects W and Rz, W anda branching unit, or a branching unit and anotherbranching unit, wherein the branching unit connects aconnection unit and W or a connection unit and anotherconnection unit,the connection unit is ,, , , -(CH2CH2V)t-, -(CH2)t(V(CH2)u)v-, or a combination thereof;where L1 is a single bond or C2-30 alkenyl, R11 is Hor C1-10 alkyl, and L2 is C2-30 alkenyl;where t is an integer from 0 to 10, u is an integerfrom 0 to 12, v is an integer from 1 to 20, V is a singlebond, -O-, or -S-,the branching unit is selected from the groupconsisting of C2-100 alkenyl, a hydrophilic amino acid, -C(=O)-, -C(=O)NRv-, -C(=O)O-, -(CH2)n1-NHC(=O)-(CH2)n2-, -(CH2)n3-C(=O)NH-(CH2)n4-, -(CH2)n1-NHC(=O)-(CH2)n2-C(=O)-, -(CH2)n3-C(=O)NH-(CH2)n4-C(=O)-, -S(=O)2NRv-, -P(=O)RwNRv-, -S(=O)NRv-, and -P(=O)2NRv-,wherein, when the branching unit is C2-100 alkenyl, acarbon atom of the alkenyl may be substituted with one ormore heteroatoms selected from the group consisting of N,O and S, and the alkenyl may be further substituted withone or more C1-20 alkyl,where Rv and Rw are each independently H, C1-8 alkyl,C3-8 cycloalkyl, C1-8 alkoxy, C1-8 alkylthio, mono- or di-C1-8 alkylamino, C3-20 heteroaryl or C5-20 aryl,n1, n2, n3 and n4 are each independently an integerfrom 0 to 10, andRz is -O-NH2, -NH2, N3, substituted or unsubstitutedC1-12 alkyl, C1-12 alkynyl, C1-3 alkoxy, substituted orunsubstituted 3- to 20-membered heteroaryl, 3- to 20-membered heterocyclyl, substituted or unsubstituted C5-20aryl, or ,where Rz' is N or C,wherein, when substituted, one or more hydrogenatoms are each independently substituted with OH, =O,halo, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, oxy, carboxy,C1-6 alkoxycarbonyl, C1-6 alkylcarbonyl, formyl, C3-8 aryl,C5-12 aryloxy, C5-12 arylcarbonyl or C3-6 heteroaryl.In an aspect of the present invention, the linkermay further contain a binding unit formed by a 1,3-dipolar cycloaddition reaction, a hetero-Diels-Alderreaction, a nucleophilic substitution reaction, a nonaldol-type carbonyl reaction, an addition to a carboncarbonmultiple bond, an oxidation reaction or a clickreaction.In an aspect of the present invention, the bindingunit is formed by a reaction between acetylene and anazide, or between an aldehyde or ketone group and ahydrazine or alkoxyamine.In an aspect of the present invention, the linkermay further contain at least one or more isoprenyl unitshaving the structure of , where iis at least 2 or more.In an aspect of the present invention, at least oneisoprenyl unit is a substrate of an isoprenoidtransferase or a product of an isoprenoid transferase.In an aspect of the present invention, the isoprenylunit of the linker is covalently bound to an antibody bya thioether bond, and the thioether bond contains asulfur atom of cysteine of the antibody.In an aspect of the present invention, the antibodycontains an amino acid motif recognized by an isoprenoidtransferase, and the thioether bond contains a sulfuratom of cysteine of the amino acid motif.In an aspect of the present invention, the dottedline may indicate the presence of a double bond betweenC2 and C3.In an aspect of the present invention, Q1 may beselected from the group consisting of substituted orunsubstituted C1-6 alkyl, substituted or unsubstituted C2-6alkenyl, substituted or unsubstituted C5-7 aryl andsubstituted or unsubstituted C3-6 heteroaryl.In an aspect of the present invention, Q2, Q3 Q5, andQ7 may each independently be -H or -OH.In an aspect of the present invention, Q4 may bemethoxy, ethoxy or butoxy.In an aspect of the present invention, X may bebonded to the moiety of Linker I.In an aspect of the present invention, Y may be -O-.In an aspect of the present invention, Q6 may be asubstituted or unsubstituted and saturated or unsaturatedC3-8 hydrocarbon chain.In an aspect of the present invention, G may be,where Rc may be hydrogen or a carboxyl protectinggroup, and each Rd may be independently hydrogen or ahydroxyl protecting group.In a specific aspect of the present invention, Rcmay be hydrogen and each Rd may be hydrogen.In an aspect of the present invention, T mayindependently be C1-8 alkyl, halogen, cyano or nitro.In an aspect of the present invention, s may be 0.In an aspect of the present invention, W may be -C(=O)-, -C(=O)NR'- or -C(=O)O-.In an aspect of the present invention, W may be -C(=O)NR'-, where C(=O) may be bonded to a phenyl ring andNR' may be bonded to L.In a specific aspect of the present invention, G maybe , and W may be -C(O)NR'-, where C(O)may be bonded to a phenyl ring, NR' may be bonded to L,and Rc and Rd may be hydrogen.In an aspect of the present invention, the branchingunit may be selected from the group consisting of C2-8alkenyl, a hydrophilic amino acid, -C(O)-, -C(O)NRv-, -C(O)O-, -(CH2)n1-NHC(=O)-(CH2)n2-, -(CH2)n3-C(O)NH-(CH2)n4-,-(CH2)n1-NHC(O)-(CH2)n2-C(O)-, and -(CH2)n3-C(O)NH-(CH2)n4-C(O)-,wherein, when the branching unit is C2-8 alkenyl, acarbon atom of the alkenyl may be substituted with one ormore heteroatoms selected from the group consisting of N,O and S, and the alkenyl may be further substituted withone or more C1-20 alkyl,where Rv may be H, C1-8 alkyl, C3-8 cycloalkyl, C1-8alkoxy, C1-8 alkylthio, mono- or di- C1-8 alkylamino, C3-20heteroaryl or C5-20 aryl, andn1, n2, n3 and n4 may each independently be aninteger from 0 to 5.In an aspect of the present invention, theconnection unit may be -(CH2)t(V(CH2)u)v-, where t may bean integer from 0 to 8, u may be an integer from 0 to 12,v may be an integer from 1 to 10, and V may be a singlebond or -O-.In an aspect of the present invention, theconnection unit may be -(CH2)t(V(CH2)u)v-, where t may bean integer of 2, u may be an integer of 2, v may be aninteger of 2, and V may be -O-.In an aspect of the present invention, theconnection unit may include ,, or ,where L1 may be a single bond or C2-8 alkenyl, R11 may be Hor C1-6 alkyl, and L2 may be C2-8 alkenyl.In an aspect of the present invention, Rz may be -ONH2,-NH2, N3, -OCH3, -OCH2CH3, -O(CH2)2CH3, or .In an aspect of the present invention, at least oneor more of B or B' may be -C(=O)-.In an aspect of the present invention, A1 and A2 mayeach independently be -C(=O)- or -NH-.In an aspect of the present invention, at least oneor more of Z1, Z2, Z3, Z1', Z2', or Z3' may be N.In an aspect of the present invention, A-1 and A-2may be selected from ,, , or, where a dotted line may mean adouble bond or a single bond, Za may be Z1 or Z1', Zb maybe Z2 or Z2', Zc may be Z3 or Z3',Z1, Z2, Z3, Z1', Z2' and Z3' may be as defined above,andR1 or R1' may be connected to Za.In a specific aspect of the present invention, A-1and A-2 may be , or, where a dotted line may mean adouble bond or a single bond, Za may be Z1 or Z1', Zb maybe Z2 or Z2', Zc may be Z3 or Z3',at least one or more of Z1, Z2, Z3, Z1', Z2' or Z3'may be N or S, andR1 or R1' may be connected to Za.In an aspect of the present invention, a1 and a2 maybe an integer of 1.In an aspect of the present invention, E1 may be abond, -NH-, or -C(=O)- and e1 may be an integer from 1 to5.In an aspect of the present invention, E2 may be abond, C1-5 alkylene, or -((CH2)p(CH2E11))q-,when E2 is -((CH2)p(CH2E11))q-, E11 may be O, p may bean integer from 1 to 3,q may be an integer from 1 to 15, and e2 may be aninteger from 1 to 5.In an aspect of the present invention, R1 and R1'may each independently be hydrogen, C1-5 alkyl, (CH2)mOH or(CH2)mNH2, where m may be an integer from 1 to 7.In an aspect of the present invention, F1 may be -OH,-OCH3, -SH, -SCH3, or ,where F11 and F12 may each independently be C or N,F21, F22 and F22' may each independently be selectedfrom -H, -(CH2)rCH3, -(CH2)rOH, -(CH2)rNH2, -F33(CH2)rCH3, -F33(CH2)rOH, -F33(CH2)rNH2 or Linker II, where F33 may beselected from --C(=O)-, -NH-, or -C(=NH)-,F21' may be selected from =CH2, =NH, =F33'(CH2)rCH3,=F33'(CH2)rOH, =F33'(CH2)rNH2 or Linker II, where F33' may beselected from =N-, =CH-, =C(OH)- or =C(NH2)-, andat least one or more of F21, F22 or F22' may be -CH3.In an aspect of the present invention, thepyrrolobenzodiazepine derivative
[13] may further comprisesthe following General Formula V:(V)where,moieties are each independently bonded to afirst linker or hydrogen, wherein the first linker isLinker I or Linker II; andSL means a second linker, wherein the second linkeris represented by the following Formula VI,L'-Rzz' (VI)where L' and Rzz' are the same as L and Rz inChemical Formula (IV), respectively.In a specific aspect of the present invention, thefirst linker may contain at least one or more branchingunits, wherein the branching unit may be selected fromthe group consisting of -C(O)-, -C(O)NRv-, -C(O)O-, -(CH2)n1-NHC(O)-(CH2)n2-, -(CH2)n3-C(O)NH-(CH2)n4-, -(CH2)n1-NHC(O)-(CH2)n2-C(O)-, -(CH2)n3-C(O)NH-(CH2)n4-C(O)-, -S(O)2NRv-, -P(O)RwNRv-, -S(O)NRv-, and -PO2NRv-,Rv and Rw may each independently be H, C1-8 alkyl, C3-8 cycloalkyl, C1-8 alkoxy, C1-8 alkylthio, mono- or di- C1-8alkylamino, C3-20 heteroaryl or C5-20 aryl,n1, n2, n3 and n4 may each independently be aninteger from 0 to 5.In an aspect of the present invention, L' mayinclude one or more branching units and connection units,wherein the branching unit may be selected from thegroup consisting of C2-8 alkenyl, a hydrophilic amino acid,-C(O)-, and -C(O)O-, andthe connection unit may be -(CH2)t(V(CH2)u)v-,where t may be an integer from 0 to 5, u may be aninteger of 2, v may be an integer from 1 to 10, and V maybe -O-; andRzz' may be -O-NH2, -NH2, N3, -OCH3, or -OCH2CH3.In a specific aspect of the present invention, thepyrrolobenzodiazepine derivative represented by ChemicalFormula I may be selected from the group consisting ofand.In an aspect of the present invention, thepyrrolobenzodiazepine derivative represented by ChemicalFormula I may be selected from the group consisting of,,,and.In an aspect of the present invention, thepyrrolobenzodiazepine derivative further comprising alinker including a tris structure may beIn the present invention
[14] , thepyrrolobenzodiazepine derivative is represented by thefollowing Chemical Formula VII, and a pharmaceuticallyacceptable salt or solvate thereof is provided:P'-B'-D' (VII)where,P' is the same as P described above;B' is Ba'-Bb'-Bc',where Ba' is -O-, -NH-, -S-, -C(=O)-, -S(=O)-, -(CH2)n'(C=O)-, -(CH2)n'-, C6-10 arylene, 5 to 20-memberedheteroarylene containing a heteroatom independentlyselected from N, O or S, or -((CH2)n'B1)m'B2-, where B1 andB2 are each CH2, NH, O, or S,Bb' is a bond, C5-20 arylene, C5-20 cycloalkylene, or5- to 20-membered heterocycloalkylene, 5- to 20-memberedheterocycloalkenylene, or 5- to 20-membered heteroarylene,in which one or more ring atoms are heteroatomsindependently selected from N, O or S, andBc' is a bond, -O-, -NH-, -S-, -C(=O)-, -S(=O)-, -CH2(C=O)-, -(CH2)n'- or -(CH2CH2O)n'-,where n' and m' are each independently an integerfrom 1 to 10, andD' is the same as D described above.In an aspect of the present invention, Ba' may be abond, -(CH2)n'- or -(CH2)n'B2-, where B2 is O and n' may bean integer from 1 to 10.In an aspect of the present invention, Bb' may be abond, , ,, or ,where the dotted line may mean a double bond or asingle bond, andB1', B2' and B3' may each independently be C, N, or S.In an aspect of the present invention, Bc' may be abond, -C(=O)-, -NH-, or -(CH2CH2O)n-, where n may be aninteger from 1 to 10.In an aspect of the present invention, D' may be thesame as D, and a1 + a2 may be an integer from 1 to 10except 2.In a specific aspect of the present invention,the pyrrolobenzodiazepine derivative represented byChemical Formula VII may be selected from the groupconsisting ofand.The present invention also provides apyrrolobenzodiazepine derivative-ligand conjugatecomprising the pyrrolobenzodiazepine derivative describedabove, or a pharmaceutically acceptable salt or solvateof the derivative-ligand conjugate.In an aspect of the present invention, the ligandmay be an antibody.In a specific aspect of the present invention, theantibody may have one or more amino acid motifs that maybe recognized by an isoprenoid transferase.In a specific aspect of the present invention, theisoprenoid transferase may be FTase (farnesyl proteintransferase) or GGTase (geranylgeranyl transferase).In a specific aspect of the present invention, theamino acid motif may be CYYX, XXCC, XCXC or CXX, where Cmay be cysteine, Y may be an aliphatic amino acid, and Xmay be an amino acid that determines substratespecificity of an isoprenoid transferase.Specifically, X in each occurrence independentlyrepresents glutamine, glutamate, serine, cysteine,methionine, alanine, or leucine; and the thioether bondcontains a sulfur atom of cysteine of the amino acidmotif.In a specific aspect of the present invention, theamino acid motif may be CYYX, and Y in each occurrencemay independently be alanine, isoleucine, leucine,methionine or valine.In an aspect of the present invention, the proteinmay be an antibody, and the antibody may include an aminoacid sequence of GGGGGGGCVIM.In an embodiment of the invention, the proteinhaving the amino acid motif may be selected from thegroup consisting of A-HC-(G)zCVIM, A-HC-(G)zCVLL, A-LC-(G)zCVIM and A-LC-(G)zCVLL, where A may represent anantibody, HC may represent a heavy chain, LC mayrepresent a light chain, G may represent a glycine unit,and z may be an integer from 0 to 20.Isoprenoid transferases can recognize substrates aswell as isosubstrates. An isosubstrate refers to asubstrate analog having modifications to the substrate.Isoprenoid transferases alkylate specific amino acidmotifs (for example, CAAX motifs) at the C-terminus ofproteins (see: Benjamin P. Duckworth et al, ChemBioChem2007, 8,98; Uyen T. T. Nguyen et al, ChemBioChem 2007, 8,408; Guillermo R. Labadie et al, J. Org. Chem. 2007,72(24), 9291; James W. Wollack et al, ChemBioChem 2009,10, 2934). Functionalized proteins may be produced usingisoprenoid transferases and isosubstrates via alkylationat the C-terminal cysteine(s).For example, the cysteine residue of the C-terminalCAAX motif may be reacted with an isosubstrate using anisoprenoid transferase. In a certain occurrence, AAX maythen be removed by a protease. The obtained cysteine maythen be methylated at the carboxy terminus by an enzyme(see: Iran M. Bell, J. Med. Chem. 2004, 47(8), 1869).Proteins of the present invention may be prepared byany molecule or cell biology technique well known in theart. For example, transient transfection may be used.The genetic sequence encoding a certain amino acid motifrecognizable by an isoprenoid transferase may be insertedinto a known plasmid vector using standard PCR techniquesso as to express a protein (fragment or analog thereof)having the certain amino acid motif at its C-terminus. Inthis way, a protein having one or more amino acid motifsrecognizable by isoprenoid transferases may be expressed.In an aspect of the present invention, when theprotein is a monoclonal antibody, one or more lightchains of a monoclonal antibody, one or more heavy chainsof a monoclonal antibody, or both may include an aminoacid moiety having an amino acid motif recognizable by anisoprenoid transferase, and those skilled in the art canreadily select a protein (for example, a target cell of asubject) that selectively binds a target of interest.In an aspect of the present invention, a fragment ofan antibody or antigen that specifically binds to atarget of interest may be included.The present invention also provides a pharmaceuticalcomposition for prevention or treatment of proliferativedisease comprising the pyrrolobenzodiazepine derivativeligandconjugate described above or a pharmaceuticallyacceptable salt or solvate thereof.In an aspect of the present invention, theproliferative disease may be one selected from the groupconsisting of neoplasia, tumor, cancer, leukemia,psoriasis, bone disease, fibroproliferative disorder, andatherosclerosis.In a specific aspect of the present invention, thecancer may be one selected from the group consisting oflung cancer, small cell lung cancer, gastrointestinalcancer, colorectal cancer, bowel cancer, breast cancer,ovarian cancer, prostate cancer, testicular cancer, livercancer, kidney cancer, bladder cancer, pancreatic cancer,brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma,and melanoma.In the present invention, the pharmaceuticalcomposition may comprise the pyrrolobenzodiazepinederivative-ligand conjugate described above or apharmaceutically acceptable salt or solvate thereof; andfurther a pharmaceutically acceptable excipient.The present invention also provides a pharmaceuticalcomposition for prevention or treatment of proliferativedisease comprising the pyrrolobenzodiazepine derivativeligandconjugate described above or a pharmaceuticallyacceptable salt or solvate thereof; one or moretherapeutic co-agents; and a pharmaceutically acceptableexcipient.The present invention also provides a method forpreventing or treating proliferative disease, whichcomprises administering the pyrrolobenzodiazepinederivative-ligand conjugate described above or apharmaceutically acceptable salt or solvate thereof to anindividual. Herein, the method for preventing or treatingproliferative disease may further comprise apharmaceutically acceptable excipient and / or one or moretherapeutic co-agents.The present invention also provides use of thepyrrolobenzodiazepine derivative-ligand conjugatedescribed above or a pharmaceutically acceptable salt orsolvate thereof in a pharmaceutical composition forprevention or treatment of proliferative disease. Herein,the composition may further comprise a pharmaceuticallyacceptable excipient and / or one or more therapeutic coagents.[Advantageous Effects of Invention]The present invention relates to apyrrolobenzodiazepine derivative compound, a conjugate ofthe same with a ligand, and the use of the same. Thepyrrolobenzodiazepine derivative compound is more stablein plasma, is stable even in circulation, and exhibitsexcellent efficacy.In particular, the conjugate of thepyrrolobenzodiazepine derivative compound with a ligandhas a great advantage in that it is possible to targetand specifically treat proliferative disease such ascancer, maximize drug efficacy, and minimize theexpression of side effects since the conjugate morestably reaches the target cell and effectively exertsdrug efficacy while toxicity is greatly reduced as alinker technology that allows drugs to be easily releasedwithin cancer cells and maximize drug efficacy isincorporated.[Brief Description of Drawings]FIG. 1 is a scheme illustrating a preparationexample of a pyrrolobenzodiazepine derivative.FIG. 2 is a scheme illustrating a synthesis exampleof ADC (antibody-drug conjugate) through apyrrolobenzodiazepine derivative.[Description of Embodiments]In the present invention, the pyrrolobenzodiazepinederivative is represented by the following ChemicalFormula I, and a pharmaceutically acceptable salt orsolvate thereof is provided. A pyrrolobenzodiazepinederivative-ligand conjugate comprising thepyrrolobenzodiazepine derivative, or a pharmaceuticallyacceptable salt or solvate of the derivative-ligandconjugate is also provided.[Embodiments]Hereinafter, embodiments of the present inventionwill be described in detail so that those of ordinaryskill in the art to which the present invention pertainscan easily carry out the present invention. Embodimentsof the present invention are provided in order to morecompletely explain the present invention to those ofordinary skill in the art. Embodiments of the presentinvention may be modified in various other forms, and thescope of the present invention is not limited to theembodiments described below.Unless defined otherwise in the present invention,scientific and technical terms used herein have themeanings commonly understood by those skilled in the art.Furthermore, unless the context specifically requiresotherwise, the singular includes the plural and theplural includes the singular.When it is said that a certain part "includes" acertain element throughout the specification of thepresent invention, this means that other elements are notexcluded but may be further included unless otherwisestated.[Definition]The following definitions apply herein:In the present invention, "conjugates" refers tocell binding agents that are covalently bound to one ormore molecules of a cytotoxic compound. Here, the "cellbinding agent" is a molecule having affinity for abiological target, and may be, for example, a ligand, aprotein, an antibody, specifically a monoclonal antibody,a protein or antibody fragment, a peptide, anoligonucleotide, or an oligosaccharide, and the bindingagent functions to direct the biologically activecompound to the biological target. In an aspect of thepresent invention, the conjugate may be designed totarget tumor cells via cell surface antigens. The antigenmay be a cell surface antigen that is overexpressed orexpressed in an abnormal cell type. Specifically, thetarget antigen may be expressed only on proliferativecells (for example, tumor cells). The target antigen mayusually be selected based on different expression betweenproliferative and normal tissues. In the presentinvention, the ligand is bound to a linker.In the present invention, an "antibody" is animmunoglobulin molecule capable of specifically bindingto a target, for example, a carbohydrate, apolynucleotide, a lipid, or a polypeptide via at leastone antigen recognition site located in the variableregion of the immunoglobulin molecule.In the present invention, an "antibody" encompassesintact polyclonal or monoclonal antibodies as well as anarbitrary antigen-binding moiety (for example, "antigenbindingfragment") of an intact antibody that retains theability to specifically bind to a given antigen or singlechain thereof, a fusion protein containing the antibody,and another arbitrary modified arrangement of animmunoglobulin molecule containing an antigen recognitionsite, for example, but not limited to, Fab; Fab'; F(ab')2Fd fragment; Fv fragment; a single domain antibody (dAb)fragments; an isolated complementarity determining region(CDR); single chain (scFv) and single domain antibodies(for example, shark and camelid antibodies), maxibodies,minibodies, intrabodies, diabodies, triabodies,tetrabodies, v-NARs and bis-scFvs (see, for example,Hollinger and Hudson, 2005, Nature Biotechnology 23(9):1126-1136). The antibody includes antibodies of anarbitrary class, such as IgG, IgA or IgM (or subclassesthereof), and the antibody is not required to be of anarbitrary particular class. Depending on the amino acidsequence of the constant region of the heavy chain of anantibody, immunoglobulins may be assigned to differentclasses. There are five main classes of immunoglobulins:IgA, IgD, IgE, IgG and IgM, and some of these may befurther divided into subclasses (isotypes), for example,IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2. The heavy chain(HC) constant domains corresponding to the differentclasses of immunoglobulins are called alpha, delta,epsilon, gamma and mu, respectively. The subunitstructures and three-dimensional configurations ofdifferent classes of immunoglobulins are well known. Theantibody of the present invention may be prepared usingtechniques well known in the art, for example,recombinant techniques, phage display techniques,synthetic techniques or combinations of these techniquesor other techniques readily known in the art.In the present invention, an "isolated antibody"refers to an antibody that is substantially free of otherantibodies with different antigenic specificities, andmay be substantially free of other cell substances and / orchemical substances.In the present invention, a "biological target"refers to an antigen located on the surface of a tumor,cancer cell, or extracellular matrix.In the present invention, being "unsubstituted orsubstituted" means a parent group that may beunsubstituted or substituted, being "substituted" means aparent group having one or more substituents, and asubstituent refers to a chemical moiety covalently boundto a parent group or fused to a parent group.In the present invention, "halo" refers to fluorine,chlorine, bromine, iodine, and the like.In the present invention, "alkyl" refers to amonovalent moiety obtained by removing a hydrogen atomfrom a carbon atom of an aliphatic or alicyclic saturatedor unsaturated (unsaturated, completely unsaturated)hydrocarbon compound. Examples of saturated alkyl includemethyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, andthe like, examples of saturated straight chain alkylinclude methyl, ethyl, n-propyl, n-butyl, n-pentyl (amyl),n-hexyl, n-heptyl, and the like, and examples ofsaturated branched chain alkyl include isopropyl,isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl,and the like.In the present invention, "alkoxy" means -OR [whereR is an alkyl group], and examples thereof includemethoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, secbutoxy,isobutoxy, tert-butoxy and the like.In the present invention, "aryl" means a monovalentmoiety obtained by removing a hydrogen atom from anaromatic ring atom of an aromatic compound having a ringatom.In the present invention, "alkenyl" is alkyl havingone or more carbon-carbon double bonds, and examples ofunsaturated alkenyl groups include ethenyl (vinyl, -CH=CH2), 1-propenyl (-CH=CHCH3), 2-propenyl, isopropenyl,butenyl, pentenyl, hexenyl, and the like.In the present invention, "alkynyl" is an alkylgroup having one or more carbon-carbon triple bonds, andexamples of unsaturated alkynyl groups include ethynyl,2-propynyl and the like.In the present invention, "carboxy" refers to -C(=O)OH.In the present invention, "formyl" refers to -C(=O)H.In the present invention, "aryl" relates to amonovalent moiety obtained by removing a hydrogen atomfrom an aromatic ring atom of an aromatic compound. Forexample, "C5-7 aryl" means a monovalent moiety, which has5 to 7 ring atoms and is obtained by removing a hydrogenatom from an aromatic ring atom of an aromatic compound,and "C5-10 aryl" means a monovalent moiety, which has 5 to10 ring atoms and is obtained by removing a hydrogen atomfrom an aromatic ring atom of an aromatic compound. Aprefix (C5-7, C5-10, and the like) herein refers to thenumber of ring atoms or the range of the number of ringatoms, whether carbon atoms or heteroatoms. For example,"C5-6 aryl" relates to an aryl group having 5 or 6 ringatoms. Here, the ring atoms may be all carbon atoms as ina "carboaryl group". Examples of carboaryl groups include,but are not limited to, those derived from benzene,naphthalene, azulene, anthracene, phenanthrene,naphthacene, and pyrene. Examples of an aryl groupcontaining fused rings of which at least one is anaromatic ring include, but are not limited to, groupsderived from indane, indene, isoindene, tetralin,acenaphthene, fluorene, phenalene, acephenanthrene andaceanthrylene
[15] . Alternatively, the ring atom mayinclude one or more heteroatoms as in a "heteroarylgroup".In the present invention, "heteroaryl" is arylcontaining one or more heteroatoms, and examples thereofinclude pyridine, pyrimidine, benzothiophene, furyl,dioxalanyl, pyrrolyl, oxazolyl, pyridyl, pyridazinyl,pyrimidinyl, and the like, more specifically, C9 with twofused rings derived from benzofuran, isobenzofuran,indole, isoindole, indolizine, indoline, isoindoline,purine (adenine or guanine), benzimidazole, indazole,benzoxazole, benzisoxazole, benzodioxole, benzofuran,benzotriazole, benzothiofuran, benzothiazole, andbenzothiadiazole; C10 with two fused rings derived fromchromene, isochromene, chromane, isochromane,benzodioxane, quinoline, isoquinoline, quinolizine,benzoxazine, benzodiazine, pyridopyridine, quinoxaline,quinazoline, cinnoline, phthalazine, naphthyridine, andpteridine; C11 with two fused rings derived frombenzodiazepine; C13 with three fused rings derived fromcarbazole, dibenzofuran, dibenzothiophene, carboline,perimidine, and pyridoindole; and C14 with three fusedrings derived from acridine, xanthene, thioxanthene,oxantrene, phenoxathiin, phenazine, phenoxazine,phenothiazine, thianthrene, phenanthridine,phenanthroline, and phenazine.In the present invention, "cycloalkyl" is an alkylgroup that is a cyclyl group, and relates to a monovalentmoiety obtained by removing a hydrogen atom from analicyclic ring atom of a cyclic hydrocarbon compound.Examples of cycloalkyl groups include, but are notlimited to, those derived from:saturated monocyclic hydrocarbon compounds:cyclopropane, cyclobutane, cyclopentane, cyclohexane,cycloheptane, methylcyclopropane, dimethylcyclopropane,methylcyclobutane, dimethylcyclobutane,methylcyclopentane, dimethylcyclopentane andmethylcyclohexane;unsaturated monocyclic hydrocarbon compounds:cyclopropene, cyclobutene, cyclopentene, cyclohexene,methylcyclopropene, dimethylcyclopropene,methylcyclobutene, dimethylcyclobutene,methylcyclopentene, dimethylcyclopentene andmethylcyclohexene; and saturated heterocyclic hydrocarboncompounds: norcarane, norpinane, and norbornane.In the present invention, "heterocyclyl" relates toa monovalent moiety obtained by removing a hydrogen atomfrom a ring atom of a heterocyclic compound. In theheterocyclic compound, the bond in the cyclic structureis not limited to a single bond, and includes both adouble bond and a triple bond. The heterocyclic compoundalso includes compounds having two or more fused rings.In the present invention, a prefix (for example, C1-12, C3-8, and the like) refers to the number of ring atomsor the range of the number of ring atoms, whether carbonatoms or heteroatoms. For example, the term "C3-6heterocyclyl" as used herein relates to a heterocyclylgroup having 3 to 6 ring atoms.Examples of monocyclic heterocyclyl groups include,but are not limited to, those derived from:N1: aziridine, azetidine, pyrrolidine, pyrroline,2H- or 3H-pyrrole, piperidine, dihydropyridine,tetrahydropyridine, and azepine;N2: imidazolidine, pyrazolidine, imidazoline,pyrazoline, and piperazine;O1: oxirane, oxetane, oxolane, oxole, oxane,dihydropyran, pyran, and oxepin;O2: dioxolane, dioxane and dioxepane;O3: trioxane;N1O1: tetrahydrooxazole, dihydrooxazole,tetrahydroisoxazole, dihydroisoxazole, morpholine,tetrahydrooxazine, dihydrooxazine, and oxazineS1: thiirane, thietane, thiolane, thiane, andthiepan;N1S1: thiazoline, thiazolidine, and thiomorpholine;N2O1: oxadiazine;O1S1: oxathiole and oxathiane; andN1O1S1: oxathiazine.In the present invention, as the "pharmaceuticallyacceptable salt", an acid addition salt formed by apharmaceutically acceptable free acid may be used, and anorganic acid or an inorganic acid may be used as the freeacid.The organic acid includes, but is not limited to,citric acid, acetic acid, lactic acid, tartaric acid,maleic acid, fumaric acid, formic acid, propionic acid,oxalic acid, trifluoroacetic acid, benzoic acid, gluconicacid, methanesulfonic acid
[16] , glycolic acid, succinicacid, 4-toluenesulfonic acid, glutamic acid and asparticacid. The inorganic acid includes, but is not limited to,hydrochloric acid, hydrobromic acid, sulfuric acid andphosphoric acid.For example, when the compound is an anion or has afunctional group that may be an anion (for example, -COOHmay be -COO-), a salt may be formed using an appropriatecation. Examples of appropriate inorganic cations include,but are not limited to, alkali metal ions such as Na+ andK+, alkaline earth metal cations such as Ca2+ and Mg2+, andother cations such as Al3+. Examples of appropriateorganic cations include, but are not limited to, ammoniumions (namely, NH4+) and substituted ammonium ions (forexample, NH3R+, NH2R2+, NHR3+, and NR4+).Examples of some appropriate substituted ammoniumions include those derived from: ethylamine, diethylamine,dicyclohexylamine, triethylamine, butylamine,ethylenediamine, ethanolamine, diethanolamine, piperazine,benzylamine, phenylbenzylamine, choline, meglumine andtromethamine, as well as amino acids, for example, lysineand arginine. Examples of a common quaternary ammoniumion include N(CH3)4+.For example, when the compound is a cation or has afunctional group that may be a cation (for example, -NH2may be NH3+), a salt may be formed using an appropriateanion. Examples of appropriate inorganic anions include,but are not limited to, those derived from the followinginorganic acids: hydrochloric acid, hydrobromic acid,hydroiodic acid, sulfuric acid, sulfurous acid, nitricacid, nitrous acid, phosphoric acid and phosphorous acid.Examples of appropriate organic anions include, butare not limited to, those derived from the followingorganic acids: 2-acetoxybenzoic acid, acetic acid,ascorbic acid, aspartic acid, benzoic acid, camphorsulfonic acid, cinnamic acid, citric acid, edetic acid,ethanedisulfonic acid, ethanesulfonic acid, fumaric acid,glucheptonic acid, gluconic acid, glutamic acid, glycolicacid, hydroxymaleic acid, hydroxynaphthalene carboxylicacid, isethionic acid, lactic acid, lactobionic acid,lauric acid, maleic acid, malic acid, methanesulfonicacid, mucous acid, oleic acid, oxalic acid, palmitic acid,pamic acid, pantothenic acid, phenylacetic acid,phenylsulfonic acid, propionic acid, pyruvic acid,salicylic acid, stearic acid, succinic acid, sulfanilicacid, tartaric acid, toluenesulfonic acid and valericacid. Examples of appropriate organic polymer anionsinclude, but are not limited to, those derived from thefollowing polymer acids: tannic acid and carboxymethylcellulose.In the present invention, a "solvate" refers to amolecular complex between the compound according to thepresent invention and solvent molecules, and examples ofthe solvate include, but are not limited to, compoundsaccording to the present invention bound to water,isopropanol, ethanol, methanol, dimethyl sulfoxide, ethylacetate, acetic acid, ethanolamine or a mixed solventthereof.It may be convenient or desirable to prepare, purifyand / or handle corresponding solvates of the activecompounds. The term "solvate" is used herein in itsconventional sense to refer to a complex of a solute (forexample, active compounds, salts of active compounds) anda solvent. When the solvent is water, the solvate mayconveniently be referred to as a hydrate, for example, amonohydrate, dihydrate, or trihydrate.The pharmaceutical composition of the presentinvention may comprise a pharmaceutically acceptableexcipient. The pharmaceutically acceptable excipient mayinclude macromolecules that are usually slowlymetabolized, for example, proteins, polysaccharides,polylactic acid, polyglycolic acid, polymeric amino acids,amino acid copolymers, lipid aggregates, and the like.Such pharmaceutically acceptable excipients may beappropriately selected and used by those skilled in theart.The composition comprising a pharmaceuticallyacceptable excipient may be various oral or parenteralformulations. In the case of being formed into apreparation, the composition is prepared using commonlyused diluents or excipients such as fillers, extenders,binders, wetting agents, disintegrants, and surfactants.Solid preparations for oral administration includetablets, pills, powders, granules, capsules, and the like.Such solid preparations are prepared by mixing one ormore compounds with at least one or more excipients, forexample, starch, calcium carbonate, sucrose or lactose,gelatin, and the like. In addition to simple excipients,lubricants such as magnesium stearate and talc may alsobe used.Liquid preparations for oral administration includesuspensions, oral liquids, emulsions, syrups, and thelike. In addition to water and liquid paraffin, which arecommonly used simple diluents, various excipients such aswetting agents, sweetening agents, fragrances,preservatives, and the like may be contained.Preparations for parenteral administration includesterile aqueous solutions, non-aqueous solutions,suspensions, emulsions, freeze-dried preparations, andsuppositories. As non-aqueous solvents and suspensionsolvents, propylene glycol, polyethylene glycol,vegetable oils such as olive oil, injectable esters suchas ethyl oleate, and the like may be used. As the base ofsuppositories, witepsol, macrogol, tween 61, cacao butter,laurin oil, glycerogelatin, and the like may be used.The pharmaceutical composition may have any oneformulation selected from the group consisting ofinjections, tablets, pills, powders, granules, capsules,suspensions, oral liquids, emulsions, syrups, sterilizedaqueous solutions, non-aqueous solutions, suspensions,emulsions, freeze-dried preparations and suppositories.For intravenous, dermal or subcutaneous injection,and the like, the active ingredient may be in the form ofan acceptable aqueous solution for parenteraladministration, which is pyrogen-free and has appropriatepH, isotonicity and stability. Those skilled in the artcan prepare appropriate solutions using isotonic vehicles,for example, aqueous sodium chloride solution, Ringer'ssolution, and lactate Ringer's solution, and thesolutions may be contained as preservatives, stabilizers,buffers, antioxidants or other additives if necessary.Solid forms suitable for injection may also be preparedas emulsions or in the form of polypeptides encapsulatedin liposomes.The phrase "effective amount" or "therapeuticallyeffective amount" as used herein refers to an amountnecessary (with respect to the dosage and duration andmeans of administration) to achieve a desired therapeuticresult. An effective amount is at least the minimumamount of an active agent necessary to confer atherapeutic benefit to a subject and is less than a toxicamount. For example, the dosage ranges from about 100ng / kg to about 100 mg / kg per patient, and may moretypically be in the range of about 1 μg / kg to about 10mg / kg. When the active compound is a salt, ester, amide,prodrug or the like, the dosage is calculated on thebasis of the parent compound, so the actual weight usedincreases proportionally. The pyrrolobenzodiazepinederivative compound according to the present inventionmay be formulated to contain 0.1 mg to 3000 mg, 1 mg to2000 mg, or 10 mg to 1000 mg of active ingredient perdosage form, but is not limited thereto. The activeingredient may be administered to obtain a peak plasmaconcentration of the active compound of about 0.05 μM to100 μM, 1 μM to 50 μM, or 5 μM to 30 μM. For example, theactive ingredient may arbitrarily be administered byintravenous injection of a 0.1 w / v% to 5 w / v% solution insaline.The concentration of the active compound in thepharmaceutical composition may be determined by theabsorption, inactivation and excretion rates of the drugand other factors known to those skilled in the art. Thedosage may vary depending on the severity of thesymptoms / disease. The dosage and administration methodfor a certain patient may be adjusted according to theprofessional judgment of the administration supervisor,taking into account the patient's severity ofsymptoms / diseases, needs, age, responsiveness to drugs,and the like, and the concentration ranges presentedherein are exemplary only and are not intended to limitthe embodiments of the claimed composition thereto. Theactive ingredient may be administered in a single dose,or may be administered in smaller dosages divided intoseveral doses.In the present invention, "proliferative disease"refers to unwanted or uncontrolled proliferation ofundesirable excessive or abnormal cells such asneoplastic or hyperplastic growth of cells in vitro or invivo. The proliferative disease includes, for example,neoplasms, tumors, cancer, leukemia, psoriasis, bonediseases, fibroproliferative disorders, atherosclerosis,and the like, and may include benign, premalignant ormalignant cell proliferation, but is not limited thereto.The cancer may be lung cancer, small cell lung cancer,gastrointestinal cancer, colorectal cancer, bowel cancer,breast cancer, ovarian cancer, prostate cancer,testicular cancer, liver cancer, kidney cancer, bladdercancer, pancreatic cancer, brain cancer, sarcoma,osteosarcoma, Kaposi's sarcoma, or melanoma, but is notlimited thereto.In the present invention, a "therapeutic agent" isan agent that exerts cytotoxic, cytostatic and / orimmunomodulatory effects on proliferative disease, forexample, cancer cells or activated immune cells. Examplesof therapeutic agents include cytotoxic agents,chemotherapeutic agents, cytostatic agents andimmunomodulators.The pyrrolobenzodiazepine derivative, its precursor,and pyrrolobenzodiazepine derivative-ligand conjugateaccording to the present invention may be synthesizedaccording to the following procedure.However, the following Examples and ExperimentalExamples are merely illustrative of the present invention,and the contents of the present invention are not limitedto the following Examples and Experimental Examples.[Examples]<Example 1> Preparation of Compound 7Preparation of Compound 1After 4-bromobutyric acid (10.0 g, 59.9 mmol) andallyl alcohol (40.7 mL, 598.7 mmol) were dissolved intoluene (240 mL), then p-toluenesulfonic acid (1.1 g, 6.0mmol) was added, and the mixture was stirred for 17 hoursunder a nitrogen atmosphere while being heated underreflux. The reaction mixture was diluted with ethylacetate (300 mL) and washed with 0.1 N aqueous sodiumhydroxide solution (200 mL). The washed organic layer waswashed with brine (200 mL) and dried over anhydroussodium sulfate. After filtration and concentration underreduced pressure, the product was purified by columnchromatography, thereby obtaining Compound 1 (11.5 g,92%). 1H-NMR(400 MHz, CDCl3) δ 5.93 (m, 1H), 5.30 (d, 1H),5.26 (d, 1H), 4.59 (d, 2H), 3.47 (t, 2H), 2.54 (t, 2H),2.19 (q, 2H).Preparation of Compound 3Compound 2 (36 g, 62.1 mmol, Compound 2 was preparedby the method described in Korean Patent Publication No.10-2020-0084802) was dissolved in N,Ndimethylformamide / distilled water (300 mL / 6 mL), thensodium acetate (6.1 g, 74.6 mmol) was added, and thereaction solution was stirred at room temperature under anitrogen atmosphere. After 3 hours, distilled water (500mL) was added, followed by extraction with ethyl acetate(2 x 200 mL). The collected organic layers were washedwith distilled water (200 mL) and brine (200 mL) in thatorder, and then dried over anhydrous sodium sulfate.Filtration, concentration, and purification by columnchromatography were performed, thereby obtaining Compound3 (26 g, 99%). 1H-NMR(400 MHz, CDCl3) δ7.77-7.76 (m, 1H),6.81-6.76 (m, 1H), 6.05-6.01 (m, 1H), 5.10-4.83 (m, 2H),4.58-4.54 (m, 1H), 3.99 (s, 3H), 3.89-3.56 (m, 3H), 3.34-3.26 (m, 1H), 2.81-2.67 (m, 2H), 0.89 (s, 9H), 0.09 (s,6H).Preparation of Compound 4Compound 3 (9.1 g, 21.7 mmol) and Compound 1 (6.8 g,32.6 mmol) were dissolved in N,N-dimethylformamide (50mL), then potassium carbonate (6.0 g, 43.5 mmol) andsodium iodide (1.6 g, 10.8 mmol) were added, and themixture was stirred at 100°C for 4 hours under a nitrogenatmosphere. The reaction mixture was diluted with ethylacetate (300 mL) and washed with distilled water (2 x 100mL). The washed organic layer was washed with brine (100mL) and dried over anhydrous sodium sulfate. Afterfiltration and concentration under reduced pressure, theproduct was purified by column chromatography, therebyobtaining Compound 4 (11.0 g, 92%). 1H-NMR(400 MHz, CDCl3)δ7.69 (s, 1H), 6.73 (s, 1H), 5.93 (m, 1H), 5.30 (d, 1H),5.26 (d, 1H), 4.98 (s, 1H), 4.83 (s, 1H), 4.59 (d, 2H),4.58 (brs, 1H), 4.13 (t, 2H), 3.89 (s, 4H), 3.75 (brs,1H), 3.71 (s, 1H), 3.31-3.27 (m, 1H), 2.73 (m, 2H), 2.57(t, 2H), 2.20 (q, 2H), 0.91 (s, 9H), 0.09 (s, 6H).Preparation of Compound 5Compound 4 (11.0 g, 20.0 mmol) was dissolved inethyl acetate (80 mL) and ethanol (120 mL), zinc dust(26.1 g, 400.2 mmol) was added at 0°C, and formic acid(15.1 mL, 400.2 mmol) was added. After stirring at roomtemperature for 2.5 hours, the reaction mixture wasdiluted with ethyl acetate (30 mL) and filtered throughCelite, and ethyl acetate (70 mL) was added. The organiclayer was washed with saturated aqueous sodium hydrogencarbonate solution (2 x 100 mL) and brine (50 mL) in thatorder, and then dried over anhydrous sodium sulfate.Filtration, concentration, and purification by columnchromatography were performed, thereby obtaining Compound5 (9.9 g, 95%). 1H-NMR(400 MHz, CDCl3) δ 6.74 (s, 1H),6.25 (s, 1H), 5.92 (m, 1H), 5.30 (d, 1H), 5.24 (d, 1H),4.97 (s, 1H), 4.90 (s, 1H), 4.59 (d, 2H), 4.33 (brs, 1H),4.18 (m, 1H), 4.09 (m, 1H), 4.03 (t, 2H), 3.76 (s, 3H),3.61 (brs, 1H), 2.68 (m, 2H), 2.57 (t, 2H), 2.16 (q, 2H),0.87 (s, 9H), 0.09 (s, 6H).Preparation of Compound 7Compound 5 (9.9 g, 19.1 mmol) was dissolved in drytetrahydrofuran (250 mL), and then triphosgene (2.0 g,6.8 mmol) and triethylamine (10.7 mL, 76.3 mmol) wereadded at 0°C, and Compound 6 (16.4 g, 21.0 mmol, Compound6 was prepared by the method described in Korean PatentPublication No. 10-2018-0110645) dissolved in drytetrahydrofuran (50 mL) was added. After stirring at roomtemperature for 17 hours, the reaction mixture wasdiluted with ethyl acetate (200 mL), washed withdistilled water (150 mL), and then dried over anhydroussodium sulfate. After filtration and concentration underreduced pressure, the product was purified by columnchromatography, thereby obtaining Compound 7 (14.4 g,60%). 1H-NMR(400 MHz, CDCl3) δ 8.95 (brs, 1H), 8.02 (s,1H), 7.83 (s, 1H), 7.72 (s, 1H), 7.49 (d, 1H), 7.43 (t,1H), 7.03 (d, 1H), 6.67 (s, 1H), 5.9 1(m, 1H), 5.40-5.22(m, 6H), 5.12 (s, 2H), 5.00 (s, 1H), 4.97 (s, 1H), 4.59(d, 2H), 4.19 (d, 2H), 3.98 (t, 2H), 3.86 (m, 2H), 3.80(s, 1H), 3.77 (s, 3H), 3.70-3.65 (m, 12H), 3.53 (m, 1H),2.68 (m, 2H), 2.56 (t, 2H), 2.15 (q, 2H), 2.05 (s, 9H),1.46 (s, 9H), 0.87 (s, 9H), 0.09 (s, 6H). EIMSm / z:[M+H]+1275.8.<Example 2> Preparation of Compound 10Preparation of Compound 8Compound 7 (14.4 g, 11.3 mmol) was dissolved intetrahydrofuran / distilled water (50 mL / 50 mL), and aceticacid (50 mL) was added at 0°C, and the mixture wasstirred at room temperature for 17 hours. The reactionmixture was diluted with ethyl acetate (100 mL), washedwith distilled water (50 mL) and saturated sodiumhydrogen carbonate solution (2 x 100 mL) in that order,and dried over anhydrous sodium sulfate. After filtrationand concentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 8 (12.6 g, 96%). 1H-NMR(400 MHz, CDCl3) δ 8.37(s, 1H), 8.03 (s, 1H), 7.74 (s, 1H), 7.72 (s, 1H), 7.51(t, 1H), 7.43 (d, 1H), 7.02 (d, 1H), 6.81 (s, 1H), 5.92(m, 1H), 5.40-5.22 (m, 6H), 5.13 (s, 2H), 5.00 (s, 1H),4.91 (s, 1H), 4.60 (d, 2H), 4.19 (d, 1H), 4.16 (s, 1H),4.11 (m, 3H), 3.98 (t, 2H), 3.78 (s, 3H), 3.73-3.65 (m,12H), 3.53 (m, 1H), 2.76 (m, 1H), 2.57 (t, 2H), 2.50 (m,1H), 2.17 (q, 2H), 2.05 (s, 9H), 1.46 (s, 9H). EIMSm / z:[M+H]+1161.6.Preparation of Compound 9Compound 8 (12.6 g, 10.9 mmol) was dissolved indichloromethane (200 mL), Dess-Martin periodinane (5.6 g,13.1 mmol) was added, and the mixture was stirred at roomtemperature for 5 hours under a nitrogen atmosphere. Thereaction mixture was diluted with dichloromethane (200mL), washed with saturated aqueous sodium hydrogencarbonate solution (150 mL) and aqueous sodiumthiosulfate solution (100 mL), and then dried overanhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 9 (6.6 g, 52%). 1H-NMR(400 MHz, CDCl3) δ 7.97 (s,1H), 7.80(s, 1H), 7.45(s, 1H), 7.23 (d, 1H), 7.19 (s, 1H),7.00 (d, 1H), 6.61 (s, 3H), 5.92 (m, 1H), 5.58 (d, 1H),5.41-5.22 (m, 8H), 5.13 (s, 2H), 4.83 (d, 1H), 4.59 (d,2H), 4.27 (m, 2H), 4.11 (m, 2H), 3.96 (m, 2H), 3.88 (s,3H), 3.74-3.65 (m, 15H), 3.52 (m, 1H), 2.90 (m, 1H), 2.70(d, 1H), 2.57 (t, 2H), 2.13 (q, 2H), 2.05 (s, 9H), 1.46(s, 9H). EI-MSm / z:[M+H]+1159.6.Preparation of Compound 10Compound 9 (600 mg, 0.52 mmol) was dissolved in N,Ndimethylformamide(10 mL), thentetrakis(triphenylphosphine)palladium(0) (238 mg, 0.21mmol) and pyrrolidine (0.05 mL, 0.57 mmol) were added,and the mixture was stirred at room temperature for 1hour under a nitrogen atmosphere. The reaction mixturewas diluted with ethyl acetate (50 mL), washed withsaturated aqueous ammonium chloride solution (50 mL) anddistilled water (50 mL), and dried over anhydrous sodiumsulfate. Filtration and concentration under reducedpressure were performed, thereby obtaining Compound 10(570 mg, 98%) as a yellow solid. EI-MS m / z : [M+H]+1119.6,[M / 2+H]+510.3.<Example 3> Preparation of Compound 14Preparation of Compound 11After 1-methylpyrrole (20.0 g, 246.5 mmol) wasdissolved in tetrahydrofuran (100 mL), trichloroacetylchloride (27.5 ml, 246.5 mmol) dissolved intetrahydrofuran (100 mL) was gradually added using adropping funnel at 0°C under a nitrogen atmosphere. Thereaction solution was heated to room temperature andstirred for 3 hours. The reaction mixture wasconcentrated, diluted with ethyl acetate (100 mL), andthen washed with distilled water (100 mL). The collectedorganic layers were dried over anhydrous sodium sulfate,thereby obtaining Compound 11 (55.7 g, 99%). 1H-NMR(400MHz, CDCl3) δ7.51-7.49 (m, 1H), 6.96 (s, 1H), 6.23-6.21 (m,1H), 3.97 (s, 3H).Preparation of Compound 12Compound 11 (15.8 g, 69.7 mmol) was dissolved inacetic anhydride (170 mL), copper (II) nitrate hydrate(17 g, 73.2 mmol) was added at 0°C under a nitrogenatmosphere, and the mixture was stirred for 2 hours.Saturated aqueous sodium hydrogen carbonate solution (200mL) was gradually added to the reaction mixture. Theaqueous layer was extracted with ethyl acetate (200 mL),followed by washing with distilled water (200 mL). Thecollected organic layers were dried over anhydrous sodiumsulfate, then filtered and concentrated.Recrystallization from dichloromethane / hexane (50 mL / 50mL) was performed, and the remaining filtrate waspurified by column chromatography, thereby obtainingCompound 12 (0.8 g, 72%) as a white solid. 1H-NMR(400 MHz,CDCl3) δ 7.94 (d, J = 1.6 Hz, 1H), 7.75 (s, 1H), 4.05 (s,1H).Preparation of Compound 13After Compound 12 (45.7 g, 168.4 mmol) was dilutedwith methanol (300 mL), sodium methoxide (1.8 g, 33.6mmol) was added at 0°C under a nitrogen atmosphere, andthe mixture was stirred at room temperature for 2 hours.The reaction mixture was neutralized by adding 6 Naqueous hydrochloric acid solution, and then concentratedunder reduced pressure, distilled water (200 mL) wasadded, followed by extraction with ethyl acetate (2 x 200mL). The collected organic layers were dried overanhydrous sodium sulfate, then filtered and concentrated.After addition of acetone (50 mL), a white solid producedwas filtered, thereby obtaining Compound 13 (29.6 g, 95%).1H-NMR(400 MHz, CDCl3) δ 7.59 (d, J = 1.6 Hz, 1H), 7.41 (d,J = 1.6 Hz, 1H), 3.99 (s, 3H), 3.86 (s, 3H).Preparation of Compound 14Compound 13 (15.1 g, 81.9 mmol) was diluted withmethanol (200 mL), sodium hydroxide (9.8 g, 245.9 mmol)dissolved in distilled water (200 mL) was added at 0°Cunder a nitrogen atmosphere, and the mixture was stirredat room temperature for 12 hours. The reaction mixturewas adjusted to have a pH of about 2 by adding 6 Naqueous hydrochloric acid solution, and then concentratedunder reduced pressure, distilled water (200 mL) wasadded, followed by extraction with ethyl acetate (2 x 100mL). The collected organic layers were dried overanhydrous sodium sulfate, then filtered and concentrated.Recrystallization from ethyl acetate / hexane (50 mL / 50 mL)was performed, thereby obtaining Compound 14 (13.4 g,96%). 1H-NMR(400 MHz, DMSO-d6) δ13.14 (brs, 1H), 8.23 (d,J = 1.6 Hz, 1H), 7.25 (d, J = 2 Hz, 1H), 3.91 (s, 3H).<Example 4> Preparation of Compound 18Preparation of Compound 15Compound 13 (7.5 g, 40.8 mmol) was dissolved inmethanol (200 mL) and ethyl acetate (200 mL), and thenpalladium / charcoal (10% w / w, 1.5 g) was added at 0°Cunder a nitrogen atmosphere. Sodium borohydride (4.6 g,122.5 mmol) dissolved in distilled water (100 mL) wasgradually added using a dropping funnel, and then themixture was stirred at room temperature for 1 hour. Thereaction mixture was filtered through Celite, thendiluted with ethyl acetate (100 mL), and washed withdistilled water (100 mL). The collected organic layerswere dried over anhydrous sodium sulfate, then filtered,concentrated, and purified by column chromatography,thereby obtaining Compound 15 (6.2 g, 99%). 1H-NMR(400MHz, CDCl3) δ 6.45 (d, J = 2.4 Hz, 1H), 6.36 (d, J = 2 Hz,1H), 3.81 (s, 3H), 3.77 (s, 3H).Preparation of Compound 16Compound 14 (4.8 g, 28.2 mmol) was dissolved in N,Ndimethylformamide(70 mL), then N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU,16.8 g, 42.3 mmol) and N,N'-diisopropylethylamine (14.7mL, 84.6 mmol) were added sequentially at 0°C under anitrogen atmosphere, and the mixture was stirred at roomtemperature for 30 minutes. Compound 15 (6.2 g, 40.8 mmol)dissolved in N,N-dimethylformamide (70 mL) was added tothe reaction solution, and the mixture was stirred atroom temperature for 12 hours. The reaction mixture wasconcentrated, diluted with dichloromethane (100 mL), andthe produced solid was filtered, thereby obtainingCompound 16 (8.5 g, 99%). 1H-NMR (400 MHz, DMSO-d6) δ10.25 (s, 1H), 8.19 (s, 1H), 7.55 (d, J = 1.6 Hz, 1H),7.45 (s, 1H), 6.88 (d, J = 1.6 Hz, 1H), 3.94 (s, 3H),3.84 (s, 3H), 3.74 (s, 3H).Preparation of Compound 17Compound 16 (6.0 g, 19.58 mmol) was dissolved inmethanol (60 mL) and N,N-dimethylformamide (60 mL), andthen palladium / charcoal (10% w / w, 1.0 g) and di-t-butyldicarbonate (13.5 mL, 58.7 mmol) were added. The reactionsolution was stirred at room temperature for 18 hoursunder a hydrogen atmosphere. The reaction mixture wasfiltered through Celite and then concentrated. Theconcentrated filtrate was diluted with ethyl acetate (200mL), washed with distilled water (150 mL), and dried overanhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 17 (5.7 g, 78%). 1H-NMR(400 MHz, CDCl3) δ 7.41(s, 2H), 6.82 (s, 1H), 6.72 (s, 1H), 6.56 (s, 1H), 6.20(s, 1H), 3.90 (s, 6H), 3.81 (s, 3H), 1.50 (s, 9H).Preparation of Compound 18After 1,4-dioxane (15 mL) was added to Compound 17(651 mg, 1.73 mmol), sodium hydroxide (345 mg, 8.64 mmol)dissolved in distilled water (5 mL) was added at 0°Cunder a nitrogen atmosphere. The solution was heated at70°C and stirred for 5 hours. After 1,4-dioxane wasconcentrated, the pH was adjusted to about 2 with 6 Naqueous hydrochloric acid solution, followed by dilutionwith ethyl acetate (50 mL), washing with distilled water(50 mL), and drying over anhydrous sodium sulfate.Filtration and concentration were performed, therebyobtaining Compound 18 (630 mg, 98%). 1H-NMR (400 MHz,CDCl3) δ 7.64 (s, 1H), 7.49 (s, 1H), 6.90 (s, 1H), 6.78 (s,1H), 6.73 (s, 1H), 6.24 (s, 1H), 3.90 (s, 6H), 1.44 (s,9H).<Example 5> Preparation of Compound 20Preparation of Compound 19Compound 18 (1.3 g, 3.72 mmol) was dissolved in N,Ndimethylformamide(30 mL), then 3-(dimethylamino)-1-propylamine (0.56 mL, 4.46 mmol), N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU,2.2 g, 5.58 mmol) and N,N'-diisopropylethylamine (2.0 mL,11.16 mmol) were sequentially added at 0°C under anitrogen atmosphere, and the mixture was stirred at roomtemperature for 19 hours. The reaction mixture wasdiluted with ethyl acetate (150 mL), then washed withsaturated aqueous ammonium chloride solution (100 mL),saturated sodium hydrogen carbonate solution (100 mL) anddistilled water (100 mL), and dried over anhydrous sodiumsulfate. Filtration, concentration, and purification bycolumn chromatography were performed, thereby obtainingCompound 19 (1.2 g, 72%). 1H-NMR(400 MHz, CDCl3) δ 7.64(s, 1H), 7.57 (s, 1H), 7.20 (s, 1H), 6.80 (s, 1H), 6.62(s, 1H), 6.44 (s, 1H), 6.31 (s, 1H), 3.90 (s, 6H), 3.48-3.43 (m, 2H), 2.56-2.53 (m, 2H), 2.38 (s, 6H), 1.81-1.76(m, 2H), 1.49 (s, 9H).Preparation of Compound 20Compound 19 (300 mg, 0.67 mmol) was dissolved indichloromethane (4 mL), then hydrochloric acid (4 M 1,4-dioxane solution, 2 mL) was added at 0°C under a nitrogenatmosphere, and the mixture was stirred for 2 hours. Thereaction mixture was concentrated under reduced pressure,thereby obtaining Compound 20 (278 mg). EI-MS m / z :[M+H]+347.53, 1 / 2[M+H]+174.32.<Example 6> Preparation of Compound 23Preparation of Compound 21Compound 10 (144 mg, 0.128 mmol) was dissolved inN,N-dimethylformamide (2 mL), then Compound 20 (70 mg,0.167 mmol), N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 77 mg, 0.193 mmol)and N,N'-diisopropylethylamine (0.11 mL, 0.645 mmol) weresequentially added at 0°C under a nitrogen atmosphere,and the mixture was stirred at room temperature for 12hours. After addition of ethyl acetate (50 mL), thereaction mixture was washed with saturated aqueousammonium chloride solution (50 mL), saturated aqueoussodium hydrogen carbonate solution (50 mL) and distilledwater (50 mL). The collected organic layers were driedover anhydrous sodium sulfate, filtered and thenconcentrated. The product was purified by columnchromatography, thereby obtaining Compound 21 (163 mg,87%). EI-MS m / z : [M+H]+1448.25, 1 / 2[M+H]+724.57.Preparation of Compound 22Compound 21 (163 mg, 0.126 mmol) was dissolved inmethanol / tetrahydrofuran (2 mL / 2 mL), and then a solutionof lithium hydroxide (14 mg, 0.337 mmol) in distilledwater (2 mL) was gradually added at -40°C under anitrogen atmosphere. The mixture was stirred for 2 hourswhile the reaction temperature was gradually raised to0°C. The reaction mixture was neutralized with aceticacid, then concentrated under reduced pressure, andfreeze-dried, thereby obtaining Compound 22 (150 mg,crude). EI-MS m / z : [M+H]+1308.03, [M / 2+H]+664.60.Preparation of Compound 23Compound 22 (150 mg, 0.1 mmol) was diluted withdichloromethane (16 mL), then trifluoroacetic acid (4 mL)was added at 0°C under a nitrogen atmosphere, and themixture was stirred for 2 hours. The reaction mixture wasconcentrated under reduced pressure, purified by HPLC,and freeze-dried, thereby obtaining Compound 23 as awhite solid (12 mg). EI-MS m / z : [M+H]+1207.93,[M / 2+H]+604.59.<Example 7> Preparation of Compound 26Preparation of Compound 24After 1,4-dioxane (100 mL) was added to Compound 16(5.46 g, 17.8 mmol), sodium hydroxide (3.56 g, 89.1 mmol)dissolved in distilled water (40 mL) was added at 0°Cunder a nitrogen atmosphere. The solution was heated at80°C and stirred for 6 hours. After 1,4-dioxane wasconcentrated, the pH was adjusted to about 2 with 6 Naqueous hydrochloric acid solution, followed by dilutionwith ethyl acetate (150 mL), washing with distilled water(100 mL), and drying over anhydrous sodium sulfate.Filtration and concentration were performed, therebyobtaining Compound 24 (4.63 g, 89%). 1H-NMR(400 MHz,DMSO-d6) δ 8.19 (s, 1H), 7.56 (s, 1H), 7.42 (s, 1H), 6.83(s, 1H), 3.95 (s, 3H), 3.83 (s, 3H).Preparation of Compound 25Compound 24 (217 mg, 0.74 mmol) was dissolved inN,N-dimethylformamide (3 mL), then 3-amino-1-propanol(0.07 mL, 0.97 mmol), N,N,N',N'-tetramethyl-O-(1Hbenzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 443mg, 1.12 mmol), and N,N'-diisopropylethylamine (0.26 mL,1.49 mmol) were sequentially added at 0°C under anitrogen atmosphere, and the mixture was stirred at roomtemperature for 4 hours. The reaction mixture was dilutedwith ethyl acetate (100 mL), washed with saturated sodiumhydrogen carbonate solution (100 mL) and distilled water(50 mL), then dried over anhydrous sodium sulfate,filtered and concentrated under reduced pressure. Theobtained compound was dissolved in N,Ndimethylformamide / dichloromethane (5 mL / 10 mL), andimidazole (101.3 mg, 1.49 mmol) and t-butyldimethylsilylchloride (168 mg, 1.12 mmol) were added at 0°C. Thereaction solution was stirred at room temperature for 17hours under a nitrogen atmosphere, the reaction mixturewas concentrated, then diluted with ethyl acetate (50 mL),and washed with a saturated aqueous ammonium chloridesolution (50 mL) and distilled water (50 mL), and theorganic layer was dried over anhydrous sodium sulfate.After filtration and concentration under reduced pressure,the product was purified by column chromatography,thereby obtaining Compound 25 (310 mg, 90%). 1H-NMR (400MHz, DMSO-d6) δ 10.22 (s, 1H), 8.17 (s, 1H), 8.01 (t, 1H),7.57 (s, 1H), 7.19 (s, 1H), 6.82 (s, 1H), 3.95 (s, 3H),3.80 (s, 3H), 3.63 (t, 2H), 3.21 (q, 2H), 1.72-1.65 (m,2H), 0.87 (s, 9H), 0.03 (s, 6H).Preparation of Compound 26Compound 25 (158 mg, 0.34 mmol) was dissolved inmethanol (5 mL), and then palladium / charcoal (10% w / w, 80mg) was added. The reaction solution was stirred at roomtemperature for 3 hours under a hydrogen atmosphere. Thereaction mixture was filtered through Celite and thenconcentrated, thereby obtaining Compound 26 (142 mg, 96%).1H-NMR(400 MHz, DMSO-d6) δ 9.55 (s, 1H), 7.93 (t, 1H),7.13 (s, 1H), 6.79 (s, 1H), 6.35 (s, 1H), 6.25 (s, 1H),3.77 (s, 3H), 3.71 (s, 3H), 3.63 (t, 2H), 3.21 (q, 2H),1.71-1.65 (m, 2H), 0.87 (s, 9H), 0.03 (s, 6H).<Example 8> Preparation of Compound 29Preparation of Compound 27Compound 10 (crude 146 mg, 0.13 mmol) was dissolvedin N,N-dimethylformamide (3 mL), then 1-hydroxybenzotriazole (27 mg, 0.20 mmol) and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride(38 mg, 0.20 mmol) were sequentially added at 0°C under anitrogen atmosphere, and Compound 26 (114 mg, 0.26 mmol)dissolved in N,N-dimethylformamide (1 mL) was added.After stirring at room temperature for 5 hours, thereaction mixture was diluted with ethyl acetate (50 mL),then washed with saturated aqueous ammonium chloridesolution (50 mL), saturated sodium hydrogen carbonatesolution (50 mL), and distilled water (50 mL) in thatorder, and then dried over anhydrous sodium sulfate.After filtration and concentration under reduced pressure,the product was purified by column chromatography,thereby obtaining Compound 27 (85 mg, 42%). EI-MS m / z :[M+H]+1534.88, 1 / 2[M+H]+768.49, 1 / 2[M-BOC+H]+718.36.Preparation of Compound 28Compound 27 (85 mg, 0.05 mmol) was dissolved inmethanol / tetrahydrofuran (1.0 mL / 1.0 mL), and then asolution of lithium hydroxide (7 mg, 0.16 mmol) indistilled water (1.0 mL) was gradually added at -40°Cunder a nitrogen atmosphere. The mixture was stirred for5 hours while the reaction temperature was graduallyraised to 0°C. The reaction mixture was neutralized withacetic acid, concentrated under reduced pressure,purified by HPLC, and freeze-dried, thereby obtainingCompound 28 (18 mg). EI-MS m / z : [M-TBS+H]+1280.82,1 / 2[M-BOC+H]+591.04.Preparation of Compound 29Compound 28 (18 mg) was diluted with dichloromethane(1.5 mL), then trifluoroacetic acid (0.5 mL) was added at0°C under a nitrogen atmosphere, and the mixture wasstirred for 1 hour. The reaction mixture was concentratedunder reduced pressure, purified by HPLC, and freezedried,thereby obtaining Compound 29 as a pale yellowsolid (6.1 mg). EI-MS m / z : [M+H]+1180.59, [M / 2+H]+591.88.<Example 9> Preparation of Compound 34Preparation of Compound 30Ethylenediamine (6 mL, 90 mmol) was dissolved indichloromethane (90 mL), then benzyl chloroformate (1.5 g,9 mmol) dissolved in dichloromethane (25 mL) wasgradually added at 0°C under a nitrogen atmosphere, andthe mixture was stirred at room temperature for 2 hours.The reaction mixture was diluted with dichloromethane(100 mL) and washed with brine (100 mL). The organiclayer was dried over anhydrous sodium sulfate, filteredand concentrated under reduced pressure, therebyobtaining Compound 30 (1.75 g, 99%). 1H-NMR(400 MHz,CDCl3) δ 7.32-7.28 (m, 5H), 5.07 (s, 2H), 3.21 (t, J = 6.4Hz, 2H), 2.73 (t, J = 2 Hz, 2H).Preparation of Compound 31Compound 30 (880 mg, 4.5 mmol) was dissolved indichloromethane (15 mL), and then N,N'-Di-Boc-1Hpyrazole-1-carboxamidine (1.68 g, 5.4 mmol) andtriethylamine (0.8 mL, 5.4 mmol) were sequentially addedat 0°C under a nitrogen atmosphere, and the mixture wasstirred at room temperature for 2 hours. The reactionmixture was concentrated and purified by columnchromatography, thereby obtaining Compound 31 (1.96 g,99%). 1H-NMR(400 MHz, CDCl3) δ 11.43 (s, 1H), 8.53 (s,1H), 7.35-7.29 (m, 5H), 5.09 (s, 1H), 3.62-3.54 (m, 2H),3.40-3.36 (m, 2H), 1.48 (s, 9H), 1.44 (s, 9H).Preparation of Compound 32Compound 31 (1.9 g, 4.3 mmol) was dissolved in ethylacetate (40 mL), and then palladium / charcoal (10% w / w,190 mg) was added. The reaction solution was stirred atroom temperature for 3 hours under a hydrogen atmosphere.The reaction mixture was filtered through Celite, thenconcentrated, and purified by column chromatography,thereby obtaining Compound 32 (0.92 g, 67%). 1H-NMR(400MHz, CDCl3) δ 11.51 (s, 1H), 8.66 (s, 1H), 3.51-3.46 (m,2H), 2.91-2.88 (m, 2H), 1.50 (s, 18H).Preparation of Compound 33Compound 24 (150 mg, 0.51 mmol) was dissolved inN,N-dimethylformamide (5 mL), then Compound 32 (186 mg,0.62 mmol), N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 305 mg, 0.77 mmol),and N,N'-diisopropylethylamine (0.18 mL, 1.02 mmol) weresequentially added at 0°C under a nitrogen atmosphere,and the mixture was stirred at room temperature for 16hours. The reaction mixture was concentrated underreduced pressure and purified by column chromatography,thereby obtaining Compound 33 (174 mg, 59%). 1H-NMR (400MHz, CDCl3) δ 11.55 (s, 1H), 8.69 (s, 1H), 7.59 (s, 1H),7.50 (s, 1H), 7.22 (s, 1H), 7.12 (s, 1H), 6.46 (s, 1H),4.02 (s, 3H), 3.92 (s, 3H), 3.74-3.62 (m, 2H), 3.56-3.52(m, 2H), 1.53 (s, 9H), 1.50 (s, 9H).Preparation of Compound 34Compound 33 (174 mg, 0.3 mmol) was dissolved inmethanol (5 mL), and then palladium / charcoal (10% w / w, 70mg) was added. The reaction solution was stirred at roomtemperature for 12 hours under a hydrogen atmosphere. Thereaction mixture was filtered through Celite and thenconcentrated, thereby obtaining Compound 34 (158 mg, 96%).EI-MS m / z : [M+H]+547.30.<Example 10> Preparation of Compound 35Compound 35 was synthesized from Compound 10 andCompound 34 in a similar manner to the synthesis ofCompound 23. EI-MS m / z : [M+H]+1207.44, [M / 2+H]+604.50.<Example 11> Preparation of Compound 37Preparation of Compound 36Compound 18 (200 mg, 0.55 mmol) was dissolved inN,N-dimethylformamide (5 mL), then NH2-PEG6-OH(232mg, 0.83mmol), N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 328 mg, 0.83 mmol),and N,N'-diisopropylethylamine (0.3 mL, 1.66 mmol) weresequentially added at 0°C under a nitrogen atmosphere,and the mixture was stirred at room temperature for 3hours. The reaction mixture was diluted with ethylacetate (50 mL), then washed with saturated aqueousammonium chloride solution (50 mL), saturated sodiumhydrogen carbonate solution (50 mL) and distilled water(50 mL), and dried over anhydrous sodium sulfate.Filtration, concentration, and purification by columnchromatography were performed, thereby obtaining Compound36 (255 mg, 74%). 1H-NMR(400 MHz, CDCl3) δ8.35(s, 1H),7.36(s, 1H), 6.95(s, 1H), 6.88(s, 1H), 6.65(s, 3H),3.91(s, 6H), 3.72-3.54(m, 24H), 1.49(s, 9H).Preparation of Compound 37Compound 36 (139 mg, 0.22 mmol) was dissolved indichloromethane (2 mL), then hydrochloric acid (4 M 1,4-dioxane solution, 1 mL) dissolved in 1,4-dioxane wasadded at 0°C under a nitrogen atmosphere, and the mixturewas stirred for 2 hours. The reaction mixture wasconcentrated under reduced pressure, thereby obtainingCompound 37 (124 mg). EI-MS m / z : [M+H]+ 526.33, 1 / 2[M+H]+ 282.37.<Example 12> Preparation of Compound 38Compound 38 was synthesized from Compound 10 andCompound 37 in a similar manner to the synthesis ofCompound 23. EI-MS m / z : [M+H]+1386.33, [M / 2+H]+694.09.<Example 13> Preparation of Compound 40Preparation of Compound 39Compound 18 (100 mg, 0.27 mmol) was dissolved inN,N-dimethylformamide (5 mL), then Compound NH2-PEG12-OH(238 mg, 0.4 mmol), N,N,N',N'-tetramethyl-O-(1Hbenzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 164mg, 0.4 mmol), and N,N'-diisopropylethylamine (0.14 mL,0.8 mmol) were sequentially added at 0°C under a nitrogenatmosphere, and the mixture was stirred at roomtemperature for 12 hours. The reaction mixture wasconcentrated under reduced pressure, thereby obtainingCompound 39 (245 mg, crude). 1H-NMR(400 MHz, CDCl3) δ8.47 (s, 1H), 7.33 (s, 1H), 6.66 (s, 2H), 3.99 (s, 3H),3.89 (s, 3H), 3.75-3.42 (m, 48H), 1.49 (s, 9H). EI-MS m / z:[M+Na]+912.42, [M+H]+890.45, 1 / 2[M-BOC+H]+395.99.Preparation of Compound 40Compound 39 (245 mg, 0.27 mmol) was diluted withdichloromethane (8 mL), then hydrochloric acid (4 M 1,4-dioxane solution, 2 mL) was added at 0°C under a nitrogenatmosphere, and the mixture was stirred for 2 hours. Thereaction mixture was concentrated under reduced pressure,thereby obtaining Compound 40 (213 mg). EI-MS m / z :[M+Na]+813.47, [M / 2+H]+395.94.<Example 14> Preparation of Compound 41Compound 41 was synthesized from Compound 10 andCompound 40 in a similar manner to the synthesis ofCompound 23. EI-MS m / z : [M+H]+1651.57, [M / 2+H]+826.17.<Example 15> Preparation of Compound 44Preparation of Compound 42After 3-(methylamino)propylamine (20.0 g, 228.02mmol) was dissolved in tetrahydrofuran (300 mL), di-tbutyldicarbonate (9.8 g, 44.9 mmol) dissolved intetrahydrofuran (200 mL) was gradually added using adropping funnel at 0°C under a nitrogen atmosphere. Thereaction solution was heated to room temperature andstirred for 5 hours. The reaction mixture wasconcentrated, diluted with dichloromethane (200 mL),washed with distilled water (100 mL), and dried overanhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 42 (5.1 g, 60%). 1H-NMR(400 MHz, CDCl3) δ 3.29(s, 2H), 2.83 (s, 3H), 2.70-2.67 (m, 2H), 1.68-1.61 (m,2H), 1.43 (s, 9H).Preparation of Compound 43Compound 24 (400 mg, 1.36 mmol) was dissolved inN,N-dimethylformamide (5 mL), then N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU,778 mg, 2.05 mmol) and N,N'-diisopropylethylamine (0.47mL, 2.73 mmol) were added at 0°C under a nitrogenatmosphere, and the mixture was stirred for 3 minutes.Compound 42 (309 mg, 1.64 mmol) was dissolved in N,Ndimethylformamide(3 mL) and then added to the reactionsolution at 0°C, the temperature was gradually raised,and the mixture was stirred at room temperature for 16hours. Saturated aqueous ammonium chloride solution (20mL) was added to the reaction mixture, followed byextraction with ethyl acetate (3 x 20 mL). The extractedsolution was washed with saturated sodium hydrogencarbonate solution (15 mL) and distilled water (15 mL),and then dried over anhydrous sodium sulfate. Filtration,concentration, and purification by column chromatographywere performed, thereby obtaining Compound 43 (582 mg,92%). 1H-NMR (400 MHz, CDCl3) δ 7.69 (brs, 1H), 7.59 (s,1H), 7.36 (brs, 1H), 7.29 (brs, 1H), 7.19 (s, 1H), 6.58(brs, 1H), 4.02 (s, 3H), 3.93 (s, 3H), 3.37 (m, 4H), 2.85(s, 3H), 1.71 (m, 2H), 1.49 (s, 9H), EI-MS m / z :[M+H]+463.39.Preparation of Compound 44Compound 43 (160 mg, 0.34 mmol) was dissolved inmethanol (5 mL), and then palladium / charcoal (10% w / w, 80mg) was added. The reaction solution was stirred at roomtemperature for 2 hours under a hydrogen atmosphere. Thereaction mixture was filtered through Celite and thenconcentrated, thereby obtaining Compound 44 (140 mg). 1HNMR(400 MHz, CDCl3) δ 7.36 (brs, 1H), 7.30 (brs, 1H), 6.53(s, 1H), 6.33 (s, 1H), 6.19 (s, 1H), 3.92 (s, 3H), 3.86(s, 3H), 3.37-3.32 (m, 4H), 2.84 (s, 3H), 1.71 (m, 2H),1.48 (s, 9H), EI-MS m / z : [M+H]+433.41.<Example 16> Preparation of Compound 45Compound 45 was synthesized from Compound 10 andCompound 44 in a similar manner to the synthesis ofCompound 23. 1H-NMR (400 MHz, Methanol-d4) δ 7.76 (brs,1H), 7.30 (m, 2H), 7.14 (s, 3H), 6.87 (s, 1H), 6.79 (s,1H), 6.76 (brs, 1H), 5.57 (d, J =8.8 Hz, 1H), 5.23-5.18(m, 3H), 5.11 (d, J =7.6 Hz, 1H), 4.25-4.21 (m, 1H), 4.15(m, 2H), 4.08-4.03 (m, 3H), 3.88-3.80 (m, 12H), 3.69-3.52(m, 13H), 3.41 (t, J =6 Hz, 2H), 3.03 (t, J =7.2 Hz, 2H),2.94 (m, 1H), 2.50 (m, 2H), 2.11 (m, 2H), 1.93(m, 2H),EI-MS m / z : [M+H]+1193.44, [M / 2+H]+597.49.<Example 17> Preparation of Compound 51Preparation of Compound 46After 1-methylimidazole (5 g, 95.9 mmol) wasdissolved in dichloromethane (40 mL), trichloroacetylchloride (6.79 ml, 95.9 mmol) dissolved indichloromethane (40 mL) was gradually added using adropping funnel at 0°C over 1 hour under a nitrogenatmosphere. The reaction solution was heated to roomtemperature and stirred for 6 hours. Triethylamine (13.3mL, 95.9 mmol) was added at room temperature, and thereaction mixture was stirred for 30 minutes. The reactionmixture was concentrated and recrystallized fromchloroform and hexane, thereby obtaining Compound 46(12.6 g, 96%). 1H-NMR(400 MHz, CDCl3) δ 7.35 (s, 1H),7.16 (s, 1H), 4.06 (s, 3H).Preparation of Compound 47After nitric acid (8 mL, 193.9 mmol) and sulfuricacid (0.35 mL, 6.6 mmol) were added to acetic anhydride(110 mL) at -10°C under a nitrogen atmosphere, Compound46 (12.6 g, 55.3 mmol) was added. After stirring at 0°Cfor 3 hours, the reaction mixture was diluted withchloroform (200 mL), and then saturated aqueous sodiumhydrogen carbonate solution (200 mL) was gradually added.The aqueous layer was extracted with chloroform (100 mL),and the collected organic layers were dried overanhydrous sodium sulfate. After filtration andconcentration, methanol (200 mL) was added, and themixture was stirred at room temperature for 2 hours.Methanol was concentrated, the resultant was diluted withdichloromethane (100 mL), and the produced solid wasfiltered, thereby obtaining Compound 47 (6.3 g, 61%). 1HNMR(400 MHz, CDCl3) δ 7.84 (s, 1H), 4.12 (s, 3H), 3.98 (s,3H).Preparation of Compound 48After methanol (300 mL) was added to Compound 47(6.3 g, 34.1 mmol), di-t-butyl dicarbonate (20 mL, 102.4mmol) and palladium / charcoal (10% w / w, 630 mg) were addedin that order, and the mixture was stirred at roomtemperature for 3 hours under a hydrogen atmosphere. Thereaction mixture was further stirred for 12 hours under anitrogen atmosphere. The reaction mixture was filteredthrough Celite, then concentrated, and purified by columnchromatography, thereby obtaining Compound 48 (7.9 g,91%). 1H-NMR(400 MHz, CDCl3) δ 9.69 (s, 1H), 7.32 (s, 1H),3.88 (s, 3H), 3.78 (s, 3H), 1.46 (s, 9H).Preparation of Compound 49Compound 48 (300 mg, 1.17 mmol) was dissolved indichloromethane (1 mL), then trifluoroacetic acid (1 mL)was added at 0°C under a nitrogen atmosphere, and themixture was stirred for 2 hours. The reaction mixture wasconcentrated under reduced pressure, then diluted withdichloromethane (30 mL), and washed with saturatedaqueous sodium hydrogen carbonate solution (30 mL). Theaqueous layer was extracted with dichloromethane (30 mL),and the collected organic layers were dried overanhydrous sodium sulfate. Filtration and concentrationwere performed, thereby obtaining Compound 49 (160 mg).1H-NMR (400 MHz, CDCl3) δ 6.37 (s, 1H), 3.92 (s, 3H).3.90 (s, 3H), 3.56 (brs, 2H) EI-MS m / z : [M+H]+156.17.Preparation of Compound 50Compound 14 (300 mg, 1.76 mmol) was dissolved inthionyl chloride (3 mL), and then the reaction solutionwas heated at 70°C for 1 hour and concentrated underreduced pressure. After dichloromethane (4 mL) and N,N'-diisopropylethylamine (0.92 mL, 5.29 mmol) were added at-50°C under a nitrogen atmosphere, Compound 49 (329 mg,2.12 mmol) diluted with dichloromethane (4 mL) was addedto the reaction solution. After the temperature wasraised to room temperature, the mixture was stirred for18 hours. Saturated aqueous ammonium chloride solution(15 mL) was added to the reaction mixture, followed byextraction with ethyl acetate (20 mL x 3), and washingwith saturated aqueous sodium hydrogen carbonate solution(20 mL), distilled water (20 mL), and aqueous sodiumchloride solution (20 mL) was performed. Drying overanhydrous sodium sulfate, filtration, concentration, andpurification by column chromatography were performed,thereby obtaining Compound 50 (140 mg, 25%). 1H-NMR (400MHz, CDCl3) δ 8.27 (brs, 1H), 7.61 (s, 1H), 7.53 (s, 1H),7.13 (d, J =1.6 Hz, 1H), 4.11 (s, 6H), 3.95 (s, 3H), EIMSm / z : [M+H]+308.20.Preparation of Compound 51Compound 50 (140 mg, 0.45 mmol) was dissolved inmethanol (2.5 mL), then a solution of lithium hydroxide(25.8 mg, 0.61 mmol) in distilled water (2.5 mL) wasgradually added at room temperature under a nitrogenatmosphere, and the mixture was heated to 70°C andstirred for 1 hour. The reaction mixture was acidifiedwith 1 N aqueous hydrochloric acid (pH of about 4) andconcentrated under reduced pressure, thereby obtainingCompound 51 (133 mg). 1H-NMR (400 MHz, DMSO-d6) δ 11.11(s, 1H), 8.19 (s, 1H), 7.80 (d, J =2 Hz, 1H), 7.64 (s,1H), 3.96 (s, 3H), 3.93 (s, 3H), EI-MS m / z : [M+H]+294.09.<Example 18> Preparation of Compound 53Preparation of Compound 52Compound 51 (133 mg, 0.45 mmol) was dissolved inN,N-dimethylformamide (3 mL), and then N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uroniumhexafluorophosphate (HBTU, 258 mg, 0.68 mmol) and N,N'-diisopropylethylamine (0.16 mL, 0.91 mmol) were added at0°C under a nitrogen atmosphere. After N,N'-dimethyl-1,3-propanediamine (0.11 mL, 0.91 mmol) was added to thereaction solution, the temperature was raised to roomtemperature, and the mixture was stirred for 17 hours.Saturated aqueous ammonium solution (15 mL) was added tothe reaction mixture, followed by extraction with ethylacetate (20 mL x 3), and washing with saturated aqueoussodium hydrogen carbonate solution (20 mL), distilledwater (20 mL), and aqueous sodium chloride solution (20mL) was performed in that order. Drying over anhydroussodium sulfate, filtration, concentration, andpurification by column chromatography were performed,thereby obtaining Compound 52 (70 mg, 40%). 1H-NMR(400MHz, DMSO-d6) δ10.78(s, 1H), 8.19(s, 1H), 8.02(t,J =6.4 Hz,1H), 7.75 (d, J =0.8 Hz, 1H), 7.51 (s, 1H), 3.95 (s, 3H),3.93 (s, 3H), 3.25 (m, 2H), 2.24 (m, 2H), 2.21 (m, 6H),1.62 (m, 2H), EI-MS m / z : [M+H]+378.30.Preparation of Compound 53Compound 52 (70 mg, 0.18 mmol) was dissolved inmethanol (3 mL), and then palladium / charcoal (10% w / w, 35mg) was added at room temperature. The reaction solutionwas stirred at room temperature for 2 hours under ahydrogen atmosphere. The reaction mixture was filteredthrough Celite and then concentrated under reducedpressure, thereby obtaining Compound 53 (58 mg). EI-MSm / z : [M+H]+348.34, [M / 2+H]+174.75.<Example 19> Preparation of Compound 54Compound 54 was synthesized from Compound 10 andCompound 53 in a similar manner to the synthesis ofCompound 23. 1H-NMR (400 MHz, Methanol-d4) δ 7.76 (brs,1H), 7.40 (brs, 1H), 7.29-7.26 (m, 2H), 7.15 (m, 2H),6.79 (m, 2H), 5.58 (d, J =10 Hz, 1H), 5.25 (d, J =12 Hz,1H), 5.17-5.12 (m, 4H), 4.24-4.15 (m, 4H), 4.11 (d, J=9.2 Hz, 2H), 4.09-3.99 (m, 6H), 3.87-3.80 (m, 11H),3.69-3.55 (m, 17H), 3.46 (t, J =6.4 Hz, 2H), 3.21 (m, 3H),2.92 (m, 10H), 2.67-2.62 (m, 2H), 2.52 (m, 2H), 2.12 (m,2H), 2.00 (m, 2H), EI-MS m / z : [M+H]+1208.43,[M / 2+H]+605.08.<Example 20> Preparation of Compound 56Preparation of Compound 55Compound 51 (156 mg, 0.53 mmol) was dissolved inN,N-dimethylformamide (3 mL), and then N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uroniumhexafluorophosphate (HBTU, 303 mg, 0.79 mmol) and N,N'-diisopropylethylamine (0.28 mL, 1.59 mmol) were added at0°C under a nitrogen atmosphere. After 3-amino-1-propanol(0.12 mL, 1.59 mmol) was added to the reaction solution,the temperature was raised to room temperature, and themixture was stirred for 18 hours. Saturated aqueousammonium chloride solution (15 mL) was added to thereaction mixture, followed by extraction with chloroform(20 mL x 3), and washing with saturated aqueous sodiumhydrogen carbonate solution (20 mL), distilled water (20mL), and aqueous sodium chloride solution (20 mL) wasperformed in that order. Drying over anhydrous sodiumsulfate, filtration, concentration, and purification bycolumn chromatography were performed, thereby obtainingCompound 55 (115 mg, 61%). 1H-NMR(400 MHz, DMSO-d6) δ10.79 (s, 1H), 8.17 (s, 1H), 7.92 (t, J =6 Hz, 1H), 7.74(d, J =1.2 Hz, 1H), 7.50 (s, 1H), 4.54 (brs, 1H), 3.93 (s,3H), 3.92 (s, 3H), 3.46 (m, 2H), 3.27 (m, 2H), 1.62 (m,2H), EI-MS m / z : [M+H]+351.26.Preparation of Compound 56Compound 55 (115 mg, 0.32 mmol) was dissolved inmethanol (5 mL), and palladium / charcoal (10% w / w, 50 mg)was added at room temperature. The reaction solution wasstirred at room temperature for 4 hours under a hydrogenatmosphere. The reaction mixture was filtered throughCelite and then concentrated under reduced pressure,thereby obtaining Compound 56 (100 mg). 1H-NMR(400 MHz,DMSO-d6) δ 9.92 (s, 1H), 7.91 (t, J =6 Hz, 1H), 7.42 (s,1H), 6.47 (d, J =1.6 Hz, 1H), 6.28 (d, J =2 Hz, 1H), 4.52(brs, 1H), 3.90 (s, 3H), 3.78 (brs, 2H), 3.71 (s, 3H),3.44 (m, 2H), 3.27 (m, 2H), 1.66 (m, 2H), EI-MS m / z :[M+H]+321.29.<Example 21> Preparation of Compound 57Compound 57 was synthesized from Compound 10 andCompound 56 in a similar manner to the synthesis ofCompound 23. 1H-NMR (400 MHz, Methanol-d4) δ 7.76 (brs,1H), 7.38 (s, 1H), 7.29-7.26 (m, 2H), 7.16 (d, J =10 Hz,2H), 6.81 (brs, 1H), 6.75 (brs, 1H), 5.58 (m, 1H), 5.27(d, J =11.6 Hz, 1H), 5.15 (m, 3H), 4.24-4.09 (m, 4H),4.09 (s, 1H), 4.00 (m, 4H), 3.87-3.79 (m, 9H), 3.68-3.55(m, 14H), 3.44 (t, J =6.8 Hz, 2H), 2.98 (m, 1H), 2.63 (m,1H), 2.50 (m, 2H), 2.11 (m, 2H), 1.80 (m, 2H), EI-MS m / z :[M+H]+1181.44, [M / 2+H]+591.51.<Example 22> Preparation of Compound 60Preparation of Compound 58After tetrahydrofuran (150 mL) was added to Compound48 (7.9 g, 31.2 mmol), sodium hydroxide (12.5 g, 312 mmol)dissolved in distilled water (150 mL) was added at 0°Cunder a nitrogen atmosphere, and the mixture was stirredat room temperature for 12 hours. After the reactionsolvent was concentrated, the reaction mixture wasacidified (pH of about 2) with 6 N aqueous hydrochloricacid solution, followed by extraction with ethyl acetate(2 x 500 mL). The collected organic layers were driedover anhydrous sodium sulfate, then filtered andconcentrated. Acetone (100 mL) was added, followed bystirring, and the produced solid was filtered, therebyobtaining Compound 58 (5.6 g, 74%). 1H-NMR(400 MHz, CDCl3)δ 9.63 (s, 1H), 7.25 (s, 1H), 3.86 (s, 3H), 1.46 (s, 9H).Preparation of Compound 59Compound 58 (686 mg, 2.84 mmol) and Compound 15 (570mg, 3.69 mmol) were dissolved in N,N-dimethylformamide (9mL), and then N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 1.61 g, 4.26 mmol)and N,N'-diisopropylethylamine (0.99 mL, 5.68 mmol) weregradually added at 0°C under a nitrogen atmosphere. Afterthe reaction temperature was raised to room temperature,the mixture was stirred for 3 hours. Saturated aqueousammonium chloride solution (10 mL) was added to thereaction mixture, followed by extraction with ethylacetate (20 mL x 3), and the collected organic layerswere washed with saturated sodium hydrogen carbonatesolution (10 mL) and distilled water (10 mL) and thendried over anhydrous sodium sulfate. After filtration andconcentration, the product was purified by columnchromatography, thereby obtaining Compound 59 (1.0 g,93%). 1H-NMR(400 MHz, CDCl3) δ 8.77 (brs, 1H), 7.41 (d, J=1.6 Hz, 1H), 7.14 (brs, 1H), 6.90 (brs, 1H), 6.78 (brs,1H), 4.04 (s, 3H), 3.91 (s, 3H), 3.81 (s, 3H), 1.51 (s,9H), EI-MS m / z : [M+H]+378.16.Preparation of Compound 60Compound 59 (260 mg, 0.68 mmol) was dissolved indichloromethane (4.8 mL), and then hydrochloric acid (4 Min 1,4-dioxane, 2.4 mL, 9.63 mmol) was gradually added at0°C under a nitrogen atmosphere. After the temperaturewas raised to room temperature, the mixture was stirredfor 24 hours, and the reaction mixture was basified (pHof about 12) with saturated aqueous sodium carbonatesolution. This solution was subjected to extraction withdichloromethane (20 mL x 3), followed by drying overanhydrous sodium sulfate. After filtration andconcentration, the product was purified by columnchromatography, thereby obtaining Compound 60 (70 mg,36%). 1H-NMR(400 MHz, CDCl3) δ 8.11 (s, 1H), 7.40 (d, J=1.6 Hz, 1H), 6.78 (d, J =2 Hz, 1H), 6.31 (s, 1H), 3.99(s, 3H), 3.90 (s, 3H), 3.80 (s, 3H), EI-MS m / z :[M+H]+278.23.<Example 23> Preparation of Compound 61Compound 61 was synthesized from Compound 10 andCompound 60 in a similar manner to the synthesis ofCompound 23. 1H-NMR (400 MHz, DMSO-d6) δ 10.22 (brs, 1H),10.07 (brs, 1H), 8.28 (brs, 1H), 7.74 (brs, 1H), 7.50 (s,1H), 7.45 (s, 1H), 7.37 (m, 1H), 7.23 (m, 1H), 7.04 (s,1H), 6.98 (s, 1H), 6.71 (brs, 1H), 5.35 (m, 1H), 5.19-5.13 (m, 4H), 4.84 (m, 1H), 4.10-3.73 (m, 18H), 3.62 (brs,3H), 3.54-3.51 (m, 6H), 2.00 (m, 1H), EI-MS m / z :[M+H]+1138.36, [M / 2+H]+569.85.<Example 24> Preparation of Compound 64Preparation of Compound 62Compound 59 (200 mg, 0.52 mmol) was dissolved inmethanol (3 mL), then a solution of lithium hydroxide(63.5 mg, 1.58 mmol) in distilled water (3 mL) wasgradually added at room temperature under a nitrogenatmosphere, and the mixture was heated to 80°C andstirred for 1 hour. The reaction mixture was diluted withethyl acetate (20 mL) and then acidified with 1 N aqueoushydrochloric acid (pH of about 4), followed by extractionwith ethyl acetate (20 mL x 3). The collected organiclayers were dried over anhydrous sodium sulfate, filteredand concentrated under reduced pressure, therebyobtaining Compound 62 (166 mg). 1H-NMR (400 MHz, DMSO-d6)δ 10.06 (brs, 1H), 9.34 (br s, 1H), 7.43 (s, 1H), 7.20(br s, 1H), 6.91 (br s, 1H), 3.92 (s, 3H), 3.82 (s, 3H),1.45 (s, 9H), EI-MS m / z : [M+H]+364.28.Preparation of Compound 63Compound 62 (166 mg, 0.45 mmol) was dissolved inN,N-dimethylformamide (5 mL), and then N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uroniumhexafluorophosphate (HBTU, 259 mg, 0.68 mmol) and N,N'-diisopropylethylamine (0.16 mL, 0.91 mmol) were added at0°C under a nitrogen atmosphere. After N,N'-dimethyl-1,3-propanediamine (0.11 mL, 0.91 mmol) was added to thereaction solution, the temperature was raised to roomtemperature, and the mixture was stirred for 18 hours.The reaction mixture was diluted with saturated aqueousammonium chloride solution (15 mL), followed byextraction with ethyl acetate (20 mL x 3), and thecollected organic layers were washed with saturatedaqueous sodium hydrogen carbonate solution (20 mL),distilled water (20 mL), and aqueous sodium chloridesolution (20 mL) in that order. Drying over anhydroussodium sulfate, filtration, concentration, andpurification by column chromatography were performed,thereby obtaining Compound 63 (188 mg, 92%). 1H-NMR(400MHz, CDCl3) δ 8.72 (s, 1H), 7.73 (br s, 1H), 7.19 (d, J=1.2 Hz, 1H), 7.13 (br s, 1H), 6.85 (br s, 1H), 6.43 (d,J =1.6 Hz, 1H), 4.04 (s, 3H), 3.92 (s, 3H), 3.46 (m, 2H),2.46 (t, J =5.6 Hz, 2H), 1.71 (m, 2H), EI-MS m / z :[M+H]+448.27, [M / 2+H]+224.93.Preparation of Compound 64Compound 63 (188 mg, 0.42 mmol) was diluted withdichloromethane (3.2 mL), then trifluoroacetic acid (1.6mL) was added at 0°C under a nitrogen atmosphere, and themixture was stirred for 3 hours. The reaction mixture wasconcentrated under nitrogen gas, thereby obtainingCompound 64 (145 mg). 1H-NMR (400 MHz, DMSO-d6) δ 10.32(s, 1H), 9.29 (br s, 1H), 8.18 (t, J =5.2 Hz, 1H), 7.23(s, 2H), 7.03 (s, 1H), 3.96 (s, 3H), 3.81 (s, 3H), 3.24(m, 2H), 3.06 (m, 2H), 2.79 (m, 6H), 1.83 (m, 2H), EI-MSm / z : [M+H]+348.34, [M / 2+H]+174.75.<Example 25> Preparation of Compound 65Compound 65 was synthesized from Compound 10 andCompound 64 in a similar manner to the synthesis ofCompound 23. 1H-NMR (400 MHz, Methanol-d4) δ 7.77 (br s,1H), 7.40 (s, 1H), 7.35-7.28 (m, 2H), 7.24 (s, 1H), 7.14(s, 1H), 6.92 (s, 1H), 6.70 (s, 1H), 5.56 (d, J =9.6 Hz,1H), 5.30 (d, J =9.6 Hz, 1H), 5.17 (m, 3H), 4.80 (d, J=11.6 Hz, 1H), 4.25-4.01 (m, 6H), 4.03-3.95 (m, 5H), 3.89(s, 3H), 3.83 (s, 3H), 3.74 (m, 2H), 3.67-3.54 (m, 14H),3.41 (t, J =6 Hz, 2H), 3.16 (t, J =7.6 Hz, 2H), 2.66 (m,1H), 2.53 (m, 2H), 2.11 (m, 2H), 1.99 (m, 2H), EI-MS m / z :[M+H]+1208.51, [M / 2+H]+605.05.<Example 26> Preparation of Compound 67Preparation of Compound 66Compound 62 (240 mg, 0.66 mmol) was dissolved inN,N-dimethylformamide (3 mL), and then N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uroniumhexafluorophosphate (HBTU, 376 mg, 0.99 mmol) and N,N'-diisopropylethylamine (0.34 mL, 1.98 mmol) were added at0°C under a nitrogen atmosphere. After 3-amino-1-propanol(0.15 mL, 1.98 mmol) was added to the reaction solution,the temperature was raised to room temperature, and themixture was stirred for 18 hours. The reaction mixturewas diluted with saturated aqueous ammonium chloridesolution (15 mL), followed by extraction with ethylacetate (20 mL x 3), and the collected organic layerswere washed with saturated aqueous sodium hydrogencarbonate solution (20 mL), distilled water (20 mL), andaqueous sodium chloride solution (20 mL) in that order.Drying over anhydrous sodium sulfate, filtration,concentration, and purification by column chromatographywere performed, thereby obtaining Compound 66 (242 mg,87%). 1H-NMR(400 MHz, CDCl3) δ 8.80 (br s, 1H), 7.14 (brs, 2H), 7.06 (br s, 1H), 6.56 (s, 1H), 6.27 (br s, 1H),4.03 (s, 3H), 3.89 (s, 3H), 3.69 (m, 2H), 3.53 (m, 2H),3.26 (br s, 1H), 1.51 (s, 9H), EI-MS m / z : [M+H]+421.33.Preparation of Compound 67Compound 66 (100 mg, 0.23 mmol) was diluted withdichloromethane (1 mL), then trifluoroacetic acid (1 mL)and distilled water (0.2 mL) were added at 0°C under anitrogen atmosphere, and the mixture was stirred for 1hour. The reaction mixture was basified with sodiumcarbonate (pH of about 8) and subjected to extractionwith dichloromethane (20 mL x 3). The collected organiclayers were dried over anhydrous sodium sulfate, filteredand concentrated, thereby obtaining Compound 67 (46 mg).1H-NMR (400 MHz, DMSO-d6) δ 9.90 (s, 1H), 7.95 (t, J =5.6Hz, 1H), 7.16 (s, 1H), 6.90 (s, 1H), 6.37 (s, 1H), 4.47(m, 1H), 4.38 (br s, 2H), 3.83 (s, 3H), 3.76 (s, 3H),3.36 (m, 2H), 3.21 (m, 2H), 1.60 (m, 2H), EI-MS m / z :[M+H]+321.30, [M / 2+H]+159.08.<Example 27> Preparation of Compound 68Compound 68 was synthesized from Compound 10 andCompound 67 in a similar manner to the synthesis ofCompound 23. EI-MS m / z : [M+H]+1181.37, [M / 2+H]+591.49.<Example 28> Preparation of Compound 75Preparation of Compound 69After ethyl 2-aminothiazole-4-carboxylate (1.0 g,5.81 mmol) was dissolved in dichloromethane (7 mL), 4-dimethylaminopyridine (14.0 mg, 0.12 mmol) and di-t-butyldicarbonate (1.76 mL, 7.55 mmol) were added under anitrogen atmosphere, and the mixture was stirred at roomtemperature for 18 hours. The reaction mixture wasdiluted with dichloromethane (50 mL), washed withdistilled water (50 mL) and brine (50 mL), and dried overanhydrous sodium sulfate. The collected organic layerswere dried over anhydrous sodium sulfate, filtered andconcentrated, thereby obtaining Compound 69 (1.7 g,crude). EI-MS m / z : [M+H]+273.21.2, [M+H]+545.17.Preparation of Compound 70Compound 69 (1.7 g, 5.81 mmol) was dissolved intetrahydrofuran (6 mL) and methanol (6 mL), then asolution of lithium hydroxide (697 mg, 17.3 mmol) indistilled water (1 mL) was added under a nitrogenatmosphere, and the mixture was stirred for 3 hours. Theorganic solvent was concentrated under reduced pressure,then the resultant was diluted with distilled water (50mL) and adjusted to have a pH of about 4 with 6 N aqueoushydrochloric acid solution, and the produced solid wasfiltered, thereby obtaining Compound 70 (1.4 g, 99%). 1HNMR(400 MHz, DMSO-d6) δ 12.80 (br s, 1H), 11.70 (s, 1H),7.91 (s, 1H), 1.48 (s, 9H).Preparation of Compound 71Compound 70 (700 mg, 2.87 mmol) was dissolved indichloromethane (20 mL), then 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (668 mg, 4.30 mmol) and1-hydroxybenzotriazole (581 mg, 4.30 mmol) were addedunder a nitrogen atmosphere, and the mixture was stirredat room temperature for 1 hour. After triethylamine (0.59mL, 4.30 mmol) and 3-amino-1-propanol (0.65 mL, 8.60 mmol)were added to the reaction solution, the mixture wasstirred at room temperature for 18 hours. The reactionmixture was washed with saturated aqueous sodium hydrogencarbonate solution (20 mL) and brine (20 mL). Thecollected organic layers were dried over anhydrous sodiumsulfate, then filtered, concentrated, and purified bycolumn chromatography, thereby obtaining Compound 71 (520mg, 60%). 1H-NMR(400 MHz, DMSO-d6) δ 11.59 (s, 1H), 7.75(t, J = 6 Hz, 1H), 7.69 (s, 1H), 4.52 (s, 1H), 3.45 (s,2H), 3.30 (s, 2H), 1.64 (m, 2H), 1.48 (s, 9H).Preparation of Compound 72Compound 71 (260.0 mg, 0.86 mmol) was diluted withdichloromethane (12 mL), then trifluoroacetic acid (3 mL)was added under a nitrogen atmosphere, and the mixturewas stirred at room temperature for 2 hours. Afteraddition of distilled water (10 mL), the reaction mixturewas adjusted to have a pH of about 11 with 2 N aqueoussodium hydroxide solution, followed by extraction withdichloromethane (10 mL x 5). The collected organic layerswere dried over anhydrous sodium sulfate, filtered andconcentrated, thereby obtaining Compound 72 (170 mg, 98%).EI-MS m / z : [M+H]+202.19.Preparation of Compound 73Compound 72 (490 mg, 0.86 mmol) was dissolved inN,N-dimethylformamide (6 mL), then imidazole (250 mg,3.66 mmol) and t-butyldimethylsilyl chloride (440 mg,2.93 mmol) were added at 0°C under a nitrogen atmosphere,and the mixture was stirred at room temperature for 2hours. After addition of ethyl acetate (20 mL), thereaction mixture was washed with aqueous sodium hydroxidesolution (20 mL) having a pH of about 11. The collectedorganic layers were dried over anhydrous sodium sulfate,then filtered, concentrated, and purified by columnchromatography, thereby obtaining Compound 73 (430 mg,80%). 1H-NMR(400 MHz, CDCl3) δ 7.42 (s, 1H), 7.33 (s, 1H),4.91 (s, 2H), 3.75 (t, J = 5.6 Hz, 2H), 3.50 (q, J = 6.4Hz, 2H), 1.80 (m, 2H), 0.91 (s, 9H), 0.08 (s, 6H).Preparation of Compound 74Compound 73 (210.0 mg, 1.24 mmol) was dissolved inthionyl chloride (6 mL) and heated under reflux for 2hours. The reaction solution was concentrated underreduced pressure, dissolved again in dichloromethane, andthen concentrated under reduced pressure several times.The produced compound was dissolved in N,Ndimethylformamide(2 mL), then N,N'-diisopropylethylamine(1.0 mL, 6.20 mmol) and Compound 14 (430 mg, 1.36 mmol)were sequentially added at 0°C under a nitrogenatmosphere, and the mixture was heated at 100°C for 3hours. After addition of ethyl acetate (20 mL), thereaction mixture was washed with distilled water (20 mL).The collected organic layers were dried over anhydroussodium sulfate, then filtered, concentrated, and purifiedby column chromatography, thereby obtaining Compound 74(130 mg, 23%). 1H-NMR(400 MHz, CDCl3) δ 9.05 (s, 1H) 7.79(s, 1H), 7.70 (s, 1H), 7.55 (s, 1H), 7.36 (s, 1H), 4.09(s, 3H), 3.79 (t, J = 5.6 Hz, 2H), 3.57 (m, 2H), 1.83 (m,2H), 0.95 (s, 9H), 0.13 (s, 6H).Preparation of Compound 75Compound 74 (130 mg, 0.27 mmol) was dissolved inmethanol (3 mL) and ethyl acetate (3 mL), and thenpalladium / charcoal (10% w / w, 60 mg) was added. Thereaction solution was stirred at room temperature for 18hours under a hydrogen atmosphere. The reaction mixturewas filtered through Celite and then concentrated,thereby obtaining Compound 75 (115 mg, 97%). EI-MS m / z :[M+H]+438.37.<Example 29> Preparation of Compound 76Compound 76 was synthesized from Compound 10 andCompound 75 in a similar manner to the synthesis ofCompound 29. EI-MS m / z : [M+H]+1184.49, [M / 2+H]+592.85.<Example 30> Preparation of Compound 84Preparation of Compound 77Compound 13 (5.5 g, 29.8 mmol) was dissolved inmethanol (100 mL) and ethyl acetate (100 mL), and thenpalladium / charcoal (10% w / w, 1.1 g) was added at 0°Cunder a nitrogen atmosphere. After sodium borohydride(NaBH4, 3.4 g, 89.6 mmol) was added to distilled water(100 mL), then this solution was gradually added to thereaction solution using a dropping funnel, and themixture was stirred at room temperature for 3 hours. Thereaction mixture was filtered through Celite, followed bydilution with dichloromethane (100 mL), washing withdistilled water (100 mL), and drying over anhydroussodium sulfate. Filtration, concentration and dilutionwith dichloromethane (450 mL) were performed. To thissolution, di-t-butyl dicarbonate (9.4 g, 43.1 mmol)dissolved in dichloromethane (300 mL) was added. Thereaction solution was heated under reflux and stirred for18 hours. The reaction mixture was washed with distilledwater (300 mL) and dried over anhydrous sodium sulfate.Filtration, concentration, and purification by columnchromatography were performed, thereby obtaining Compound77 (6.0 g, 80%). 1H-NMR(400 MHz, CDCl3) δ 7.08 (s, 1H), δ6.60 (s, 1H), δ 6.21 (s, 1H), 3.86 (s, 3H), 3.79 (s, 3H),1.49 (s, 9H).Preparation of Compound 78Compound 77 (3.7 g, 14.51 mmol) was diluted with1,4-dioxane (30 mL), and then sodium hydroxide (1.1 g,29.0 mmol) dissolved in distilled water (15 mL) was addedat 0°C under a nitrogen atmosphere. The solution wasstirred for 3 hours while being heated at 70°C. After thereaction solvent was concentrated, the pH was adjusted toabout 2 with 6 N aqueous hydrochloric acid solution,followed by dilution with ethyl acetate (100 mL), washingwith distilled water (50 mL), and drying over anhydroussodium sulfate. Filtration and concentration wereperformed, thereby obtaining Compound 78 (3.4 g, 97%).1H-NMR (400 MHz, CDCl3) δ 7.18 (s, 1H), δ 6.72 (s, 1H), δ6.28 (s, 1H), 3.86 (s, 3H), 1.50 (s, 9H).Preparation of Compound 79After 2-chloro-5-nitrobenzaldehyde (3.7 g, 19.9 mmol)was dissolved in N,N-dimethylformamide (40 mL), methylmercaptoacetate (1.82 mL, 19.9 mmol) and potassiumcarbonate (3.3 g, 24 mmol) were added, and the mixturewas stirred at room temperature for 18 hours. Distilledwater (50 mL) was added to the reaction mixture, and theproduced solid was filtered, thereby obtaining Compound79 (4.65 g, 95%). 1H-NMR(400 MHz, DMSO-d6) δ 9.00 (d, J =1.6 Hz, 1H), 8.45 (s, 1H), 8.38-8.30 (m, 2H), 3.93 (s,3H).Preparation of Compound 80Compound 79 (1.6 g, 6.74 mmol) was dissolved inmethanol (50 mL), and then palladium / charcoal (10% w / w,312 mg) was added. The reaction solution was stirred atroom temperature for 1.5 hours under a hydrogenatmosphere. The reaction mixture was filtered throughCelite and then concentrated, thereby obtaining Compound80 (1.23 g, 81%). 1H-NMR (400 MHz, DMSO-d6) δ 7.92 (s,1H), 7.65 (d, J = 8.8 Hz, 1H), 7.04 (s, 1H), 6.88 (d, J =8.8 Hz, 1H), 5.28 (s, 2H), 3.84 (s, 3H).Preparation of Compound 81Compound 78 (564 mg, 2.35 mmol) and Compound 80 (444mg, 2.14 mmol) were dissolved in N,N-dimethylformamide(20 mL), then 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (821 mg, 4.28 mmol) and4-dimethylaminopyridine (645 mg, 5.35 mmol) were added at0°C under a nitrogen atmosphere, and the mixture wasstirred at room temperature for 16 hours. After additionof ethyl acetate (30 mL), the reaction mixture was washedwith saturated aqueous ammonium chloride solution (30 mL),saturated aqueous sodium hydrogen carbonate solution (30mL) and distilled water (30 mL) in that order. Thecollected organic layers were dried over anhydrous sodiumsulfate, filtered and then concentrated.Recrystallization from diethyl ether and hexane wasperformed, thereby obtaining Compound 81 (770 mg, 84%).1H-NMR(400 MHz, DMSO-d6) δ 9.99 (s, 1H), 9.15 (s, 1H),8.96 (d, J = 1.6 Hz, 1H), 8.18 (s, 1H), 7.98-7.96 (m, 1H),7.80-7.78 (m, 1H), 6.98 (d, J = 7.6 Hz, 2H), 3.88 (s, 3H),3.81 (s, 3H), 1.46 (s, 9H). EI-MS m / z : [M+H]+430.1.Preparation of Compound 82Compound 81 (270 mg, 0.627 mmol) was dissolved inmethanol (10 mL), and then a solution of sodium hydroxide(250 mg, 6.26 mmol) in distilled water (10 mL) wasgradually added under a nitrogen atmosphere. The mixturewas stirred for 4 hours under reflux. The reactionmixture was adjusted to have a pH of about 3 with 1 Naqueous hydrochloric acid solution, followed byextraction with dichloromethane, drying over anhydroussodium sulfate, and concentration under reduced pressure,thereby obtaining Compound 82 (227 mg, 87%). 1H-NMR (400MHz, DMSO-d6) δ 9.96 (s, 1H), 9.14 (s, 1H), 8.45 (s, 1H),8.06 (s, 1H), 7.95-7.93 (m, 1H), 7.77-7.75 (m, 1H), 6.98(d, J = 7.6 Hz, 2H), 3.83 (s, 3H), 1.46 (s, 9H).Preparation of Compound 83Compound 82 (227 mg, 0.54 mmol) and 3-(dimethylamino)-1-propylamine (0.75 mL, 0.59 mmol) weredissolved in N,N-dimethylformamide (10 mL), then 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (209 mg, 1.09 mmol)and 4-dimethylaminopyridine (167 mg, 1.36 mmol) wereadded at 0°C under a nitrogen atmosphere, and the mixturewas stirred at room temperature for 16 hours. Afteraddition of ethyl acetate (10 mL), the reaction mixturewas washed with saturated aqueous ammonium chloridesolution (10 mL), saturated aqueous sodium hydrogencarbonate solution (10 mL) and distilled water (10 mL) inthat order. The collected organic layers were dried overanhydrous sodium sulfate, filtered and concentrated,thereby obtaining Compound 83 (280 mg). EI-MS m / z :[M+H]+500.23.Preparation of Compound 84Compound 83 (170 mg, 0.34 mmol) was dissolved indichloromethane (2 mL), hydrochloric acid (4 M 1,4-dioxane solution, 2 mL) was added, and the mixture wasstirred at room temperature for 1 hour. The reactionmixture was concentrated under reduced pressure, therebyobtaining Compound 84 (160 mg). EI-MS m / z : [M+H]+400.3.<Example 31> Preparation of Compound 85Compound 85 was synthesized from Compound 10 andCompound 84 in a similar manner to the synthesis ofCompound 23. EI-MS m / z : [M+H]+ 1260.41, [M / 2+H]+ 631.1.<Example 32> Preparation of Compound 87Preparation of Compound 86Compound 82 (253 mg, 0.609 mmol) and 3-amino-1-propanol (0.07 mL, 0.913 mmol) were dissolved in N,Ndimethylformamide(5 mL), then 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (233 mg, 1.21 mmol) and4-dimethylaminopyridine (186 mg, 1.52 mmol) were added at0°C under a nitrogen atmosphere, and the mixture wasstirred at room temperature for 16 hours. After additionof ethyl acetate (10 mL), the reaction mixture was washedwith saturated aqueous ammonium chloride solution (10 mL),saturated aqueous sodium hydrogen carbonate solution (10mL) and distilled water (10 mL) in that order. Thecollected organic layers were dried over anhydrous sodiumsulfate, filtered, and diluted with dichloromethane (10mL) and diethyl ether (20 mL), and then the producedsolid was filtered, thereby obtaining Compound 86 (123 mg,43%). 1H-NMR(400 MHz, DMSO-d6) δ 9.92(s, 1H), 9.14 (s,1H), 8.68 (t, J = 5.6 Hz, 1H), 8.32 (s, 1H), 7.98-7.89 (m,2H), 7.75-7.73 (m, 1H), 6.96 (s, 1H), 4.49 (t, J = 5.2 Hz,1H) 3.82 (s, 3H), 3.60-3.45 (m, 2H), 3.35-3.30 (m, 2H),1.73-1.66 (m, 2H), 1.46 (s, 9H).Preparation of Compound 87Compound 86 (123 mg, 0.26 mmol) was dissolved indichloromethane (2 mL), hydrochloric acid (4 M 1,4-dioxane solution, 2 mL) was added, and the mixture wasstirred at room temperature for 3 hours, followed byconcentration under reduced pressure, washing with ethylacetate (10 mL) and aqueous sodium carbonate solution (10mL), and concentration to dryness over anhydrous sodiumsulfate, thereby obtaining Compound 87 (97 mg). 1HNMR(400 MHz, DMSO-d6) δ 9.92(s, 1H), 9.14 (s, 1H), 8.79(br,2H), 8.68 (t, J = 5.6 Hz, 1H), 8.32 (s, 1H), 7.98-7.89 (m,2H), 7.75-7.73 (m, 1H), 6.96 (s, 1H), 4.49 (t, J = 5.2 Hz,1H) 3.82 (s, 3H), 3.60-3.45 (m, 2H), 3.35-3.30 (m, 2H),1.73-1.66 (m, 2H), 1.46 (s, 9H).<Example 33> Preparation of Compound 88Compound 88 was synthesized from Compound 10 andCompound 87 in a similar manner to the synthesis ofCompound 23. EI-MS m / z : [M+H]+1234.41, [M / 2+H]+617.56.<Example 34> Preparation of Compound 93Preparation of Compound 89To Compound 14 (300 mg, 1.72 mmol) was added thionylchloride (2 mL), and the mixture was stirred for 30minutes under reflux. The reaction solution wasconcentrated under reduced pressure, dried, and dissolvedin dichloromethane (8 mL), and this solution was added toa solution of 3-(dimethylamino)-1-propylamine (466 mg,5.29 mmol) and triethylamine (0.74 mL, 5.29 mmol) indichloromethane (5 mL) at -50°C under a nitrogenatmosphere. The mixture was stirred for 2 hours while thereaction temperature was gradually raised to 0°C. Thereaction mixture was diluted with dichloromethane (30 mL),washed with distilled water (20 mL), and dried overanhydrous sodium sulfate. Filtration and concentrationwere performed, thereby obtaining Compound 89 (396 mg,94%). 1H-NMR(400 MHz, DMSO-d6) δ 8.40 (t, 1H), 8.11 (d,1H), 7.40 (d, 1H), 3.90 (s, 3H), 3.20 (m, 2H), 2.23 (t,2H), 1.61 (m, 2H).Preparation of Compound 90Compound 89 (150 mg, 0.59 mmol) was dissolved inmethanol (6 mL), and then palladium / charcoal (10% w / w, 80mg) was added. The reaction solution was stirred at roomtemperature for 2 hours under a hydrogen atmosphere. Thereaction mixture was filtered through Celite and thenconcentrated, thereby obtaining Compound 90 (132 mg,100%).Preparation of Compound 91After methanol (5.5 mL) was added to Compound 79(300 mg, 1.26 mmol), 1 M aqueous sodium hydroxidesolution (5 mL)) was added at 0°C under a nitrogenatmosphere, and the mixture was heated under reflux for 3hours. After concentration of methanol, the pH wasadjusted to about 2 with 1 N aqueous hydrochloric acidsolution, and the produced solid was filtered, therebyobtaining Compound 91 (248 mg, 88%). 1H-NMR(400 MHz,DMSO-d6) δ 8.98 (d, J = 1.6 Hz, 1H), 8.35-8.28 (m, 3H).Preparation of Compound 92After thionyl chloride (3 mL) was added to Compound91 (166 mg, 0.744 mmol), the mixture was stirred at 70°Cfor 1 hour and concentrated under reduced pressure. Afterdichloromethane (5 mL) was added and dissolved,triethylamine (0.3 mL, 2.23 mmol) and Compound 90 (217 mg,0.967 mmol) were added at 0° under a nitrogen atmosphere,and the mixture was stirred at room temperature for 3hours. Concentration under reduced pressure, andpurification by column chromatography were performed,thereby obtaining Compound 92 (189 mg, 60%). 1H-NMR(400MHz, DMSO-d6) δ 10.57(s, 1H), 8.96 (d, J = 1.6 Hz, 1H),8.41 (s, 1H), 8.35-8.32 (m, 1H), 8.28-8.25 (m, 1H), 8.16(t, J = 5.6 Hz, 1H), 7.28 (s, 1H), 6.88 (s, 1H), 3.83 (s,3H), 3.22-3.18 (m, 2H), 2.32-2.26 (m, 2H), 2.16 (s, 6H),1.66-1.59 (m, 2H), 1.24-1.21 (m, 1H). EI-MS m / z :[M+H]+430.2.Preparation of Compound 93Compound 92 (110 mg, 0.25 mmol) was dissolved inmethanol (20 mL), then palladium / charcoal (10% w / w, 110mg) was added, and the mixture was stirred at roomtemperature for 1 hour under a hydrogen atmosphere. Thereaction mixture was filtered through Celite and thenconcentrated under reduced pressure, thereby obtainingCompound 93 (102 mg, 99%). EI-MS m / z : [M+H]+400.2.<Example 35> Preparation of Compound 94Compound 94 was synthesized from Compound 10 andCompound 93 in a similar manner to the synthesis ofCompound 23. EI-MS m / z : [M+H]+1260.61, [M / 2+H]+630.90.<Example 36> Preparation of Compound 99Preparation of Compound 95After thionyl chloride (10 mL) was added to Compound14 (600 mg, 3.526 mmol), the mixture was stirred at 70°Cfor 1 hour and concentrated under reduced pressure. Afterdichloromethane (15 mL) was added and dissolved,triethylamine (1.47 mL, 10.58 mmol) and 3-amino-1-propanol (0.8 mL, 10.6 mmol) were added at 0° under anitrogen atmosphere, and the mixture was stirred at roomtemperature for 1 hour. After addition of dichloromethane(200 mL), the reaction mixture was washed with saturatedaqueous sodium hydrogen carbonate solution (20 mL). Thecollected organic layers were dried over anhydrous sodiumsulfate, filtered and concentrated under reduced pressure,thereby obtaining Compound 95 (527 mg, crude). 1H-NMR(400MHz, CDCl3) δ 7.55 (s, 1H), 7.08 (s, 1H), 6.72 (br, 1H),3.99(s, 3H), 3.78-3.75 (m, 2H), 3.59-3.54 (m, 2H), 3.03-2.98 (m, 1H), 1.88-1.78(m, 2H).Preparation of Compound 96Compound 95 (527 mg, 2.32 mmol) was dissolved indichloromethane (30 mL), t-butyldimethylsilyl chloride(524 mg, 3.48 mmol) and imidazole (315 mg, 4.64 mmol)were added at 0°C, and the mixture was stirred at roomtemperature for 16 hours. The reaction mixture was washedwith saturated aqueous ammonium chloride solution (30 mL),and the organic layer was dried over anhydrous sodiumsulfate. Filtration, concentration under reduced pressure,and purification by column chromatography were performed,thereby obtaining Compound 96 (660 mg, 83%). 1H-NMR(400MHz, CDCl3) δ 7.53 (s, 1H), 7.07 (s, 1H), 6.88 (br, 1H),3.98 (s, 3H), 3.84-3.81 (m, 2H), 3.54-3.50 (m, 2H), 1.84-1.20 (m, 2H), 0.91 (s, 9H), 0.10 (s, 6H).Preparation of Compound 97Compound 96 (400 mg, 1.17 mmol) was dissolved inmethanol (30 mL), then palladium / charcoal (10% w / w, 200mg) was added, and the mixture was stirred at roomtemperature for 1 hour under a hydrogen atmosphere. Thereaction mixture was filtered through Celite and thenconcentrated under reduced pressure, thereby obtainingCompound 97 (293 mg, 76%). 1H-NMR(400 MHz, CDCl3) δ 7.53(s, 1H), 7.07 (s, 1H), 6.88 (br, 1H), 6.66 (br, 2H), 3.98(s, 3H), 3.84-3.81 (m, 2H), 3.54-3.50 (m, 2H), 1.84-1.20(m, 2H), 0.91 (s, 9H), 0.10 (s, 6H).Preparation of Compound 98Compound 91 (100 mg, 0.446 mmol) and Compound 97(145 mg, 0.490 mmol) were dissolved in N,Ndimethylformamide(5 mL), then 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (171 mg, 0.892 mmol) and4-dimethylaminopyridine (136 mg, 1.11 mmol) were added at0°C under a nitrogen atmosphere, and the mixture wasstirred at room temperature for 16 hours. After additionof ethyl acetate (10 mL), the reaction mixture was washedwith saturated aqueous ammonium chloride solution (10 mL),saturated aqueous sodium hydrogen carbonate solution (10mL) and distilled water (10 mL) in that order. Thecollected organic layers were dried over anhydrous sodiumsulfate, filtered, then concentrated, and purified bycolumn chromatography, thereby obtaining Compound 98 (117mg, 51%). 1H-NMR(400 MHz, DMSO-d6) δ 10.85 (2, 1H), 8.96(s, 1H), 8.41 (s, 1H), 8.35-8.31 (m, 1H), 8.28-8.25 (m,1H), 8.05 (t, J = 5.2 Hz, 1H), 7.28 (s, 1H), 6.89 (s, 1H),3.82 (s, 3H), 3.67-3.62 (m, 2H), 3.24-3.21 (m, 2H), 1.73-1.68 (m, 2H), 0.87 (s, 9H), 0.06 (s, 6H).Preparation of Compound 99Compound 98 (117 mg, 0.226 mmol) was dissolved inmethanol (20 mL), then palladium / charcoal (10% w / w, 100mg) was added, and the mixture was stirred at roomtemperature for 16 hours under a hydrogen atmosphere. Thereaction mixture was filtered through Celite and thenconcentrated under reduced pressure, thereby obtainingCompound 99 (110 mg, crude). EI-MS m / z : [M+H]+487.33.<Example 37> Preparation of Compound 100Compound 100 was synthesized from Compound 10 andCompound 99 in a similar manner to the synthesis ofCompound 29. EI-MS m / z : [M+H]+1234.41, [M / 2+H]+617.60.<Example 38> Preparation of Compound 109Preparation of Compound 101In dichloromethane (30 mL) was dissolved 3-amino-1-propanol (1.5 g, 20.0 mmol), t-butyldimethylsilylchloride (3.15 g, 21.0 mmol) and imidazole (2.72 g, 40.0mmol) were added at 0°C, and the mixture was stirred atroom temperature for 16 hours. Concentration underreduced pressure and purification by columnchromatography were performed, thereby obtaining Compound101 (3.65 g, 96%). 1H-NMR (400 MHz, CDCl3) δ 3.71-3.67 (m,2H), 2.81-2.78 (m, 2H), 2.06 (br, 2H), 1.69-1.62 (m, 2H),0.88 (s, 9H), 0.04 (s, 6H).Preparation of Compound 102After 3-(methylamino)-1-propanol (1.2 g, 13.4 mmol)was dissolved in dichloromethane (15 mL), di-t-butyldicarbonate (3.2 g, 14.74 mmol) dissolved indichloromethane (5 mL) was gradually added at 0°C under anitrogen atmosphere. After stirring at room temperaturefor 1 hour, 0.1 N aqueous hydrochloric acid solution (10mL) was added at 0°C. The organic layer was washed withdistilled water (10 mL) and brine (10 mL), dried overanhydrous sodium sulfate, concentrated under reducedpressure, and then purified by column chromatography,thereby obtaining Compound 102 (2.0 g, 78%). 1H-NMR (400MHz, CDCl3) δ 3.54-3.48 (m, 2H), 3.42-3.39 (m, 2H), 2.83(s, 3H), 1.78-1.68 (m, 2H), 1.46 (s, 9H).Preparation of Compound 103Compound 102 (1 g, 5.28 mmol) was dissolved indichloromethane (16 mL), and then triphenylphosphine(2.12 g, 8.08 mmol) was added. At 0°C under a nitrogenatmosphere, carbon tetrabromide (2.6 g, 8.08 mmol)dissolved in dichloromethane (10 mL) was added, and themixture was stirred for 30 minutes, then concentratedunder reduced pressure, and purified by columnchromatography, thereby obtaining Compound 103 (0.6 g,45%). 1H-NMR (400 MHz, CDCl3) δ 3.41-3.33 (m, 4H), 2.87(s, 3H), 2.10-2.06 (m, 2H), 1.46 (s, 9H).Preparation of Compound 104In acetone (20 mL) was dissolved ethyl 4-nitro-1Hpyrrole-2-carboxylate (292 mg, 1.56 mmol), Compound 103(0.6 g, 2.38 mmol) and potassium carbonate (493 mg, 3.57mmol) were added, and the mixture was stirred at 60°C for12 hours under a nitrogen atmosphere. The reactionmixture was concentrated under reduced pressure andsubjected to extraction with dichloromethane (20 mL) anddistilled water (20 mL), and drying over anhydrous sodiumsulfate was performed. Filtration, concentration, andpurification by column chromatography were performed,thereby obtaining Compound 104 (0.53 g, 98%). 1H-NMR (400MHz, CDCl3) δ 7.74 (br s, 1H), 7.52 (s, 1H), 4.37-4.28 (m,4H), 3.42 (s, 2H), 2.86 (s, 3H), 2.06-1.99 (m, 2H), 1.46(s, 9H), 1.38-1.30 (t, J = 7.2 Hz, 3H).Preparation of Compound 105Compound 104 (0.53 g, 1.55 mmol) was dissolved inethanol (10 mL), 1 N aqueous sodium hydroxide solution(10 mL)) was added under a nitrogen atmosphere, and themixture was stirred at 60°C for 2 hours. Afterconcentration of ethanol, the pH was adjusted to about 5with 1 N aqueous hydrochloric acid solution, extractionwith ethyl acetate (20 mL) was performed, and the organiclayer was dried over anhydrous sodium sulfate. Filtrationand concentration were performed, thereby obtainingCompound 105 (493 mg, 96%). 1H-NMR (400 MHz, CDCl3) δ7.80 (br s, 1H), 7.55 (s, 1H), 4.39-4.35 (m, 2H), 3.32 (s,2H), 2.87 (s, 3H), 2.17-2.03 (m, 2H), 1.46 (s, 9H).Preparation of Compound 106Compound 105 (350 mg, 1.07 mmol) and Compound 101(303 mg, 1.6 mmol) were dissolved in N,Ndimethylformamide(10 mL), N,N,N',N'-tetramethyl-O-(1Hbenzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 637mg, 1.60 mmol) and N,N'-diisopropylethylamine (0.55 mL,3.20 mmol) were sequentially added at 0°C under anitrogen atmosphere, and the mixture was stirred at roomtemperature for 12 hours. The reaction mixture wasdiluted with ethyl acetate (20 mL) and washed withdistilled water (20 mL) and brine (20 mL), and theorganic layer was dried over anhydrous sodium sulfate.After filtration and concentration under reduced pressure,the product was purified by column chromatography,thereby obtaining Compound 106 (290 mg, 54%). 1H-NMR (400MHz, CDCl3) δ 7.65 (br s, 1H), 7.01 (s, 1H), 6.89 (br s,1H), 4.37-4.30 (m, 2H), 3.83-3.81 (m, 2H), 3.53-3.49 (m,2H), 3.28-3.26 (m, 2H), 2.84 (s, 3H), 2.07-2.00 (m, 2H),1.83-1.78 (m, 2H), 1.45 (s, 9H), 0.90 (s, 9H), 0.10 (s,6H).Preparation of Compound 107Compound 106 (290 mg, 0.58 mmol) was dissolved inmethanol (30 mL), then palladium / charcoal (10% w / w, 100mg) was added under a hydrogen atmosphere, and themixture was stirred at room temperature for 2 hours. Thereaction mixture was filtered through Celite and thenconcentrated under reduced pressure, thereby obtainingCompound 107 (250 mg, 92%). 1H-NMR (400 MHz, CDCl3) δ6.99 (br s, 1H), 6.83 (br s, 1H), 6.61 (br s, 2H), 4.28-4.24 (m, 2H), 3.71-3.70 (m, 2H), 3.45-3.40 (m, 2H), 3.23-3.19 (m, 2H), 2.84 (s, 3H), 1.97-1.94 (m, 2H), 1.81-1.75(m, 2H), 1.45 (s, 9H), 0.88 (s, 9H), 0.11 (s, 6H).Preparation of Compound 108Compound 14 (76 mg, 0.44 mmol) and Compound 107 (250mg, 0.53 mmol) were dissolved in N,N-dimethylformamide(10 mL), then 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (171 mg, 0.88 mmol) and4-dimethylaminopyridine (136 mg, 1.11 mmol) were added at0°C under a nitrogen atmosphere, and the mixture wasstirred at room temperature for 16 hours. After additionof ethyl acetate (10 mL), the reaction mixture was washedwith saturated aqueous ammonium chloride solution (10 mL),saturated aqueous sodium hydrogen carbonate solution (10mL) and distilled water (10 mL). The collected organiclayers were dried over anhydrous sodium sulfate, filtered,and then purified by column chromatography, therebyobtaining Compound 108 (197 mg, 72%). 1H-NMR (400 MHz,CDCl3) δ 7.60 (s, 1H), 7.19 (br s, 2H), 6.54 (br s, 1H),6.37 (br s, 1H), 4.29 (s, 2H), 4.03 (s, 3H), 3.78-3.75 (m,2H), 3.50-3.46 (m, 2H), 3.26 (s, 2H), 2.84 (s, 3H), 2.04-1.99 (m, 2H), 1.82-1.76 (m, 2H), 1.45 (s, 9H), 0.98 (s,9H), 0.08 (s, 6H). EI-MS m / z : [M+H]+621.80.Preparation of Compound 109Compound 108 (197 mg, 0.317 mmol) was dissolved inmethanol (20 mL), then palladium / charcoal (10% w / w, 80 mg)was added under a hydrogen atmosphere, and the mixturewas stirred at room temperature for 5 hours. The reactionmixture was filtered through Celite and then concentratedunder reduced pressure, thereby obtaining Compound 109(185 mg, 99%). 1H-NMR (400 MHz, CDCl3) δ 7.29 (br s, 1H),7.19 (br s, 1H), 6.54 (br s, 1H), 6.33 (br s, 2H), 6.15(s, 1H), 4.30-4.26 (m, 2H), 3.88 (s, 3H), 3.77-3.74 (m,2H), 3.48-3.44 (m, 2H), 3.29 (s, 2H), 2.84 (s, 3H), 2.05-1.98 (m, 2H), 1.79-1.76 (m, 2H), 1.40 (s, 9H), 0.90 (s,9H), 0.08 (s, 6H).<Example 39> Preparation of Compound 110Compound 110 was synthesized from Compound 10 andCompound 109 in a similar manner to the synthesis ofCompound 29. EI-MS m / z : [M+H]+1238.03, [M / 2+H]+619.81.<Example 40> Preparation of Compound 117Preparation of Compound 111In dichloromethane (20 mL) was dissolved 3-bromo-1-propanol (1.0 g, 7.19 mmol), t-butyldimethylsilylchloride (1.08 g, 7.19 mmol) and imidazole (0.49 g, 7.19mmol) were added at 0°C, and the mixture was stirred atroom temperature for 16 hours. Concentration underreduced pressure and purification by columnchromatography were performed, thereby obtaining Compound111 (1.47 g, 81%). 1H-NMR (400 MHz, CDCl3) δ 3.72 (t, J =5.6 Hz, 2H), 3.51 (t, J = 5.62 Hz, 2H), 2.06-2.00 (m, 2H),0.89 (s, 9H), 0.06 (s, 6H).Preparation of Compound 112In acetone (30 mL) was dissolved ethyl 4-nitro-1Hpyrrole-2-carboxylate (500 mg, 2.71 mmol), Compound 111(1.03 g, 4.07 mmol) and potassium carbonate (1.12 g, 8.14mmol) were added, and the mixture was stirred at 60°C for12 hours under a nitrogen atmosphere. The reactionmixture was concentrated under reduced pressure, dilutedwith dichloromethane (20 mL), and washed with distilledwater (20 mL). The collected organic layers were driedover anhydrous sodium sulfate, filtered, concentrated,and then purified by column chromatography, therebyobtaining Compound 112 (894 mg, 92%). 1H-NMR (400 MHz,CDCl3) δ 7.67 (s, 1H), 7.45 (s, 1H), 4.50-4.47 (m, 2H),4.35-4.29 (m, 2H), 3.59-3.56 (m, 2H), 2.02-1.96 (m, 2H),1.38-1.36 (m, 2H), 0.93 (s, 9H), 0.07 (s, 6H).Preparation of Compound 113Compound 112 (890 mg, 2.49 mmol) was dissolved inethanol (20 mL), 1 M aqueous sodium hydroxide solution(10 mL)) was added under a nitrogen atmosphere, and themixture was stirred at 60°C for 2 hours. Afterconcentration of ethanol, the pH was adjusted to about 2with 1 N aqueous hydrochloric acid solution, extractionwith ethyl acetate (20 mL) was performed, and the organiclayer was concentrated to dryness over anhydrous sodiumsulfate, thereby obtaining Compound 113 (724 mg, 88%).1H-NMR (400 MHz, CDCl3) δ 7.70 (br s, 1H), 7.55 (s, 1H),4.48 (br s, 2H), 3.56 (s, 2H), 1.99 (s, 2H), 0.91 (s, 9H),0.10 (s, 6H).Preparation of Compound 114Compound 113 (548 mg, 1.66 mmol) and Compound 101(537 mg, 2.83 mmol) were dissolved in N,Ndimethylformamide(20 mL), N,N,N',N'-tetramethyl-O-(1Hbenzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 999mg, 2.50 mmol) and N,N'-diisopropylethylamine (0.58 mL,3.30 mmol) were sequentially added at 0°C under anitrogen atmosphere, and the mixture was stirred at roomtemperature for 12 hours. After addition of ethyl acetate(20 mL), the reaction mixture was washed with distilledwater (20 mL) and brine (20 mL), and the organic layerwas dried over anhydrous sodium sulfate. Filtration,concentration under reduced pressure, and purification bycolumn chromatography were performed, thereby obtainingCompound 114 (556 mg, 67%). 1H-NMR (400 MHz, CDCl3) δ7.60 (s, 1H), 7.01 (s, 1H), 6.87 (br s, 1H), 4.49-4.45 (m,2H), 3.83-3.81 (m, 2H), 3.56-3.49 (m, 4H), 2.01-1.98 (m,2H), 1.81-1.76 (m, 2H), 0.91 (s, 18H), 0.10 (s, 6H), 0.05(s, 6H).Preparation of Compound 115Compound 114 (300 mg, 0.60 mmol) was dissolved inmethanol (30 mL), then palladium / charcoal (10% w / w, 100mg) was added under a hydrogen atmosphere, and themixture was stirred at room temperature for 2 hours. Thereaction mixture was filtered through Celite and thenconcentrated under reduced pressure, thereby obtainingCompound 115 (276 mg, 98%). 1H-NMR (400 MHz, CDCl3) δ6.35 (s, 1H), 6.27 (br s, 1H), 6.05 (s, 1H), 4.30-4.27 (m,2H), 3.77-3.74 (m, 2H), 3.58-3.56 (m, 2H), 3.46-3.43 (m,2H), 1.96-1.89 (m, 2H), 1.80-1.76 (m, 2H), 1.72 (br s,2H), 0.91 (s, 18H), 0.08 (s, 6H), 0.05 (s, 6H). EI-MSm / z : [M+H]+470.5.Preparation of Compound 116Compound 14 (83 mg, 0.48 mmol) and Compound 115 (276mg, 0.58 mmol) were dissolved in N,N-dimethylformamide(10 mL), N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 350 mg, 0.73 mmol)and N,N'-diisopropylethylamine (0.20 mL, 0.97 mmol) weresequentially added at 0°C under a nitrogen atmosphere,and the mixture was stirred at room temperature for 12hours. Concentration under reduced pressure andpurification by column chromatography were performed,thereby obtaining Compound 116 (208 mg, 57%). 1H-NMR (400MHz, CDCl3) δ 7.71 (s, 1H), 7.60 (s, 1H), 7.20 (br s, 1H),6.55 (s, 1H), 6.36 (br s, 1H), 4.40-4.36 (m, 2H), 4.02 (s,3H), 3.77-3.74 (m, 2H), 3.61-3.58 (m, 2H), 3.49-3.45 (m,2H), 2.07-1.94 (m, 2H), 1.82-1.80 (m, 2H), 0.91 (s, 18H),0.08 (s, 6H), 0.05 (s, 6H). EI-MS m / z : [M+H]+622.7.Preparation of Compound 117Compound 116 (100 mg, 0.16 mmol) was dissolved inmethanol (20 mL), then palladium / charcoal (10% w / w, 30 mg)was added under a hydrogen atmosphere, and the mixturewas stirred at room temperature for 2 hours. The reactionmixture was filtered through Celite and then concentratedunder reduced pressure, thereby obtaining Compound 117(88 mg, 93%). EI-MS m / z : [M+H]+592.5.<Example 41> Preparation of Compound 118Compound 118 was synthesized from Compound 10 andCompound 117 in a similar manner to the synthesis ofCompound 29. EI-MS m / z : [M+H]+1224.9, [M / 2+H]+623.08.<Example 42> Preparation of Compound 124Preparation of Compound 120Compound 5 (1.84 g, 3.6 mmol) was dissolved indichloromethane (10 mL), then triphosgene (767 mg, 2.59mmol) and N,N'-diisopropylethylamine (1.69 mL, 9.72 mmol)were added at 0°C, and the mixture was stirred for 10minutes. To the reaction solution were added dibutyltindilaurate (227 mg, 0.36 mmol) and N,N'-diisopropylethylamine (1.25 mL, 7.2 mmol), and themixture was stirred for 5 minutes. A solution of Compound119 (16.4 g, 21.0 mmol, Compound 119 was prepared by themethod described in Korean Patent Publication No. 10-2018-0110645) in dichloromethane (5 mL) was added, thenthe temperature was gradually raised, the mixture wasstirred at room temperature for 1.5 hours, and then thereaction mixture was concentrated under reduced pressure.Saturated aqueous ammonium chloride solution (15 mL) wasadded to the reaction mixture, followed by extractionwith ethyl acetate (30 mL x 3), washing with distilledwater (50 mL) and aqueous sodium chloride solution (50mL), and drying over anhydrous sodium sulfate. Afterfiltration and concentration under reduced pressure, theproduct was purified by column chromatography, therebyobtaining Compound 120 (2.84 g, 72%). 1H-NMR(400 MHz,CDCl3) δ 8.93 (br s, 1H), 8.04 (d, J =2.4 Hz, 1H), 7.83(br s, 1H), 7.52-7.44 (m, 2H), 7.05 (d, J =8.8 Hz, 1H),6.81 (s, 1H), 5.93 (m, 1H), 5.41-5.22 (m, 7H), 5.13 (s,2H), 4.97 (br s, 1H), 4.89 (br s, 1H), 4.59 (d, J =5.6 Hz,2H), 4.18 (d, J =8.4 Hz, 2H), 4.12 (m, 3H), 3.80 (s, 3H),3.73 (s, 3H), 3.69 (m, 1H), 3.62-3.53 (m, 4H), 3.41 (s,3H), 2.66 (m, 2H), 2.58 (t, J =7.6 Hz, 2H), 2.19 (m, 2H),2.05-2.04 (m, 9H), 0.87 (s, 9H), 0.02 (br s, 6H), EI-MSm / z : [M+H]+1087.49, [M / 2+H]+544.13.Preparation of Compound 121Compound 120 (2.84 g, 2.6 mmol) was dissolved intetrahydrofuran / distilled water (4 mL / 4 mL), and aceticacid (8 mL) was added at 0°C, and the mixture was stirredat room temperature for 15 hours. After concentrationunder reduced pressure, saturated aqueous sodium hydrogencarbonate solution (50 mL) was added, followed byextraction with ethyl acetate (50 mL x 3). The extractedsolution was washed with distilled water (30 mL) andaqueous sodium chloride solution (30 mL), and dried overanhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 121 (2.34 g, 92%). 1H-NMR(400 MHz, CDCl3) δ 8.37(br s, 1H), 8.06 (s, 1H), 7.74 (br s, 1H), 7.52 (m, 1H),7.44 (dd, J =8.8 Hz, 2 Hz, 1H), 7.05 (d, J =8.4 Hz, 1H),6.81 (s, 1H), 5.93 (m, 1H), 5.42-5.22 (m, 7H), 5.14 (br s,2H), 5.00 (br s, 1H), 4.91 (br s, 1H), 4.59 (m, 3H), 4.18(d, J =8.4 Hz, 2H), 4.13-4.04 (m, 5H), 3.83 (s, 3H),3.72-3.67 (m, 6H), 3.62-3.53 (m, 4H), 3.41 (s, 3H), 2.81(m, 1H), 2.59 (t, J =7.6 Hz, 2H), 2.52 (m, 1H), 2.22 (m,2H), 2.05-2.04 (m, 9H), EI-MS m / z : [M+H]+972.48,[M / 2+H]+486.99.Preparation of Compound 122Compound 121 (2.34 g, 2.4 mmol) was dissolved indichloromethane (24 mL), then Dess-Matin periodinane(1.23 g, 2.9 mmol) was added at 0°C, the temperature wasraised to room temperature, and the mixture was stirredfor 1 hour under a nitrogen atmosphere. The reactionmixture was diluted with saturated aqueous sodiumthiosulfate solution / saturated aqueous sodium hydrogencarbonate solution (v / v=1 / 1, 30 mL) and stirred for 10minutes. After extraction with dichloromethane (30 mL x3), washing with distilled water (30 mL) and brine (30 mL)was performed. The collected organic layers were driedover anhydrous sodium sulfate, filtered, concentrated,and then purified by column chromatography, therebyobtaining Compound 122 (1.75 g, 75%). 1H-NMR(400 MHz,CDCl3) δ 7.99 (br s, 1H), 7.50 (br s, 1H), 7.23-7.19 (m,2H), 7.01 (d, J =7.2 Hz, 1H), 6.60 (s, 1H), 5.92 (m, 1H),5.59 (m, 1H), 5.43-5.22 (m, 7H), 5.14 (m, 2H), 4.89 (d, J=11.6 Hz, 1H), 4.59 (d, J =5.6 Hz, 2H), 4.30-4.23 (m, 2H),4.15-4.09 (m, 2H), 3.95 (m, 1H), 3.88 (s, 3H), 3.72-3.69(m, 4H), 3.63-3.52 (m, 5H), 3.41 (s, 3H), 2.89 (m, 1H),2.70 (d, J =12 Hz, 1H), 2.56 (t, J =7.2 Hz, 2H), 2.10 (m,2H), 2.05-2.04 (m, 9H), EI-MS m / z : [M+H]+970.46,[M / 2+H]+485.97.Preparation of Compound 123Compound 122 (250 mg, 0.25 mmol) was dissolved inN,N-dimethylformamide (2.5 mL),tetrakis(triphenylphosphine)palladium(0) (119 mg, 0.10mmol) and pyrrolidine (0.02 mL, 0.28 mmol) were graduallyadded at 0°C under a nitrogen atmosphere, and the mixturewas stirred at room temperature for 1 hour. The reactionmixture was acidified (pH ~4) with 1 N aqueoushydrochloric acid solution, followed by extraction withdichloromethane (20 mL x 3) and washing with sodiumchloride aqueous solution (20 mL). Drying over anhydroussodium sulfate, filtration, and concentration underreduced pressure were performed, thereby obtainingCompound 123 (239 mg). EI-MS m / z : [M+H]+930.40,[M / 2+H]+466.13.Preparation of Compound 124Compound 123 (239 mg, 0.25 mmol) was dissolved inN,N-dimethylformamide (2 mL), and then N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uroniumhexafluorophosphate (HBTU, 146 mg, 0.38 mmol) and N,N'-diisopropylethylamine (0.09 mL, 0.51 mmol) were added at0°C under a nitrogen atmosphere. A solution of Compound44 (133 mg, 0.30 mmol) in N,N-dimethylformamide (1 mL)was added to the reaction solution, and the mixture wasstirred at room temperature for 1 hour. Saturated aqueousammonium chloride solution (10 mL) was added to thereaction mixture, followed by extraction with ethylacetate (20 mL x 3), and washing with saturated sodiumhydrogen carbonate solution (10 mL) and distilled water(10 mL) and drying over anhydrous sodium sulfate wereperformed. After filtration and concentration, theproduct was purified by column chromatography, therebyobtaining Compound 124 (267 mg, 77%). EI-MS m / z :[M+H]+1344.69, [M / 2+H]+673.20.<Example 43> Preparation of Compound 129Preparation of Compound 125Compound 124 (170 mg, 0.12 mmol) was diluted withdichloromethane (1.6 mL), then trifluoroacetic acid (0.4mL) was added at 0°C under a nitrogen atmosphere, and themixture was stirred for 1 hour. The reaction mixture wasconcentrated under nitrogen gas, thereby obtainingCompound 125 (156 mg). EI-MS m / z : [M+H]+ 1244.67,[M / 2+H]+ 623.13.Preparation of Compound 127Compound 125 (156 mg, 0.25 mmol) was dissolved inN,N-dimethylformamide (3 mL), and then N,N'-diisopropylethylamine (0.06 mL, 0.37 mmol) was added at0°C under a nitrogen atmosphere. Compound 126 (123 mg,0.13 mmol, Compound 126 was prepared by the methoddescribed in Patent Publication No. WO 2017089890), 1-hydroxy-7-azabenzotriazole (3.4 mg, 0.38 mmol) and N,N'-diisopropylethylamine (0.04 mL, 0.19 mmol) weresequentially added, the temperature was gradually raised,and the mixture was stirred at room temperature for 17hours. Saturated aqueous ammonium chloride solution (10mL) was added to the reaction mixture, followed byextraction with ethyl acetate (20 mL x 3), washing withdistilled water (10 mL) and aqueous sodium chloridesolution (10 mL), and drying over anhydrous sodiumsulfate. After filtration and concentration, the productwas purified by column chromatography, thereby obtainingCompound 127 (143 mg, 56%). EI-MS m / z : [M+H]+ 2001.40,[M / 2+H]+ 1001.52.Preparation of Compound 128Compound 127 (142 mg, 0.07 mmol) was dissolved inmethanol / tetrahydrofuran (2 mL / 2 mL), and then a solutionof lithium hydroxide (18 mg, 0.42 mmol) in distilledwater (3 mL) was gradually added at -40°C under anitrogen atmosphere. The mixture was stirred for 4 hourswhile the reaction temperature was gradually raised to0°C. The reaction mixture was acidified with acetic acid(pH of about 4), concentrated under reduced pressure,purified by HPLC, and freeze-dried, thereby obtainingCompound 128 (70.4 mg, 57%). EI-MS m / z : [M+H]+ 1721.15,[M / 2+H]+ 861.25.Preparation of Compound 129Compound 128 (70.4 mg, 0.04 mmol) was diluted withdichloromethane (1.6 mL), then trifluoroacetic acid (0.4mL) was added at 0°C under a nitrogen atmosphere, and themixture was stirred for 1 hour. The reaction mixture wasconcentrated under nitrogen gas, purified by HPLC, andfreeze-dried, thereby obtaining Compound 129 (53.8 mg,81%). EI-MS m / z : [M+H]+ 1621.35, [M / 2+H]+ 811.21.<Example 44> Preparation of Compound 134Preparation of Compound 130In carbon tetrachloride (20 mL) was dissolved ethylm-tolyl acetate (3 g, 16.83 mmol), then Nbromosuccinimide(NBS, 3.6 g, 20.19 mm) and 2,2'-azobis(isobutyronitrile) (AIBN, 111 mg, 0.67 mmol) wereadded, and the mixture was stirred under reflux for 18hours. After cooling to room temperature, the producedsolid was filtered and washed with hexane (20 mL), andthe filtrate was concentrated under reduced pressure andpurified by column chromatography, thereby obtainingCompound 130 (2.63 g, 60%). 1H-NMR(400 MHz, CDCl3) δ7.35-7.28 (m, 3H), 7.24-7.20 (m, 1H), 4.49 (s, 2H), 4.16(q, 2H), 3.61 (s, 2H), 1.26 (t, 3H).Preparation of Compound 131Compound 3 (3.5 g, 8.28 mmol) and Compound 130 (2.4g, 9.33 mmol) were dissolved in N,N-dimethylformamide (20mL), then potassium carbonate (1.72 g, 12.42 mmol) andsodium iodide (0.25 g, 1.65 mmol) were added, and themixture was stirred at room temperature for 12 hoursunder a nitrogen atmosphere. The reaction mixture wasdiluted with ethyl acetate (100 mL) and washed withdistilled water (2 x 60 mL). The washed organic layer waswashed with brine (60 mL) and dried over anhydrous sodiumsulfate. After filtration and concentration under reducedpressure, the product was purified by columnchromatography, thereby obtaining Compound 131 (4.7 g,94%). 1H-NMR(400 MHz, CDCl3)(rotamers) δ 7.67 (s, 1H),7.32-7.24 (m, 3H), 7.19 (m, 1H), 6.68 (s, 1H), 5.10 (s,2H), 5.01 (d, 1H), 4.89 (s, 1H), 4.75 (s, 1H), 4.10-4.01(m, 2H), 3.87 (s, 3H), 3.79 (m, 1H), 3.70-3.60 (m, 2H),3.55 (s, 2H), 2.76-2.58 (m, 2H), 1.16 (t, 3H), 0.80 (s,6H), 0.70 (s, 3H), -0.09 (s, 4H), -0.21 (d, 2H).Preparation of Compound 132Compound 131 (4.7 g, 7.85 mmol) was dissolved in1,4-dioxane (20 mL), 1 N aqueous sodium hydroxidesolution (9.4 mL) was added at 0°C, and the mixture wasstirred at room temperature for 2 hours. The reactionsolvent was concentrated under reduced pressure, the pHwas adjusted to about 3 with 1 N aqueous hydrochloricacid solution, extraction with dichloromethane (3 x 40 mL)was performed, and the collected organic layers weredried over anhydrous sodium sulfate. Filtration andconcentration were performed, thereby obtaining Compound132 (4.56 g, 100%). 1H-NMR(400 MHz, CDCl3)(rotamers) δ7.73 (s, 1H), 7.37-7.34 (m, 2H), 7.25 (t, 1H), 7.18 (s,1H), 6.75 (s, 1H), 5.22 9s, 2H), 5.09 (d, 1H), 4.99 (s,1H), 4.84 9s, 1H), 4.59 (m, 1H), 3.89 (s, 4H), 3.75 (s,2H), 3.71 (s, 8H), 3.58 (s, 3H), 2.82-2.64 (m, 2H), 0.89(s, 6H), 0.79 (s, 3H), 0.09 (s, 4H), -0.11 (d, 3H).Preparation of Compound 133Compound 132 (4.56 g, 7.85 mmol) was dissolved inN,N-dimethylformamide (40 mL), then potassium carbonate(1.63 g, 11.77 mmol) and allyl bromide (0.81 mL, 9.42mmol) were added at 0°C, and the mixture was stirred atroom temperature for 4 hours. The reaction mixture wasdiluted with ethyl acetate (70 mL) and washed withsaturated aqueous ammonium chloride solution (50 mL) anddistilled water (2 x 60 mL). The washed organic layer waswashed with brine (60 mL) and dried over anhydrous sodiumsulfate. After filtration and concentration under reducedpressure, the product was purified by columnchromatography, thereby obtaining Compound 133 (4.36 g,91%). 1H-NMR(400 MHz, CDCl3)(rotamers) δ 7.76 (s, 1H),7.39-7.36 (m, 3H), 7.28 (t, 1H), 6.77 (s, 1H), 5.95-5.86(m, 1H), 5.30-5.19 (m, 5H), 5.09 (m, 1H), 4.99 (s, 1H),4.84 (s, 1H), 4.60 (d, 3H), 4.03-3.95 (m, 4H), 3.93-3.85(m, 1H), 3.81-3.72 (m, 2H), 3.68 (s, 3H), 3.32 (m, 1H),2.84-2.65 (m, 2H), 0.90 (s, 9H), 0.09 (s, 6H).Preparation of Compound 134Compound 133 (4.36 g, 7.13 mmol) was dissolved inethyl acetate (30 mL) and ethanol (60 mL), then zinc dust(14 g, 214 mmol) was added at 0°C, and formic acid (5.38mL, 143 mmol) was added. After stirring at roomtemperature for 4 hours, the reaction mixture was dilutedwith ethyl acetate (30 mL) and filtered through Celite,and ethyl acetate (70 mL) was added. The organic layerwas washed with saturated aqueous sodium hydrogencarbonate solution (2 x 100 mL) and brine (50 mL) in thatorder, and then dried over anhydrous sodium sulfate.Filtration, concentration, and purification by columnchromatography were performed, thereby obtaining Compound134 (2.52 g, 61%). 1H-NMR(400 MHz, CDCl3) δ 7.38-7.30 (m,3H), 7.24 (s, 1H), 6.77 (s, 1H), 6.26 (s, 1H), 5.95-5.85(m, 1H), 5.30-5.10 (m, 2H), 5.10 (s, 2H), 5.10-4.85 (m,2H), 4.59 (d, 2H), 4.40-4.18 (m, 3H), 4.20-4.05 (m, 2H),3.80 (s, 3H), 3.66 (s, 2H), 3.61 (m, 1H), 2.68 (m, 2H),0.87 (s, 9H), 0.02 (s, 6H). EI-MS m / z : [M+H]+581.42.<Example 45> Preparation of Compound 138Preparation of Compound 135Compound 134 (2.4 g, 4.13 mmol) was dissolved in drytetrahydrofuran (40 mL), then triphosgene (0.44 g, 1.48mmol) and triethylamine (2.32 mL, 16.5 mmol) were addedat -10°C, and Compound 6 (3.32 g, 4.54 mmol) dissolved indry tetrahydrofuran (20 mL) was added. After stirring atroom temperature for 17 hours, the reaction mixture wasdiluted with ethyl acetate (100 mL), washed withdistilled water (50 mL), and then dried over anhydroussodium sulfate. After filtration and concentration underreduced pressure, the product was purified by columnchromatography, thereby obtaining Compound 135 (4.2 g,76%). EI-MS m / z : [M+H]+1337.94.Preparation of Compound 136Compound 135 (4.21 g, 3.14 mmol) was dissolved intetrahydrofuran / distilled water (20 mL / 20 mL), aceticacid (20 mL) was added at 0°C, and the mixture wasstirred at room temperature for 17 hours. The reactionmixture was diluted with ethyl acetate (100 mL), washedwith distilled water (50 mL) and saturated sodiumhydrogen carbonate solution (2 x 70 mL), and then driedover anhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 136 (3.5 g, 91%). EI-MS m / z : [M+H]+1223.61.Preparation of Compound 137Compound 136 (3.5 g, 2.68 mmol) was dissolved indichloromethane (140 mL), Dess-Martin periodinane (1.33 g,3.14 mmol) was added, and the mixture was stirred at roomtemperature for 5 hours under a nitrogen atmosphere. Thereaction mixture was diluted with dichloromethane (200mL), washed with distilled water (80 mL), and then driedover anhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 137 (2.03 g, 58%). 1H-NMR(400 MHz, CDCl3) δ 7.97(s, 1H), 7.80 (s, 1H), 7.45 (s, 1H), 7.23 (d, 1H), 7.19(s, 1H), 7.00 (d, 1H), 6.61 (s, 1H), 5.92 (m, 1H), 5.58(d, 1H), 5.41-5.22 (m, 8H), 5.13 (s, 2H), 4.83 (d, 1H),4.59 (d, 2H), 4.27 (m, 2H), 4.11 (m, 2H), 3.96 (m, 2H),3.88 (s, 3H), 3.74-3.65 (m, 15H), 3.52 (m, 1H), 2.90 (m,1H), 2.70 (d, 1H), 2.57 (t, 2H), 2.13 (q, 2H) 2.05 (s,9H), 1.46 (s, 9H). EI-MS m / z : [M+H]+1121.65.Preparation of Compound 138Compound 137 (350 mg, 0.286 mmol) was dissolved inN,N-dimethylformamide (5 mL), thentetrakis(triphenylphosphine)palladium(0) (132 mg, 0.114mmol) and pyrrolidine (0.026 mL, 0.314 mmol) were added,and the mixture was stirred at room temperature for 1.5hours under a nitrogen atmosphere. The solvent wasconcentrated under reduced pressure, and thenpurification by column chromatography was performed,thereby obtaining Compound 138 (279 mg, 83%). EI-MS m / z :[M+H]+1181.52.<Example 46> Preparation of Compound 139Compound 139 was synthesized from Compound 138 andCompound 26 in a similar manner to the synthesis ofCompound 29. EI-MS m / z : [M+H]+1228.7.<Example 47> Preparation of Compound 147Preparation of Compound 140After 2-chloroethanol (5.0 g, 62.1 mmol) and sodiumazide (5.6 g, 86.9 mmol) were dissolved in N,Ndimethylformamide(15 mL), and the solution was stirredat 100°C for 18 hours under a nitrogen atmosphere. Afterthe reaction mixture was cooled to room temperature, 4-toluenesulfonyl chloride (13.0 g, 68.3 mmol) andtriethylamine (13.0 mL, 93.1 mmol) were added, and themixture was stirred at room temperature for 18 hours. Thereaction mixture was diluted with diethyl ether (200 mL),washed with distilled water (150 mL), and then dried overanhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 140 (8.8 g, 58%). 1H-NMR(400 MHz, CDCl3) δ 7.82(d, 2H), 7.37 (d, 2H), 4.16 (t, 2H), 3.48 (t, 2H), 2.46(s, 3H).Preparation of Compound 142Compound 141 (2.26 g, 4.73 mmol, Compound 141 wasprepared by the method described in Korean PatentPublication No. 10-2020-0084802) and Compound 140 (1.7 g,7.10 mmol) were dissolved in N,N-dimethylformamide (30mL), then potassium carbonate (1.3 g, 9.46 mmol) wasadded, and the mixture was stirred at 100°C for 2 hoursunder a nitrogen atmosphere. The reaction mixture wasdiluted with ethyl acetate (200 mL) and washed withdistilled water (2 x 100 mL) and brine (100 mL). Thecollected organic layers were dried over anhydrous sodiumsulfate, filtered, concentrated under reduced pressure,and then purified by column chromatography, therebyobtaining Compound 142 (2.3 g, 89%). 1H-NMR(400 MHz,CDCl3)(rotamers) δ 7.86 (s, 1H), 6.84 (s, 1H), 5.98-5.91(m, 1H), 5.35 (d, 1H), 5.24 (d, 1H), 4.99 (br s, 1H),4.92 (br s, 1H), 4.25 (t, 2H), 4.17 (br s, 1H), 3.82 (s,3H), 3.66 (t, 2H), 2.70 (br s, 2H), 0.91 (s, 9H), 0.09 (s,6H).Preparation of Compound 143Compound 142 (2.3 g, 4.21 mmol) was dissolved in1,2-dichloroethane (50 mL), and then trimethyltinhydroxide (7.6 g, 42.1 mmol) was added. The mixture washeated under reflux and stirred for 18 hours under anitrogen atmosphere. The reaction mixture was dilutedwith dichloromethane (200 mL), washed with 0.01 N aqueouspotassium hydrogen sulfate (100 mL) and brine (100 mL),and then dried over anhydrous sodium sulfate. Afterfiltration and concentration under reduced pressure, theproduct was purified by column chromatography, therebyobtaining Compound 143 (1.7 g, 88%). EI-MS m / z :[M+H]+462.25.Preparation of Compound 144Compound 143 (1.7 g, 3.69 mmol) was dissolved in drytetrahydrofuran (40 mL), then triphosgene (393 mg, 1.33mmol) and triethylamine (2.1 mL, 14.8 mmol) were added at0°C, and a solution of Compound 6 (3.2 g, 4.43 mmol) indry tetrahydrofuran (20 mL) was added. After stirring atroom temperature for 2 hours, the reaction mixture wasdiluted with ethyl acetate (200 mL), washed withdistilled water (100 mL), and then dried over anhydroussodium sulfate. After filtration and concentration underreduced pressure, the product was purified by columnchromatography, thereby obtaining Compound 144 (3.5 g,78%). EI-MS m / z : [M+H]+1218.70, 1 / 2[M-BOC+H]+559.82.Preparation of Compound 145Compound 144 (3.5 g, 2.87 mmol) was dissolved intetrahydrofuran / distilled water (10 mL / 10 mL), aceticacid (10 mL) was added at 0°C, and the mixture wasstirred at room temperature for 18 hours. The reactionmixture was diluted with ethyl acetate (100 mL), washedwith distilled water (50 mL) and saturated sodiumhydrogen carbonate solution (2 x 100 mL), and then driedover anhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 145 (2.9 g, 92%). EI-MS m / z : [M+H]+1104.53,1 / 2[M-BOC+H]+502.74.Preparation of Compound 146Compound 145 (2.9 g, 2.63 mmol) was dissolved indichloromethane (60 mL), Dess-Martin periodinane (1.3 g,3.15 mmol) was added, and the mixture was stirred at roomtemperature for 6 hours under a nitrogen atmosphere. Thereaction mixture was diluted with dichloromethane (200mL), washed with saturated aqueous sodium hydrogencarbonate solution (150 mL), and then dried overanhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 146 (1.37 g, 47%). EI-MS m / z : [M+H]+1102.45,1 / 2[M+H]+501.98.Preparation of Compound 147Compound 146 (150 mg, 0.14 mmol) and propiolic acid(0.01 mL, 0.16 mmol) were dissolved in ethanol (4 mL) anddistilled water (2 mL), then copper sulfate pentahydrate(14 mg, 0.05 mmol) and sodium L-ascorbate (22 mg, 0.11mmol) were added, and the mixture was stirred at roomtemperature for 2 hours under a nitrogen atmosphere. Thereaction mixture was diluted with dichloromethane (50 mL),washed with distilled water (50 mL), and then dried overanhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 147 (154 mg, 96%). EI-MS m / z : [M+H]+1172.26.<Example 48> Preparation of Compound 148Compound 148 was synthesized from Compound 147 andCompound 26 in a similar manner to the synthesis ofCompound 29. EI-MS m / z : [M+H]+1233.49, [M / 2+H]+617.29.<Example 49> Preparation of Compound 151Preparation of Compound 149After propiolic acid (4 ml, 64.52 mmol) wasdissolved in N,N-dimethylformamide (25 mL), sodiumhydrogen carbonate (10.9 g, 129.1 mmol) was added, andthe mixture was stirred at room temperature for 1 hour.To the reaction solution was added allyl bromide (8.4 mL,96.8 mmol), and the mixture was stirred at roomtemperature for 12 hours. The reaction mixture wasdiluted with diethyl ether (25 mL), washed with distilledwater (50 x 3 mL
[17] ) and brine (50 mL), and then driedover anhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 149 (6.9 g, 97%). 1H-NMR(400 MHz, CDCl3) δ 5.98-5.41 (m, 1H), 5.39 (dd, 1H), 5.31 (dd, 1H), 4.69 (d, 2H),2.89 (s, 1H).Preparation of Compound 150Compound 149 (800 mg, 7.26 mmol) and 3-azido-1-propanol (734 mg, 7.26 mmol) were dissolved in t-butylalcohol / distilled water (8 mL / 2 mL) at 0°C under anitrogen atmosphere, then a solution of copper sulfatepentahydrate (180 mg, 0.72 mmol) and sodium L-ascorbate(718 mg, 3.62 mmol) in distilled water (1 mL) was addedto the reaction solution, and the mixture was stirred atroom temperature for 5 hours. The reaction product wasfiltered through Celite, and then concentrated underreduced pressure. The filtered solution was subjected toextraction with dichloromethane (20 mL x 3), followed bydrying over anhydrous sodium sulfate, filtration, andconcentration under reduced pressure. The product waspurified by column chromatography, thereby obtainingCompound 150 (720 mg, 46%). 1H-NMR(400 MHz, CDCl3) δ 8.15(s, 1H), 6.09-5.99 (m, 1H), 5.44 (dd, J = 17.2 Hz, 1.6 Hz,1H), 5.31 (dd, J = 10.8 Hz, 1.2 Hz, 1H), 4.86 (d, J =6 Hz,2H), 4.61 (t, J =6.8 Hz, 2H), 3.67 (q, J =4.8 Hz, 2H),2.17 (quin, 2H), 1.91 (t, 1H).Preparation of Compound 151Compound 150 (265 mg, 1.25 mmol) was dissolved indichloromethane (10 mL), then methanesulfonyl chloride(0.11 mL, 1.38 mmol) and triethylamine (0.34 mL, 2.51mmol) were added at 0°C under a nitrogen atmosphere, andthe mixture was stirred at 0°C for 2 hours. Saturatedaqueous ammonium chloride solution (10 mL) was added tothe reaction mixture, followed by extraction withdichloromethane (20 mL x 2), washing with distilled water(10 mL) and brine (10 mL), and drying over anhydroussodium sulfate. Compound 151 obtained after filtrationand concentration was used in the next reaction withoutfurther purification. 1H-NMR(400 MHz, CDCl3) δ 8.18 (s,1H), 6.09-5.99 (m, 1H), 5.42 (dd, J = 17.2 Hz, 1.2 Hz,1H), 5.31 (dd, J = 10.8 Hz, 1.2 Hz, 1H), 4.86 (d, J =6 Hz,2H), 4.61 (t, J =7.2 Hz, 2H), 4.25 (t, J =6 Hz, 2H), 3.02(s, 3H), 2.43 (m, 2H).<Example 50> Preparation of Compound 157Preparation of Compound 152Compound 3 (528 mg, 1.25 mmol) and Compound 151 (361mg, 1.25 mmol) were dissolved in N,N-dimethylformamide(12 mL), then cesium carbonate (488 mg, 1.49 mmol) wasadded at 0°C under a nitrogen atmosphere, and the mixturewas stirred at 60°C for 2 hours. Saturated aqueousammonium chloride solution (10 mL) was added to thereaction mixture, followed by extraction with ethylacetate (40 mL), washing with distilled water (10 mL x 2)and brine (10 mL), and drying over anhydrous sodiumsulfate. After filtration and concentration, the productwas purified by column chromatography, thereby obtainingCompound 152 (455 mg, 60%). 1H-NMR (400 MHz,CDCl3)(rotamers) δ 8.25 (s, 1H), 7.69 (d, 2H), 6.81 (d,1H), 6.09-6.00 (m, 1H), 5.45 (d, 1H), 5.32 (d, 1H), 5.11-5.00 (m, 1H), 4.87 (d, 2H), 4.71 (t, 2H), 4.61 (t, 1H),4.16-4.15 (m, 2H), 3.97 (s, 3H), 3.79-3.71 (m, 2H), 2.79-2.69 (m, 2H), 2.58-2.52 (m, 2H). EI-MS m / z : [M+H]+616.4.Preparation of Compound 153Compound 152 (455 mg, 0.73 mmol) was dissolved inethyl acetate (6 mL), then zinc dust (1.5 g, 22.2 mmol)and formic acid solution (0.56 mL, 14.8 mmol) dilutedwith ethanol (6 mL) were sequentially added at 0°C undera nitrogen atmosphere, and the mixture was stirred atroom temperature for 3 hours. The reaction mixture wasfiltered through Celite and then concentrated underreduced pressure. The filtered solution was basified withsaturated aqueous sodium hydrogen carbonate solution (pHof about 8) and subjected to extraction with ethylacetate, followed by drying over anhydrous sodium sulfate.After filtration and concentration under reduced pressure,the product was purified by column chromatography,thereby obtaining Compound 153 (406 mg, 94%). 1H-NMR (400MHz, CDCl3)(rotamers) δ 8.26 (s, 1H), 6.76 (s, 1H), 6.21(s, 1H), 6.07-5.98 (m, 1H), 5.41 (dd, J = 17.2 Hz, 1.6 Hz,1H), 5.29 (dd, J = 10.4 Hz, 1.6 Hz, 1H), 4.98 (bs, 1H),4.91 (bs, 1H), 4.86 (d, J = 6 Hz, 2H), 4.59 (t, 2H),4.26-4.19 (m, 2H), 3.96 (t, 2H), 3.79 (s, 3H), 2.71 (m,2H), 2.48-2.42 (m, 2H), 0.87 (s, 9H), 0.03 (s, 6H). EI-MSm / z : [M+H]+587.5.Preparation of Compound 154Compound 153 (406 mg, 0.69 mmol) was dissolved indichloromethane (12 mL), then triphosgene (74 mg, 0.25mmol) and triethylamine (0.29 mL, 2.07 mmol) were addedat 0°C, and the mixture was stirred for 10 minutes. Asolution of Compound 6 (607 mg, 0.83 mmol) andtriethylamine (0.19 mL, 1.38 mmol) in dichloromethane (8mL) was added to the reaction solution, the temperaturewas gradually raised, and the mixture was stirred at roomtemperature for 15 hours. The reaction mixture wasdiluted with dichloromethane (20 mL), distilled water (20mL) was added, and then extraction was performed. Theaqueous layer was extracted with dichloromethane (20 mL x2), and the collected organic layers were washed withbrine (20 mL) and dried over anhydrous sodium sulfate.After filtration and concentration under reduced pressure,the product was purified by column chromatography,thereby obtaining Compound 154 (780 mg, 84%). 1H-NMR (400MHz, CDCl3) δ 8.46 (s, 1H), 8.04-8.03 (m, 1H), 7.84 (s,1H), 7.51-7.42 (m, 2H), 7.04-7.02 (m, 1H), 6.82 (s, 1H),6.07-6.01 (m, 1H), 5.44-5.25 (m, 6H), 5.12 (s, 2H), 4.98(m, 1H), 4.87-4.86 (m, 3H), 4.59 (t, J =6.8 Hz, 2H),4.20-4.11 (m, 5H), 4.01-3.97 (m, 3H), 3.83 (s, 3H), 3.74-3.53 (m, 18H), 2.69 (m, 2H), 2.47 (m, 2H), 2.05-2.03 (m,9H), 1.85-1.83 (m, 2H), 1.47-1.46 (m, 9H), 0.87 (s, 9H),0.03 (s, 6H). EI-MS m / z : [M+H]+1343.3.Preparation of Compound 155Compound 154 (780 mg, 0.58 mmol) was dissolved intetrahydrofuran / distilled water (3 mL / 3 mL), acetic acid(6 mL) was added at 0°C, and the mixture was stirred atroom temperature for 15 hours. After concentration underreduced pressure, the reaction mixture was diluted withsaturated sodium hydrogen carbonate solution (50 mL),followed by extraction with ethyl acetate (50 mL x 3).The extracted solution was dried over anhydrous sodiumsulfate, then filtered, concentrated under reducedpressure, and purified by column chromatography, therebyobtaining Compound 155 (460 mg, 63%). EI-MS m / z :[M+H]+1229.1.Preparation of Compound 156Compound 155 (460 mg, 0.37 mmol) was dissolved indichloromethane (5 mL), then Dess-Matin periodinane (190mg, 0.45 mmol) was added at 0°C, the temperature wasraised to room temperature, and the mixture was stirredfor 3 hours under a nitrogen atmosphere. The reactionmixture was diluted with saturated aqueous sodiumthiosulfate solution / saturated aqueous sodium hydrogencarbonate solution (v / v=1 / 1, 30 mL) and stirred for 10minutes. After extraction with dichloromethane (20 mL x3), washing with distilled water (20 mL) and aqueoussodium chloride solution (20 mL) was performed. Dryingover anhydrous sodium sulfate, filtration, concentration,and purification by column chromatography were performed,thereby obtaining Compound 156 (340 mg, 72%). EI-MS m / z :[M+H]+1226.9.Preparation of Compound 157Compound 156 (340 mg, 0.27 mmol) was dissolved inN,N-dimethylformamide (3.5 mL), thentetrakis(triphenylphosphine)palladium(0) (128 mg, 0.11mmol) and pyrrolidine (0.04 mL, 0.54 mmol) were added at0°C under a nitrogen atmosphere, and the mixture wasstirred at room temperature for 1 hour. Saturated aqueousammonium chloride solution (10 mL) was added to thereaction mixture, followed by extraction with ethylacetate (20 mL x 3) and drying over anhydrous sodiumsulfate. Compound 157 (165 mg) obtained after filtrationand concentration under reduced pressure was used in thenext reaction without further purification. EI-MS m / z :[M+H]+1187.1.<Example 51> Preparation of Compound 158Compound 158 was synthesized from Compound 157 andCompound 20 in a similar manner to the synthesis ofCompound 23. EI-MS m / z : [M+H]+1375.3.<Example 52> Preparation of Compound 161Preparation of Compound 159After 4-chloro-1-butanol (3 g, 27.6 mmol) wasdissolved in N,N-dimethylformamide (30 mL), then sodiumazide (3.58 g, 55.2 mmol) was added at 0°C under anitrogen atmosphere, and the mixture was heated to 70°Cand stirred for 17 hours. The reaction mixture wasdiluted with diethyl ether (30 mL), washed with distilledwater (50 mL) and brine (50 mL), and then dried overanhydrous sodium sulfate. Filtration and concentrationunder reduced pressure were performed, thereby obtainingCompound 159 (2.21 g, 69%). 1H-NMR(400 MHz, CDCl3) δ 3.70(m, 2H), 3.33 (t, J =6.4 Hz, 2H), 1.73-1.64 (m, 4H).Preparation of Compound 160Compound 149 (1 g, 9.1 mmol) and Compound 159 (1.04g, 9.1 mmol) were dissolved in tertiary butylalcohol / distilled water (12 mL / 3 mL) at 0°C under anitrogen atmosphere, followed by stirring. Copper sulfatepentahydrate (227 mg, 0.91 mmol) and sodium L-ascorbate(901 mg, 4.55 mmol) were dissolved in distilled water (3mL) and then added to the reaction solution, and themixture was stirred at room temperature for 17 hours. Thereaction product was filtered through Celite, and thenconcentrated under reduced pressure. The filteredsolution was subjected to extraction with dichloromethane(20 mL x 3), followed by drying over anhydrous sodiumsulfate, filtration, and concentration under reducedpressure. The product was purified by columnchromatography, thereby obtaining Compound 160 (997 mg,48%). 1H-NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), 6.09-5.99(m, 1H), 5.42 (dd, J = 17.2 Hz, 1.6 Hz, 1H), 5.31 (dd, J= 10.8 Hz, 1.2 Hz, 1H), 4.86 (d, J =6 Hz, 2H), 4.49 (t, J=7.2 Hz, 2H), 3.71 (q, J =4.8 Hz, 2H), 2.07 (m, 2H), 1.60(m, 2H), 1.35 (br, 1H). EI-MS m / z : [M+H]+226.20,[M / 2+H]+113.82.Preparation of Compound 161Compound 160 (450 mg, 1.99 mmol) was dissolved indichloromethane (10 mL), then methanesulfonyl chloride(251 mg, 0.17 mL) and triethylamine (404 mg, 3.99 mmol)were sequentially added at 0°C under a nitrogenatmosphere, and the mixture was stirred at 0°C for 1 hour.Saturated aqueous ammonium chloride solution (10 mL) wasadded to the reaction mixture, followed by extractionwith ethyl acetate (20 mL x 3), and the collected organiclayers were washed with distilled water (10 mL) and brine(10 mL) and then dried over anhydrous sodium sulfate.Filtration and concentration were performed, therebyobtaining Compound 161 (606 mg). 1H-NMR (400 MHz, CDCl3)δ 8.11 (s, 1H), 6.09-5.99 (m, 1H), 5.42 (dd, J = 17.2 Hz,1.2 Hz, 1H), 5.31 (dd, J = 10.8 Hz, 1.2 Hz, 1H), 4.86 (d,J =6 Hz, 2H), 4.49 (t, J =7.2 Hz, 2H), 4.27 (t, J =6 Hz,2H), 3.02 (s, 3H), 2.12 (m, 2H), 1.81 (m, 2H).<Example 53> Preparation of Compound 162Compound 162 was synthesized from Compound 3 andCompound 161 in a similar manner to the synthesis ofCompound 157. EI-MS m / z : [M+H]+1200.91.<Example 54> Preparation of Compound 163Compound 163 was synthesized from Compound 158 andCompound 20 in a similar manner to the synthesis ofCompound 23. 1H-NMR (400 MHz, Methanol-d4) δ 8.53 (s, 1H),7.75 (s, 1H), 7.35 (m, 1H), 7.29-7.27 (m, 2H), 7.18-7.15(m, 2H), 7.01 (s, 1H), 6.90 (s, 1H), 6.73 (s, 1H), 5.57(d, J =7.2 Hz, 1H), 5.28-5.24 (m, 1H), 5.17-5.11 (m, 3H),4.57 (m, 2H), 4.23-4.06 (m, 6H), 3.92-3.89 (m, 11H), 3.78(m, 3H), 3.67-3.54 (m, 15H), 3.39 (t, J =6.4 Hz, 2H),3.17 (t, J =7.6 Hz, 2H), 2.91 (s, 8H), 2.10 (m, 2H),2.02-1.97 (m, 3H), 1.75 (m, 2H). EI-MS m / z : [M+H]+1289.09,[M / 2+H]+645.13.<Example 55> Preparation of Compound 166Preparation of Compound 164After 1-chloro-5-hydroxypentane (1 g, 8.15 mmol) wasdissolved in N,N-dimethylformamide (30 mL), then sodiumazide (2.1 g, 32.6 mmol) was added at 0°C under anitrogen atmosphere, and the mixture was heated to 80°Cand stirred for 15 hours. The reaction mixture wasdiluted with diethyl ether (30 mL), washed with distilledwater (50 mL) and brine (50 mL), and then dried overanhydrous sodium sulfate. Filtration and concentrationunder reduced pressure were performed, thereby obtainingCompound 164 (980 mg, 93%). 1H-NMR (400 MHz, CDCl3) δ3.66 (t, J = 6 Hz 2H), 3.29 (t, J = 6.8 Hz, 2H), 1.68-1.53 (m, 4H), 1.54-1.42 (m, 2H).Preparation of Compound 165Compound 149 (919 mg, 8.34 mmol) and Compound 164(980 mg, 7.58 mmol) were dissolved in tertiary butylalcohol / distilled water (16 mL / 4 mL) at 0°C under anitrogen atmosphere, followed by stirring. Copper sulfatepentahydrate (189 mg, 0.75 mmol) and sodium L-ascorbate(751 mg, 3.79 mmol) were dissolved in distilled water (1mL) and then added to the reaction solution, and themixture was stirred at room temperature for 5 hours. Thereaction product was filtered through Celite, and thenconcentrated under reduced pressure. The filteredsolution was subjected to extraction with dichloromethane(20 mL x 3), followed by drying over anhydrous sodiumsulfate, filtration, and concentration under reducedpressure. The product was purified by columnchromatography, thereby obtaining Compound 165 (920 mg,50%). 1H-NMR(400 MHz, CDCl3) δ 8.09 (s, 1H), 6.09-5.99 (m,1H), 5.42 (dd, J = 17.2 Hz, 1.6 Hz, 1H), 5.31 (dd, J =10.8 Hz, 1.2 Hz, 1H), 4.86 (d, J = 6 Hz, 2H), 4.43 (t, J= 7.2 Hz, 2H), 3.65 (bs, 2H), 1.98 (quin, 2H), 1.61 (quin,2H), 1.41 (quin, 2H).Preparation of Compound 166Compound 165 (920 mg, 3.84 mmol) was dissolved indichloromethane (40 mL), then methanesulfonyl chloride(0.32 ml, 4.22 mmol) and triethylamine (1.07 ml, 7.68mmol) were added at 0°C under a nitrogen atmosphere, andthe mixture was stirred at 0°C for 2 hours. Saturatedaqueous ammonium chloride solution (40 mL) was added tothe reaction mixture, followed by extraction withdichloromethane (20 mL x 2), washing with distilled water(10 mL) and brine (10 mL), and drying over anhydroussodium sulfate. The product was filtered and concentrated,and used in the next reaction without purification. 1HNMR(400 MHz, CDCl3) δ 8.11 (s, 1H), 6.09-5.99 (m, 1H),5.42 (dd, J = 17.2 Hz, 1.2 Hz, 1H), 5.31 (dd, J = 10.8 Hz,1.2 Hz, 1H), 4.86 (d, J = 6 Hz, 2H), 4.44 (t, J = 7.2 Hz,2H), 4.22 (t, J = 6 Hz, 2H), 3.01 (s, 3H), 2.01 (quin, J= 7.6 Hz, 2H), 1.81 (quin, J = 7.6 Hz, 2H), 1.512-1.452(m, 2H).<Example 56> Preparation of Compound 167Compound 167 was synthesized from Compound 3 andCompound 166 in a similar manner to the synthesis ofCompound 157. EI-MS m / z : [M+H]+1215.2.<Example 57> Preparation of Compound 168Compound 168 was synthesized from Compound 167 andCompound 20 in a similar manner to the synthesis ofCompound 23. EI-MS m / z : [M+H]+1303.4, [M+Na]+ 652.1<Example 58> Preparation of Compound 171Preparation of Compound 169After 1-bromo-7-hydroxyheptane (1 g, 5.12 mmol) wasdissolved in N,N-dimethylformamide (30 mL), then sodiumazide (666 mg, 10.2 mmol) was added at 0°C under anitrogen atmosphere, and the mixture was heated to 80°Cand stirred for 15 hours. The reaction mixture wasdiluted with ethyl acetate (30 mL), washed with distilledwater (50 mL) and brine (50 mL), and then dried overanhydrous sodium sulfate. Filtration and concentrationunder reduced pressure were performed, thereby obtainingCompound 169 (800 mg, 99%). 1H-NMR (400 MHz, CDCl3) δ3.64 (t, J = 6 Hz, 2H), 3.26 (t, J = 6.8 Hz, 2H), 1.61-1.54 (m, 4H), 1.42-1.36 (m, 6H).Preparation of Compound 170Compound 149 (564 mg, 5.12 mmol) and Compound 169(800 mg, 5.12 mmol) were dissolved in tertiary butylalcohol / distilled water (8 mL / 2 mL) at 0°C under anitrogen atmosphere, followed by stirring. Copper sulfatepentahydrate (127 mg, 0.51 mmol) and sodium L-ascorbate(507 mg, 2.5 mmol) were dissolved in distilled water (1mL) and then added to the reaction solution, and themixture was stirred at room temperature for 5 hours. Thereaction product was filtered through Celite, and thenconcentrated under reduced pressure. The filteredsolution was subjected to extraction with dichloromethane(20 mL x 3), followed by drying over anhydrous sodiumsulfate, filtration, and concentration under reducedpressure. The product was purified by columnchromatography, thereby obtaining Compound 170 (566 mg,41%). 1H-NMR(400 MHz, CDCl3) δ 8.09 (s, 1H), 6.09-5.99 (m,1H), 5.42 (dd, J = 17.2 Hz, 1.6 Hz, 1H), 5.31 (dd, J =10.8 Hz, 1.2 Hz, 1H), 4.86 (d, J = 6 Hz, 2H), 4.41 (t, J= 7.2 Hz, 2H), 3.63 (bs, 2H), 1.98 (quin, 2H), 1.61-1.54(m, 4H), 1.42-1.36 (m, 6H).Preparation of Compound 171Compound 170 (566 mg, 2.11 mmol) was dissolved indichloromethane (20 mL), then methanesulfonyl chloride(0.19 mL, 2.54 mol) and triethylamine (0.59 ml, 4.23 mmol)were added at 0°C under a nitrogen atmosphere, and themixture was stirred at 0°C for 2 hours. Saturated aqueousammonium chloride solution (20 mL) was added to thereaction mixture, followed by extraction withdichloromethane (20 mL x 2), washing with distilled water(10 mL) and brine (10 mL), and drying over anhydroussodium sulfate. The product was filtered and concentrated,and used in the next reaction without purification. 1HNMR(400 MHz, CDCl3) δ 8.09 (s, 1H), 6.09-5.99 (m, 1H),5.42 (dd, J = 17.2 Hz, 1.6 Hz, 1H), 5.31 (dd, J = 10.8 Hz,1.2 Hz, 1H), 4.86 (d, J =6 Hz, 2H), 4.41 (t, J =7.2 Hz,2H), 3.63 (bs, 2H), 3.01 (s, 3H), 1.98 (quin, 2H), 1.61-1.54 (m, 4H), 1.42-1.36 (m, 6H).<Example 59> Preparation of Compound 172Compound 172 was synthesized from Compound 3 andCompound 171 in a similar manner to the synthesis ofCompound 157. EI-MS m / z : [M+H]+1243.2.<Example 60> Preparation of Compound 173Compound 173 was synthesized from Compound 167 andCompound 26 in a similar manner to the synthesis ofCompound 29. EI-MS m / z : [M+H]+1467.8.<Example 61> Preparation of Compound 175Preparation of Compound 174After 4-pyrazolecarboxylic acid (500 mg, 4.46 mmol)was dissolved in N,N-dimethylformamide (5 mL) anddichloromethane (5 mL), then allyl alcohol (0.37 mL, 5.35mmol), 4-dimethylaminopyridine (54 mg, 0.45 mmol), and1,3-diisopropylcarbodiimide (0.83 mL, 5.35 mmol) wereadded, and the mixture was stirred at room temperaturefor 17 hours, heated to 60°C, and further stirred for 3hours. The reaction mixture was diluted with ethylacetate (100 mL), washed with distilled water (2 x 100mL), and then dried over anhydrous sodium sulfate. Afterfiltration and concentration under reduced pressure, theproduct was purified by column chromatography, therebyobtaining Compound 174 (328 mg, 48%). 1H-NMR(400 MHz,CDCl3) δ 8.07 (s, 1H), 6.04-5.96 (m, 1H), 5.38 (d, 1H),5.27 (d, 1H), 4.76 (d, 2H).Preparation of Compound 175Compound 174 (328 mg, 2.16 mmol) and 1,4-diodobutane(0.71 mL, 5.39 mmol) were dissolved in N,Ndimethylformamide(20 mL), then cesium carbonate (913 mg,2.80 mmol) was added, and the mixture was stirred at roomtemperature for 2 hours. The reaction mixture was dilutedwith ethyl acetate (100 mL), washed with distilled water(2 x 100 mL), and then dried over anhydrous sodiumsulfate. After filtration and concentration under reducedpressure, the product was purified by columnchromatography, thereby obtaining Compound 175 (535 mg,74%). 1H-NMR(400 MHz, CDCl3) δ 7.93 (s, 1H), 7.90 (s, 1H),6.03-5.96 (m, 1H), 5.37 (d, 1H), 5.27 (d, 1H), 4.74 (d,2H), 4.16 (t, 2H), 3.18 (t, 2H), 2.05-1.98 (m, 2H), 1.84-1.79 (m, 2H).<Example 62> Preparation of Compound 176Compound 176 was synthesized from Compound 3 andCompound 175 in a similar manner to the synthesis ofCompound 157. EI-MS m / z : [M+H]+1200.21.<Example 63> Preparation of Compound 177Compound 177 was synthesized from Compound 176 andCompound 20 in a similar manner to the synthesis ofCompound 23. EI-MS m / z : [M+H]+1288.24, 1 / 2[M+H]+644.73.<Example 64> Preparation of Compound 181Preparation of Compound 179After 3-(2-(3-methoxy-3-oxopropoxy)ethoxy)propanoicacid (200 mg, 0.85 mmol) was dissolved in dichloromethane(4 mL), then N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 440 mg, 1.11 mmol),N,N'-diisopropylethylamine (0.22 mL, 1.28 mmol), andCompound 178 (259 mg, 0.94 mmol) were sequentially addedat 0°C under a nitrogen atmosphere, and the mixture wasstirred at room temperature for 5 hours. Saturatedaqueous sodium hydrogen carbonate solution (10 mL) wasadded to the reaction mixture, followed by extractionwith dichloromethane (20 mL x 3), washing with distilledwater (10 mL) and brine (10 mL), and drying overanhydrous sodium sulfate. After filtration andconcentration, the product was purified by columnchromatography, thereby obtaining Compound 179 (391 mg,93%). 1H-NMR(400 MHz, CDCl3)δ 7.68 (d, 1H), 7.44-7.24 (m,7H), 6.53 (t, 1H), 5.14 (d, 1H), 4.15 (q, 2H), 3.79-3.44(m, 9H), 3.42-3.30 (m, 1H), 3.28-3.14 (m, 2H), 2.59 (t,2H), 2.56-2.46 (m, 1H), 2.33 (t, 2H), 2.02-1.92 (m, 2H),1.25 (t, 3H).Preparation of Compound 180Compound 179 (391 mg, 0.79 mmol) was dissolved inmethanol / tetrahydrofuran (5 mL / 5 mL), then a solution oflithium hydroxide (50 mg, 1.19 mmol) in distilled water(5 mL) was gradually added at 0°C under a nitrogenatmosphere, and the mixture was stirred for 2 hours. ThepH was adjusted to about 4 with 0.1 N aqueoushydrochloric acid solution, followed by extraction withethyl acetate (20 mL x 3), and the collected organiclayers were dried over anhydrous sodium sulfate.Filtration and concentration were performed, therebyobtaining Compound 180 (380 mg, 100%). 1H-NMR(400 MHz,CDCl3) δ 7.66 (d, 1H), 7.46-7.22 (m, 7H), 6.83 (t, 1H),5.15 (d, 1H), 3.79-3.44 (m, 9H), 3.42-3.32 (m, 1H), 3.28-3.12 (m, 2H), 2.56 (t, 2H), 2.51 (t, 1H), 2.42-2.32 (m,2H), 2.12 (t, 1H).Preparation of Compound 181Compound 180 (200 mg, 0.36 mmol) was dissolved indichloromethane (5 mL), then N-hydroxysuccinimide (50 mg,0.43 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimamide (84 mg, 0.43 mmol)were added at 0°C under a nitrogen atmosphere, and themixture was stirred at room temperature for 2 hours. Thereaction was terminated with distilled water (10 mL),followed by extraction with dichloromethane (10 mL x 2),washing with distilled water (10 mL) and brine (10 mL),and then drying over anhydrous sodium sulfate. Afterfiltration and concentration, Compound 181 (220 mg, crude)was used in the next reaction without purification. EI-MSm / z : [M+H]+562.5.<Example 65> Preparation of Compound 186Preparation of Compound 183Compound 5 (500 mg, 0.96 mmol) was dissolved in drydichloromethane (20 mL), then triphosgene (206 mg, 0.69mmol) and N,N-diisopropylethylamine (0.45 mL, 2.60 mmol)were added at 0°C, and Compound 182 (679 mg, 1.06 mmol,Compound 182 was prepared by the method described inKorean Patent Publication No. 10-2018-0110645) dissolvedin dry dichloromethane (3 mL) was added. After stirringat room temperature for 17 hours, the reaction mixturewas diluted with dichloromethane (30 mL), washed withdistilled water (50 mL), and dried over anhydrous sodiumsulfate. After filtration and concentration under reducedpressure, the product was purified by columnchromatography, thereby obtaining Compound 183 (1.14 g,79%). EI-MS m / z : [M+H]+1185.8.Preparation of Compound 184Compound 183 (899 mg, 0.76 mmol) was dissolved intetrahydrofuran / distilled water (5 mL / 5 mL), acetic acid(5 mL) was added at 0°C, and then the mixture was stirredat room temperature for 17 hours. The reaction mixturewas diluted with ethyl acetate (10 mL), washed withdistilled water (5 mL) and saturated sodium hydrogencarbonate solution (2 x 10 mL) in that order, and thendried over anhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 184 (812 mg, 86%). EI-MS m / z : [M+H]+1071.7.Preparation of Compound 185Compound 184 (700 mg, 0.65 mmol) was dissolved indichloromethane (60 mL), Dess-Martin periodinane (333 mg,0.78 mmol) was added, and the mixture was stirred at roomtemperature for 5 hours under a nitrogen atmosphere. Thereaction mixture was diluted with dichloromethane (40 mL),washed with saturated aqueous sodium hydrogen carbonatesolution (150 mL) and aqueous sodium thiosulfate solution(100 mL), and then dried over anhydrous sodium sulfate.After filtration and concentration under reduced pressure,the product was purified by column chromatography,thereby obtaining Compound 185 (460 mg, 66%). EI-MS m / z :[M+H]+1069.9.Preparation of Compound 186Compound 185 (450 mg, 0.42 mmol) was dissolved inN,N-dimethylformamide (10 mL), thentetrakis(triphenylphosphine)palladium(0) (97 mg, 0.08mmol) and pyrrolidine (0.04 mL, 0.51 mmol) were added,and the mixture was stirred at room temperature for 1hour under a nitrogen atmosphere. The reaction mixturewas diluted with ethyl acetate (50 mL), washed withsaturated aqueous ammonium chloride solution (50 mL) anddistilled water (50 mL), and dried over anhydrous sodiumsulfate. Filtration and concentration under reducedpressure were performed, thereby obtaining Compound 186(354 mg, 82%). EI-MS m / z : [M+H]+1029.7.<Example 66> Preparation of Compound 190Preparation of Compound 187Compound 186 (354 mg, 0.35 mmol) and Compound 26(164 mg, 0.38 mmol) were dissolved in N,Ndimethylformamide(8 mL), N,N,N',N'-tetramethyl-O-(1Hbenzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 196mg, 0.52 mmol) and N,N'-diisopropylethylamine (0.09 mL,0.52 mmol) were sequentially added at 0°C under anitrogen atmosphere, and the mixture was stirred at roomtemperature for 16 hours. Saturated aqueous ammoniumchloride solution (10 mL) was added to the reactionmixture, followed by extraction with ethyl acetate (20mL), washing with distilled water (10 x 2 mL
[18] ) and brine(10 mL), and drying over anhydrous sodium sulfate. Afterfiltration and concentration, the product was purified bycolumn chromatography, thereby obtaining Compound 187(497 mg, 70%). EI-MS m / z : [M+H]+1145.4Preparation of Compound 188Compound 187 (325 mg, 0.24 mmol) was dissolved inmethanol (4 mL), and then a solution of sodium hydroxide(41 mg, 0.97 mmol) in distilled water (4 mL) wasgradually added at -40°C under a nitrogen atmosphere. Themixture was stirred for 2 hours while the reactiontemperature was gradually raised to 0°C. The reactionmixture was neutralized with acetic acid, thenconcentrated under reduced pressure, and freeze-dried,thereby obtaining Compound 188 (297 mg). EI-MS m / z :[M+H]+1305.1.Preparation of Compound 189Compound 188 (297 mg, 0.11 mmol) was diluted withdichloromethane (5 mL), then trifluoroacetic acid (1 mL)was added at 0°C under a nitrogen atmosphere, and themixture was stirred for 2 hours. The reaction mixture wasconcentrated under reduced pressure, then purified byHPLC, and freeze-dried, thereby obtaining Compound 189 asa white solid (51 mg, 41%). EI-MS m / z : [M / 2+H]+1090.9,[M / 2+H]+546.1.Preparation of Compound 190Compound 189 (51 mg, 0.047 mmol) and Compound 181(29 mg, 0.052 mmol) were dissolved in N,Ndimethylformamide(2.7 mL), then N,Ndiisopropylethylamine(0.02 mL, 0.12 mmol) was addedsequentially at 0°C under a nitrogen atmosphere, and themixture was stirred at room temperature for 4 hours. Thereaction mixture was concentrated under reduced pressure,then purified by HPLC, and freeze-dried, therebyobtaining Compound 190 as a white solid (38 mg, 52%). EIMSm / z : [M / 2+H]+769.4<Example 67> Preparation of Compound 192Preparation of Compound 191After 3-hydroxybenzoic acid (2.0 g, 14.5 mmol) wasdissolved in distilled water (15 mL), potassium hydroxide(893 mg, 15.9 mmol) was added, the mixture was stirred atroom temperature for 10 minutes under a nitrogenatmosphere, and the reaction mixture was concentrated.The concentrated reaction product was diluted with N,Ndimethylformamide(30 mL), then allyl bromide (1.4 mL,15.9 mmol) was added, and the mixture was stirred at roomtemperature for 17 hours under a nitrogen atmosphere. Thereaction mixture was diluted with ethyl acetate (300 mL),then washed with distilled water (2 x 100 mL) and brine(100 mL), and dried over anhydrous sodium sulfate. Afterfiltration and concentration under reduced pressure, theproduct was purified by column chromatography, therebyobtaining Compound 191 (2.5 g, 96%). 1H-NMR(400 MHz,CDCl3) δ 7.65 (d, 1H), 7.57 (s, 1H), 7.32 (t, 1H), 7.07-7.05 (m, 1H), 6.06-5.98 (m, 1H), 5.41 (d, 1H), 5.36 (s,1H), 5.29 (d, 1H), 4.82 (d, 2H).Preparation of Compound 192Compound 191 (2.5 g, 14.0 mmol) and 1,5-diodopentane(6.5 mL, 43.5 mmol) were dissolved in acetone (100 mL),then potassium carbonate (2.2 g, 15.95 mmol)was added,and the mixture was heated under reflux and stirred for18 hours under a nitrogen atmosphere. The reactionmixture was concentrated under reduced pressure andpurified by column chromatography, thereby obtainingCompound 192 (3.8 g, 70%). 1H-NMR(400 MHz, CDCl3) δ 7.65(d, 1H), 7.56 (s, 1H), 7.34 (t, 1H), 7.10-7.08 (m, 1H),6.09-5.99 (m, 1H), 5.41 (d, 1H), 5.29 (d, 1H), 4.82 (d,2H), 4.01 (t, 2H), 3.22 (t, 2H), 1.94-1.87 (m, 2H), 1.86-1.79 (m, 2H), 1.64-1.5 (m, 2H).<Example 68> Preparation of Compound 193Compound 193 was synthesized from Compound 3 andCompound 192 in a similar manner to the synthesis ofCompound 157. EI-MS m / z : [M+H]+1240.09, [M / 2+H]+570.48.<Example 69> Preparation of Compound 194Compound 194 was synthesized from Compound 193 andCompound 20 in a similar manner to the synthesis ofCompound 23. EI-MS m / z : [M+H]+1328.38, [M / 2+H]+664.82.<Example 70> Preparation of Compound 200Preparation of Compound 195After 5-hydroxypyridine-3-carboxylic acid (500 mg,3.6 mmol) was dissolved in N,N-dimethylformamide (10 mL),then allyl alcohol (0.3 mL, 4.31 mmol), 4-dimethylaminopyridine (44 mg, 0.36 mmol), and 1,3-diisopropylcarbodiimide (0.67 mL, 4.31 mmol) were added,and the mixture was stirred at room temperature for 17hours. The reaction mixture was diluted with ethylacetate (100 mL), washed with distilled water (2 x 100mL), and then dried over anhydrous sodium sulfate. Afterfiltration and concentration under reduced pressure, theproduct was purified by column chromatography, therebyobtaining Compound 195 (347 mg, 54%). 1H-NMR(400 MHz,CDCl3) δ 8.81 (s, 1H), 8.45 (s, 1H), 7.83 (s, 1H), 6.06-5.98 (m, 1H), 5.42 (d, 1H), 5.32 (d, 1H), 4.85 (d, 2H).Preparation of Compound 196After 1,5-pentanediol (2.0 g, 19.2 mmol) wasdissolved in dichloromethane (3 mL), 4-toluenesulfonylchloride (4.4 g, 23.04 mmol), 4-dimethylaminopyridine(234 mg, 1.92 mmol), and triethylamine (8.0 mL, 57.6 mmol)were added, and the mixture was stirred at roomtemperature for 3 hours. The reaction mixture was dilutedwith dichloromethane (100 mL), then washed with distilledwater (2 x 100 mL), and dried over anhydrous sodiumsulfate. After filtration and concentration under reducedpressure, the product was purified by columnchromatography, thereby obtaining Compound 196 (2.6 g,52%). 1H-NMR(400 MHz, CDCl3) δ 7.79 (d, 2H), 7.35 (d, 2H),4.03 (t, 2H), 3.60 (t, 2H), 2.45 (s, 3H), 1.72-1.65 (m,2H), 1.54-1.48 (m, 2H), 1.42-1.38 (m, 2H).Preparation of Compound 197Compound 3 (1.78 g, 4.19 mmol) and Compound 196 (1.3g, 5.03 mmol) were dissolved in N,N-dimethylformamide (40mL), then cesium carbonate (1.78 g, 5.45 mmol) was added,and the mixture was stirred at room temperature for 18hours. The reaction mixture was diluted with ethylacetate (100 mL), washed with distilled water (2 x 100mL), and then dried over anhydrous sodium sulfate. Afterfiltration and concentration under reduced pressure, theproduct was purified by column chromatography, therebyobtaining Compound 197 (1.42 g, 67%). 1H-NMR(400 MHz,CDCl3)(rotamers) δ 7.71(s, 1H), 6.75 (s, 1H), 4.98 (br s,1H), 4.83 (br s, 1H), 4.59 (br s, 1H), 4.11 (t, 2H), 3.95(s, 3H), 3.73-3.69 (m, 4H), 2.82-2.67 (m, 2H), 1.94-1.91(m, 2H), 1.69-1.56 (m, 4H), 0.91 (s, 9H), 0.09 (s, 6H).Preparation of Compound 198Compound 197 (1.1 g, 2.61 mmol) and Compound 195(342 mg, 1.90 mmol) were dissolved in tetrahydrofuran (25mL), then diethyl azodicarboxylate (40% toluene solution,1.4 mL, 2.85 mmol) and triphenylphosphine (750 mg, 2.85mmol) were added, and the mixture was stirred at roomtemperature for 3 hours. The reaction mixture wasconcentrated under reduced pressure and purified bycolumn chromatography, thereby obtaining Compound 198(915 mg). EI-MS m / z : [M+H]+671.85, [M / 2+H]+336.07.Preparation of Compound 199Compound 198 (915 mg) was dissolved in ethyl acetate(10 mL) and ethanol (20 mL), then zinc dust (2.2 g, 33.5mmol) was added at 0°C, and formic acid (1.3 mL, 33.48mmol) was added. After stirring at room temperature for 3hours, the reaction mixture was diluted with ethylacetate (30 mL) and filtered through Celite, and ethylacetate (70 mL) was added. The organic layer was washedwith saturated aqueous sodium hydrogen carbonate solution(2 x 100 mL) and brine (50 mL) in that order, and thendried over anhydrous sodium sulfate. Filtration,concentration, and purification by column chromatographywere performed, thereby obtaining Compound 199 (582 mg).EI-MS m / z : [M+H]+640.74, [M / 2+H]+320.99.Preparation of Compound 200Compound 199 (582 mg) was dissolved in drytetrahydrofuran (10 mL), then triphosgene (61.4 mg, 0.24mmol) and triethylamine (0.4 mL, 2.69 mmol) were added at0°C, and Compound 6 (589 mg, 0.81 mmol) dissolved in drytetrahydrofuran (5 mL) was added. After stirring at roomtemperature for 4 hours, the reaction mixture was dilutedwith ethyl acetate (100 mL), washed with distilled water(50 mL), and then dried over anhydrous sodium sulfate.After filtration and concentration under reduced pressure,the product was purified by column chromatography,thereby obtaining Compound 200 (330 mg, 35%). EI-MS m / z :[M+H]+1397.36, 1 / 2[M-BOC+H]+649.30.<Example 71> Preparation of Compound 203Preparation of Compound 201Compound 200 (330 mg, 0.24 mmol) was dissolved intetrahydrofuran / distilled water (2 mL / 2 mL), acetic acid(6 mL) was added at 0°C, and then the mixture was stirredat room temperature for 17 hours. The reaction mixturewas diluted with ethyl acetate (100 mL), washed withdistilled water (50 mL) and saturated sodium hydrogencarbonate solution (2 x 100 mL), and then dried overanhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 201 (254 mg, 84%). EI-MS m / z : [M+H]+1283.09,1 / 2[M-BOC+H]+592.09.Preparation of Compound 202Compound 201 (254 mg, 0.20 mmol) was dissolved indichloromethane (8 mL), Dess-Martin periodinane (100 mg,0.24 mmol) was added, and the mixture was stirred at roomtemperature for 22 hours under a nitrogen atmosphere. Thereaction mixture was diluted with dichloromethane (100mL), washed with saturated aqueous sodium hydrogencarbonate solution (50 mL), and then dried over anhydroussodium sulfate. After filtration and concentration underreduced pressure, the product was purified by columnchromatography, thereby obtaining Compound 202 (139 mg,55%). EI-MS m / z : [M+H]+1281.20, 1 / 2[M-BOC+H]+591.08.Preparation of Compound 203Compound 202 (139 mg, 0.11 mmol) was dissolved inN,N-dimethylformamide (3 mL), thentetrakis(triphenylphosphine)palladium(0) (50 mg, 0.04mmol) and pyrrolidine (0.01 mL, 0.13 mmol) were added,and the mixture was stirred at room temperature for 1.5hours under a nitrogen atmosphere. The reaction mixturewas diluted with ethyl acetate (50 mL), washed withsaturated aqueous ammonium chloride solution (50 mL) anddistilled water (50 mL), and dried over anhydrous sodiumsulfate. Filtration and concentration under reducedpressure were performed, thereby obtaining Compound 203(144 mg). EI-MS m / z : [M+H]+1241.18, 1 / 2[M-BOC+H]+571.21.<Example 72> Preparation of Compound 204Compound 204 was synthesized from Compound 203 andCompound 20 in a similar manner to the synthesis ofCompound 23. EI-MS m / z : [M+H]+1329.71, [M / 2+H]+665.39.<Example 73> Preparation of Compound 209Preparation of Compound 206Compound 205 (500 mg, 0.97 mmol, Compound 205 wasprepared by the method described in Korean PatentPublication No. 10-2018-0110645) and bis(4-nitrophenyl)carbonate (356 mg, 1.17 mmol) were dissolvedin N,N-dimethylformamide (10 mL), then N,Ndiisopropylethylamine(0.25 mL, 1.46 mmol) was added at0°C, and the mixture was stirred at room temperature for15 hours under a nitrogen atmosphere. To the reactionmixture was added ethyl acetate (30 mL), followed byextraction with distilled water (30 x 3 mL
[19] ). Thecollected organic layers were washed with brine (50 mL)and dried over anhydrous sodium sulfate. After filtrationand concentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 206 (528 mg, 79%). EI-MS m / z : [M+H]+687.5.Preparation of Compound 207Compound 125 (687 mg, 0.51 mmol) was dissolved inN,N-dimethylformamide (10 mL), and then N,N'-diisopropylethylamine (0.26 mL, 1.51 mmol) was added at0°C under a nitrogen atmosphere. Compound 206 (451 mg,0.66 mmol), 1-hydroxy-7-azabenzotriazole (30 mg, 0.22mmol), and N,N-diisopropylethylamine (0.26 mL, 1.51 mmol)were sequentially added, the temperature was graduallyraised, and the mixture was stirred at room temperaturefor 17 hours. Saturated aqueous ammonium chloridesolution (20 mL) was added to the reaction mixture,followed by extraction with ethyl acetate (40 mL),washing with distilled water (20 x 3 mL
[110] ) and brine (10mL), and drying over anhydrous sodium sulfate. Filtration,concentration, and purification by column chromatographywere performed, thereby obtaining Compound 207 (629 mg,70%). EI-MS m / z : [M+H]+1792.8.Preparation of Compound 209Compound 207 (273 mg, 0.15 mmol) and Compound 208(50 mg, 0.069 mmol, Compound 208 was prepared by themethod described in Korean Patent Publication No. 10-2020-0127891) were dissolved in tertiary butylalcohol / distilled water (2.3 mL / 0.8 mL) at 0°C under anitrogen atmosphere, followed by stirring. Copper sulfatepentahydrate (3.46 mg, 0.013 mmol) and sodium L-ascorbate(13.7 mg, 0.069 mmol) were dissolved in distilled water(1 mL) and then added to the reaction solution, then3,3',3''-(4,4',4''-(nitrotris(methylene))tris(1H-1,2,3-triazole-4,1-diyl))tris( propane-1-ol) (THPTA, 12 mg,0.027 mmol) was added, and the mixture was stirred atroom temperature for 2.5 hours. The reaction product wasallowed to pass through Celite to filter inorganicsubstances, followed by concentration under reducedpressure. The filtered solution was subjected toextraction with dichloromethane (20 mL x 3), followed bydrying over anhydrous sodium sulfate, filtration, andconcentration under reduced pressure. The product waspurified by column chromatography, thereby obtainingCompound 209 (210 mg, 69%). EI-MS m / z : [M / 3+H]+1435.4.<Example 74> Preparation of Compound 211Preparation of Compound 210Compound 209 (210 mg, 0.05 mmol) was dissolved inmethanol / tetrahydrofuran (1 mL / 1 mL), and then a solutionof lithium hydroxide (8.2 mg, 0.19 mmol) in distilledwater (1 mL) was gradually added at -40°C under anitrogen atmosphere. The mixture was stirred for 2 hourswhile the reaction temperature was gradually raised to0°C. The reaction mixture was neutralized with aceticacid, then concentrated under reduced pressure, andfreeze-dried, thereby obtaining Compound 210 (220 mg).EI-MS m / z : [M / 2+H]+1872.6, [M / 3+H]+1248.6.Preparation of Compound 211Compound 210 (220 mg, 0.05 mmol) was diluted withdichloromethane (4 mL), then trifluoroacetic acid (1 mL)was added at 0°C under a nitrogen atmosphere, and themixture was stirred for 2 hours. The reaction mixture wasconcentrated under reduced pressure, then purified byHPLC, and freeze-dried, thereby obtaining Compound 211 asa white solid (45 mg, 21%). EI-MS m / z : [M / 2+H]+1822.4,[M / 3+H]+1215.4.<Example 75> Preparation of Compound 214Preparation of Compound 213To Compound 14 (300 mg, 1.72 mmol) was added thionylchloride (2 mL), and the mixture was stirred for 30minutes under reflux. The solvent was concentrated underreduced pressure, thereby obtaining Compound 212.After 3-(dimethylamino)-1-propylamine (466 mg, 5.29mmol) was dissolved in dichloromethane (5 mL),triethylamine (0.74 mL, 5.29 mmol) was added at -50°Cunder a nitrogen atmosphere. Synthesized Compound 212 wasdissolved in dichloromethane (8 mL) and added, and themixture was stirred for 2 hours while the reactiontemperature was gradually raised to 0°C. The reactionmixture was diluted with dichloromethane (30 mL), washedwith distilled water (20 mL), and dried over anhydroussodium sulfate. Filtration and concentration wereperformed, thereby obtaining Compound 213 (396 mg, 94%).1H-NMR(400 MHz, DMSO-d6) δ 8.40 (t, 1H), 8.11 (d, 1H),7.40 (d, 1H), 3.90 (s, 3H), 3.20 (m, 2H), 2.23 (t, 2H),1.61 (m, 2H).Preparation of Compound 214Compound 213 (150 mg, 0.59 mmol) was dissolved inmethanol (6 mL), and then palladium / charcoal (10% w / w, 80mg) was added. The reaction solution was stirred at roomtemperature for 2 hours under a hydrogen atmosphere. Thereaction mixture was filtered through Celite and thenconcentrated, thereby obtaining Compound 214 (132 mg,100%).<Example 76> Preparation of Compound 215Compound 215 was synthesized from Compound 10 andCompound 214 in a similar manner to the synthesis ofCompound 23. EI-MS m / z : [M+H]+1085.68, [M / 2+H]+543.46.<Example 77> Preparation of Compound 217Preparation of Compound 216After 3-chloropropanol (3.0 g, 31.7 mmol) and sodiumazide (3.1 g, 47.6 mmol) were dissolved in N,Ndimethylformamide(15 mL), and the solution was stirredat 100°C for 18 hours under a nitrogen atmosphere. Afterthe reaction mixture was cooled to room temperature, 4-toluenesulfonyl chloride (6.6 g, 34.9 mmol) andtriethylamine (6.7 mL, 47.6 mmol) were added, and themixture was stirred at room temperature for 18 hours. Thereaction mixture was diluted with diethyl ether (200 mL),washed with distilled water (150 mL), and then dried overanhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 216 (1.9 g, 23%). 1H-NMR(400 MHz, CDCl3) δ 7.80(d, 2H), 7.36 (d, 2H), 4.11 (t, 2H), 3.38 (t, 2H), 2.45(s, 3H), 1.92-1.86 (m, 2H).Preparation of Compound 217Compound 217 was synthesized from Compound 141 andCompound 216 in a similar manner to the synthesis ofCompound 146. EI-MS m / z : [M+H]+1116.42.<Example 78> Preparation of Compound 223Preparation of Compound 218After 4-methoxy-4-oxobutanoic acid (2.0 g, 15.13mmol) was dissolved in tetrahydrofuran (30 mL), thenborane dimethylsulfide (1.0 M, 19.6 mL, 19.6 mmol) wasadded at 0°C under a nitrogen atmosphere, and the mixturewas stirred for 48 hours. Distilled water and calciumcarbonate were gradually added to the reaction mixture,and then the mixture was filtered through Celite andconcentrated. The concentrated compound was dissolved indichloromethane (30 mL), then t-butylchlorodiphenylsilane(TBDPS-Cl, 4.3 mL, 16.65 mmol), 4-dimethylaminopyridine(184 mg, 1.51 mmol), and triethylamine (4.2 mL, 30.27mmol) were sequentially added, and the mixture wasstirred at room temperature for 18 hours. The reactionmixture was diluted with dichloromethane (200 mL), washedwith saturated aqueous ammonium chloride solution (150mL), and then dried over anhydrous sodium sulfate. Afterfiltration and concentration under reduced pressure, theproduct was purified by column chromatography, therebyobtaining Compound 218 (2.3 g, 42%). 1H-NMR(400 MHz,CDCl3) δ 7.65-7.63 (m, 4H), 7.42-7.35 (m, 6H), 3.68 (t,2H), 3.65 (s, 3H), 2.46 (t, 2H), 1.92-1.84 (m, 2H), 1.04(s, 9H).Preparation of Compound 219Compound 218 (500 mg, 1.40 mmol) was dissolved in1,2-dichloroethane (10 mL), and then trimethyltinhydroxide (1.2 g, 7.01 mmol) was added. The reactionsolution was heated under reflux and stirred for 8 hoursunder a nitrogen atmosphere. The reaction mixture wasdiluted with dichloromethane (100 mL), washed with 0.01 Naqueous potassium hydrogen sulfate (50 mL) and brine (50mL), and then dried over anhydrous sodium sulfate.Filtration and concentration under reduced pressure wereperformed, thereby obtaining Compound 219 (451 mg, 94%).1H-NMR(400 MHz, CDCl3) δ 7.66-7.64 (m, 4H), 7.44-7.38 (m,6H), 3.70 (t, 2H), 2.52 (t, 2H), 1.92-1.89 (m, 2H), 1.07(s, 9H).Preparation of Compound 220Compound 217 (472 mg, 0.42 mmol) was dissolved inethyl acetate (4 mL) and ethanol (4 mL), then zinc dust(1.1 g, 16.91 mmol) was added at 0°C, and acetic acid(1.0 mL, 16.91 mmol) was added. After stirring at roomtemperature for 5 hours, the reaction mixture was dilutedwith ethyl acetate (30 mL) and filtered through Celite,and ethyl acetate (70 mL) was added. The organic layerwas washed with saturated aqueous sodium hydrogencarbonate solution (2 x 100 mL) and brine (50 mL) in thatorder, and then dried over anhydrous sodium sulfate.Filtration and concentration were performed, therebyobtaining Compound 220 (423 mg, 92%). EI-MS m / z :[M+H]+1090.85, 1 / 2[M-BOC+H]+496.13.Preparation of Compound 221Compound 220 (423 mg, 0.42 mmol) was dissolved inN,N-dimethylformamide (5 mL), then Compound 24 (185 mg,0.50 mmol), N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 252 mg, 0.63 mmol)and diisopropylethylamine
[111] (0.2 mL, 1.26 mmol) weresequentially added at 0°C under a nitrogen atmosphere,and the mixture was stirred at room temperature for 17hours. The reaction mixture was concentrated and purifiedby column chromatography, thereby obtaining Compound 221(321 mg, 56%). EI-MS m / z : [M+H]+1364.84, 1 / 2[MBOC+H]+633.20.Preparation of Compound 222Compound 221 (321 mg, 0.24 mmol) was dissolved inethyl acetate (4 mL) and ethanol (4 mL), then zinc dust(615 mg, 9.41 mmol) was added at 0°C, and acetic acid(0.5 mL, 9.41 mmol) was added. After stirring at roomtemperature for 5 hours, the reaction mixture was dilutedwith ethyl acetate (30 mL) and filtered through Celite,and ethyl acetate (70 mL) was added. The organic layerwas washed with saturated aqueous sodium hydrogencarbonate solution (2 x 100 mL) and brine (50 mL) in thatorder, and then dried over anhydrous sodium sulfate.Filtration and concentration were performed, therebyobtaining Compound 222 (266 mg, 85%). EI-MS m / z :[M+H]+1334.92, [M / 2+H]+668.29, 1 / 2[M-BOC+H]+618.19.Preparation of Compound 223Compound 222 (266 mg, 0.11 mmol) was dissolved inN,N-dimethylformamide (5 mL), then Compound 219 (75 mg,0.22 mmol), N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 96 mg, 0.24 mmol)and diisopropylethylamine
[112] (0.06 mL, 0.33 mmol) weresequentially added at 0°C under a nitrogen atmosphere,and the mixture was stirred at room temperature for 3hours. The reaction mixture was concentrated and purifiedby column chromatography, thereby obtaining Compound 223(122 mg, 66%). EI-MS m / z : [M+H]+1660.02, [M / 2+H]+830.52,1 / 2[M-BOC+H]+780.43.<Example 79> Preparation of Compound 225Preparation of Compound 224Compound 223 (122 mg, 0.07 mmol) was dissolved inmethanol / tetrahydrofuran (1.0 mL / 1.0 mL), and then asolution of lithium hydroxide (9.2 mg, 0.22 mmol) indistilled water (2.0 mL) was gradually added at -40°Cunder a nitrogen atmosphere. The mixture was stirred for4 hours while the reaction temperature was graduallyraised to 0°C. The reaction mixture was neutralized withacetic acid, concentrated under reduced pressure,purified by HPLC, and freeze-dried, thereby obtainingCompound 224 (22 mg). EI-MS m / z : [M+H]+1519.97,[M / 2+H]+760.30, 1 / 2[M-BOC+H]+710.32.Preparation of Compound 225Compound 224 (22 mg) was diluted withdichloromethane (1.5 mL), then trifluoroacetic acid (0.5mL) was added at 0°C under a nitrogen atmosphere, and themixture was stirred for 2 hours. The reaction mixture wasconcentrated under reduced pressure, then purified byHPLC, and freeze-dried, thereby obtaining Compound 225(4.5 mg). EI-MS m / z : [M+H]+1182.18, [M / 2+H]+591.16.<Example 80> Preparation of Compound 230Preparation of Compound 226Compound 16 (4.6 g, 15.0 mmol) was dissolved inmethanol (70 mL) and N,N-dimethylformamide (70 mL), andthen palladium / charcoal (10% w / w, 0.9 g) was added at 0°Cunder a nitrogen atmosphere. After sodium borohydride(1.7 g, 45.0 mmol) dissolved in distilled water (35 mL)was gradually added using a dropping funnel, the mixturewas stirred at room temperature for 1 hour. The reactionmixture was filtered through Celite, then diluted withethyl acetate (100 mL), and washed with distilled water(50 mL). The collected organic layers were dried overanhydrous sodium sulfate, then filtered, concentrated,and purified by column chromatography, thereby obtainingCompound 226 (4.08 g, 99%). 1H-NMR(400 MHz, DMSO-d6)δ9.59 (s,1H), 7.42 (d, J = 1.6 Hz, 1H), 6.85 (d, J = 1.6Hz, 1H), 6.33 (d, J = 2 Hz, 1H), 6.26 (d, J = 2 Hz, 1H),3.82 (s, 3H), 3.73 (s, 3H), 3.72 (s, 3H).Preparation of Compound 227Compound 14 (2.3 g, 13.5 mmol) was dissolved in N,Ndimethylformamide(40 mL), then N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU,8.0 g, 20.2 mmol) and N,N'-diisopropylethylamine (7.0 mL,40.5 mmol) were added sequentially at 0°C under anitrogen atmosphere, and the mixture was stirred at roomtemperature for 30 minutes. Compound 226 (4.1 g, 14.8mmol) dissolved in N,N-dimethylformamide (20 mL) wasadded to the reaction solution, and the mixture wasstirred at room temperature for 12 hours. The reactionmixture was concentrated, then chloroform (50 mL) wasadded, and the produced solid was filtered, therebyobtaining Compound 227 (5.65 g, 99%). 1H-NMR(400 MHz,DMSO-d6) δ10.28 (s, 1H), 9.97 (s, 1H), 8.18 (d, J = 1.6 Hz,1H), 7.58 (d, J = 2 Hz, 1H), 7.46 (d, J = 1.6 Hz, 1H),7.26 (d, J = 1.6 Hz, 1H), 7.05 (d, J = 1.6 Hz, 1H), 6.90(d, J = 2 Hz, 1H), 3.96 (s, 3H), 3.85 (s, 3H), 3.83 (s,3H), 3.73 (s, 3H).Preparation of Compound 228After methanol (120 mL) was added to Compound 227(3.7 g, 8.6 mmol), sodium hydroxide (1.72 g, 43.1 mmol)dissolved in distilled water (90 mL) was added at 0°Cunder a nitrogen atmosphere. The reaction solution washeated to 90°C and stirred for 12 hours. Afterconcentration of methanol, the pH was adjusted to about 2with 6 N aqueous hydrochloric acid solution, and theproduced solid was filtered, thereby obtaining Compound228 (3.5 g, 99%). 1H-NMR(400 MHz, DMSO-d6) δ 12.15 (bs,1H), 10.30 (s, 1H), 9.95 (s, 1H), 8.18 (d, J = 1.2 Hz,1H), 7.59 (d, J = 2 Hz, 1H), 7.42 (d, J = 1.6 Hz, 1H),7.26 (d, J = 1.6 Hz, 1H), 7.05 (d, J = 1.2 Hz, 1H), 6.85(d, J = 1.6 Hz, 1H), 3.96 (s, 3H), 3.85 (s, 3H), 3.82 (s,3H).Preparation of Compound 229Compound 228 (500 mg, 1.2 mmol) was dissolved inN,N-dimethylformamide (10 mL), then 3-(dimethylamino)-1-propylamine (0.18 mL, 1.4 mmol), N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU,623 mg, 1.5 mmol) and diisopropylethylamine
[113] (0.63 mL,3.6 mmol) were sequentially added at 0°C under a nitrogenatmosphere, and the mixture was stirred at roomtemperature for 12 hours. The reaction mixture wasconcentrated, then dichloromethane (20 mL) was added, themixture was stirred, and then the produced solid wasfiltered, thereby obtaining Compound 229 (600 mg, 99%).1H-NMR(400 MHz, DMSO-d6) δ 10.31 (s, 1H), 9.96 (s, 1H),8.19 (s, 1H), 7.60 (s, 1H), 7.27 (s, 1H), 7.19 (s, 1H),7.04 (s, 1H), 6.90 (s, 1H), 3.96 (s, 3H), 3.85 (s, 3H),3.81 (s, 3H), 3.25-3.22 (m, 2H), 2.68-2.64 (m, 2H), 1.77-1.76 (m, 2H).Preparation of Compound 230Compound 229 (300 mg, 0.6 mmol) was dissolved inmethanol (30 mL), and then palladium / charcoal (10% w / w,240 mg) was added. The reaction solution was stirred atroom temperature for 5 hours under a hydrogen atmosphere.The reaction mixture was filtered through Celite and thenconcentrated, thereby obtaining Compound 230 (275 mg,98%). EI-MS m / z : [M+H]+469.20.<Example 81> Preparation of Compound 231Compound 231 was synthesized from Compound 10 andCompound 230 in a similar manner to the synthesis ofCompound 23. EI-MS m / z : [M+H]+1330.07, [M / 2+H]+665.5.<Example 82> Preparation of Compound 234Preparation of Compound 232Compound 228 (980 mg, 2.36 mmol) and 3-amino-1-propanol (0.26 mL, 3.54 mmol) were dissolved in N,Ndimethylformamide(12 mL), then N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU,1.4 g, 3.54 mmol), and N,N'-diisopropylethylamine (0.82mL, 4.72 mmol) were sequentially added at 0°C under anitrogen atmosphere, and the mixture was stirred at roomtemperature for 4 hours. The reaction mixture was dilutedwith ethyl acetate (100 mL) and washed with distilledwater (60 mL x 3). The collected organic layers weredried over anhydrous sodium sulfate, filtered andconcentrated under reduced pressure, thereby obtainingCompound 232 (3.93 g). EI-MS m / z : [M+H]+1491.80,1 / 2[M+H]+746.41.Preparation of Compound 233Compound 232 (3.93 g, 2.36 mmol) was dissolved indichloromethane (200 mL) and N,N-dimethylformamide (10mL), then imidazole (321 mg, 4.72 mmol) and tbutyldimethylsilylchloride (534 mg, 3.54 mmol) wereadded at 0°C under a nitrogen atmosphere, and the mixturewas stirred at room temperature for 6 hours. The reactionmixture was concentrated under reduced pressure, dilutedwith ethyl acetate (80 mL), washed with saturated aqueousammonium chloride solution (50 mL) and distilled water(50 mL) in that order, and then dried over anhydroussodium sulfate. After filtration and concentration underreduced pressure, the product was purified by columnchromatography, thereby obtaining Compound 233 (1.01 g,74%). 1H-NMR(400 MHz, DMSO-d6) δ 10.30 (s, 1H), 9.96 (s,1H), 8.02 (s, 1H), 7.99 (t, 1H), 7.60 (d, 1H), 7.28 (d,1H), 7.19 (d, 1H), 7.03 (d, 1H), 6.84 (d, 1H), 3.96 (s,3H), 3.86 (s, 3H), 3.79 (s, 3H), 3.63 (t, 2H), 3.22 (m,2H), 1.69 (m, 2H), 0.87 (s, 9H), 0.04 (s, 6H).Preparation of Compound 234Compound 233 (750 mg, 1.28 mmol) was dissolved inmethanol (20 mL) and ethyl acetate (10 mL), and thenpalladium / charcoal (10% w / w, 440 mg) was added. Thereaction solution was stirred at room temperature for 3hours under a hydrogen atmosphere. The reaction mixturewas filtered through Celite and then concentrated,thereby obtaining Compound 234 (704 mg, 99%). 1H-NMR(400MHz, DMSO-d6) δ 9.88 (s, 1H), 9.63 (s, 1H), 7.96 (t, 1H),7.21 (d, 1H), 7.17 (d, 1H), 7.00 (d, 1H), 6.84 (d, 1H),6.39 (d, 1H), 6.28 (d, 1H), 3.83 (s, 3H), 3.79 (s, 3H),3.74 (s, 3H), 3.63 (t, 2H), 3.22 (m, 2H), 1.69 (m, 2H),0.87 (s, 9H), 0.04 (s, 6H) EI-MS m / z : [M+H]+556.30.<Example 83> Preparation of Compound 235Compound 235 was synthesized from Compound 10 andCompound 234 in a similar manner to the synthesis ofCompound 29. EI-MS m / z : [M+H]+1303.22, [M / 2+H]+652.07.<Example 84> Preparation of Compound 239Preparation of Compound 236Compound 5 (2.49 g, 4.8 mmol) was dissolved indichloromethane (25 mL), then pyridine (0.85 mL, 10.56mmol) and allyl chloroformate (0.56 mL, 5.28 mmol) weresequentially added at -78°C under a nitrogen atmosphere,the temperature was raised to room temperature, and themixture was stirred for 0.5 hour. The reaction mixturewas concentrated under reduced pressure, and theconcentrated solution was washed with distilled water (20mL) and brine (20 mL) and then dried over anhydroussodium sulfate. Filtration and concentration underreduced pressure were performed, thereby obtainingCompound 236 (2.86 g). 1H-NMR(400 MHz, CDCl3) δ7.82 (s,1H), 6.81 (s, 1H), 5.94 (m, 1H), 5.36-5.32 (m, 2H), 5.27(m, 2H), 4.98 (brs, 1H), 4.90 (brs, 1H), 4.64-4.59 (m,5H), 4.20 (m. 2H), 4.12 (t,J =6.4 Hz, 2H), 3.81 (s, 3H),2.69 (m, 2H), 2.57 (t, J =7.6 Hz, 2H), 2.19 (m, 2H), 0.87(s, 9H), 0.03 (s, 6H), EI-MS m / z : [M+H]+603.54.Preparation of Compound 237Compound 236 (2.86 g, 4.7 mmol) was dissolved intetrahydrofuran / distilled water (5 mL / 5 mL), and aceticacid (15 mL) was added at 0°C, and the mixture wasstirred at room temperature for 17 hours. After furtheraddition of acetic acid (1.5 mL), the mixture was stirredat room temperature for 6 hours, and the reaction wasterminated. After concentration under reduced pressure,the reaction mixture was subjected to extraction withethyl acetate (50 mL x 3), followed by washing withsaturated aqueous sodium hydrogen carbonate solution (50mL), distilled water (30 mL), and brine (30 mL) in thatorder, and then drying over anhydrous sodium sulfate.Filtration, concentration under reduced pressure, andpurification by column chromatography were performed,thereby obtaining Compound 237 (1.96 g, 85%). 1H-NMR(400MHz, CDCl3) δ8.50 (brs, 1H), 7.75 (brs, 1H), 6.82 (s, 1H),5.96 (m, 1H), 5.37-5.30 (m, 2H), 5.26-5.22 (m, 2H), 5.02(brs, 1H), 4.94 (brs, 1H), 4.64-4.59 (m, 5H), 4.18(m, 2H),4.12(t,J = 6.4 Hz, 2H), 3.83 (s, 3H), 3.70 (br s, 1H),2.79 (m, 1H), 2.57 (t, J =7.2 Hz, 2H), 2.47 (m, 2H), 2.19(m, 2H), EI-MS m / z : [M+H]+490.39.Preparation of Compound 238Compound 237 (1.95 g, 4 mmol) was dissolved indichloromethane (40 mL), then Dess-Matin periodinane(2.03 g, 4.8 mmol) was added at 0°C, the temperature wasraised to room temperature, and the mixture was stirredfor 2 hours under a nitrogen atmosphere. The reactionmixture was diluted with saturated aqueous sodiumthiosulfate solution / saturated aqueous sodium hydrogencarbonate solution (20 mL / 20 mL) and stirred for 10minutes. After extraction with dichloromethane (30 mL x3), washing was performed with saturated aqueous sodiumthiosulfate solution / saturated aqueous sodium hydrogencarbonate solution (15 mL / 15 mL), distilled water (20 mL),and brine (20 mL). Drying over anhydrous sodium sulfate,filtration, concentration, and purification by columnchromatography were performed, thereby obtaining Compound238 (899 mg, 46%). 1H-NMR(400 MHz, CDCl3) δ7.21 (s, 1H),6.86 (brs, 1H), 5.94 (m, 1H), 5.80 (m, 1H), 5.56 (m, 1H),5.32 (m, 1H), 5.30 (m, 1H), 5.13 (m, 4H), 4.67 (dd, J=13.2 Hz, 5.2 Hz, 1H), 4.66 (d, J = 5.6 Hz, 2H), 4.45 (m,1H), 4.32 (d, J = 15.6 Hz, 1H), 4.15 (d, J = 15.6 Hz, 1H),4.09 (m, 2H), 3.90 (s, 3H), 3.63 (m, 1H), 3.48 (m, 1H),2.91 (m, 1H), 2.71 (m, 1H), 2.57 (t, J = 7.2 Hz, 2H),2.17 (m, 2H), EI-MS m / z : [M+H]+487.39.Preparation of Compound 239Compound 238 (100 mg, 0.20 mmol) was dissolved intetrahydrofuran (3 mL), and then a solution of lithiumhydroxide (17.2 mg, 0.41 mmol) in distilled water (3 mL)was gradually added at 0°C under a nitrogen atmosphere.The mixture was stirred for 6 hours while the reactiontemperature was maintained at 0°C. The reaction mixturewas washed with dichloromethane (5 mL), and then theaqueous layer was acidified (pH of about 4) with 1 Naqueous hydrochloric acid solution. Extraction with ethylacetate (20 mL x 3), drying over anhydrous sodium sulfate,and concentration under reduced pressure were performed,thereby obtaining Compound 239 (91.5 mg). 1H-NMR(400 MHz,CDCl3) δ 7.22 (s, 1H), 6.75 (brs, 1H), 5.77 (m, 1H), 5.58(d, J = 10 Hz, 1H), 5.14 (m, 4H), 4.66 (dd, J = 13.2 Hz,5.2 Hz, 1H), 4.43 (m, 1H), 4.32 (d, J = 16 Hz, 1H), 4.16-4.06 (m, 5H), 3.90 (s, 3H), 3.63 (t, J = 8 Hz, 1H), 2.90(m, 1H), 2.70 (m, 1H), 2.58 (t, J = 6.4 Hz, 2H), 2.16 (m,2H), EI-MS m / z : [M+H]+447.24.<Example 85> Preparation of Compound 242Preparation of Compound 240Compound 239 (141 mg, 0.32 mmol) was dissolved inN,N-dimethylformamide (3 mL), then Compound 26 (150 mg,0.35 mmol), N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 163 mg, 0.41 mmol)and diisopropylethylamine
[114] (0.11 mL, 0.63 mmol) weresequentially added at 0°C under a nitrogen atmosphere,and the mixture was stirred at room temperature for 2hours. The reaction mixture was diluted with ethylacetate (50 mL), then washed with saturated aqueousammonium chloride solution (50 mL), saturated sodiumhydrogen carbonate solution (50 mL) and distilled water(50 mL), and dried over anhydrous sodium sulfate. Afterfiltration and concentration, the product was purified bycolumn chromatography, thereby obtaining Compound 240(178 mg, 66%). EI-MS m / z : [M+H]+862.44, [M-TBS+H]+748.36,[M / 2+H]+423.04, 1 / 2[M-TBS+H]+374.92.Preparation of Compound 241Compound 240 (178 mg, 0.20 mmol) was dissolved intetrahydrofuran (5 mL), then tetra-n-butylammoniumfluoride (1.0 M tetrahydrofuran solution, 1.2 mL, 1.2mmol) was gradually added at 0°C under a nitrogenatmosphere, and the mixture was stirred at roomtemperature for 5 hours. The reaction mixture was washedwith saturated aqueous ammonium chloride solution (50 mL)and distilled water (50 mL), and then dried overanhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 241 (115 mg, 74%). EI-MS m / z : [M+H]+748.42,[M / 2+H]+374.96.Preparation of Compound 242Compound 241 (115 mg, 0.15 mmol) was dissolved indichloromethane (4 mL), thentetrakis(triphenylphosphine)palladium(0) (8.8 mg, 0.01mmol) and pyrrolidine (0.05 mL, 0.62 mmol) were added,and the mixture was stirred at room temperature for 0.5hour under a nitrogen atmosphere. After concentrationunder reduced pressure, the product was purified bycolumn chromatography, thereby obtaining Compound 242 (74mg, 75%). EI-MS m / z : [M+H]+646.18.<Example 86> Preparation of Compound 244Preparation of Compound 243Compound 239 (155 mg, 0.35 mmol) was dissolved inN,N-dimethylformamide (3 mL), then Compound 37 (200 mg,0.38 mmol), N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 179 mg, 0.45 mmol)and diisopropylethylamine
[115] (0.18 mL, 1.04 mmol) weresequentially added at 0°C under a nitrogen atmosphere,and the mixture was stirred at room temperature for 3hours. The reaction mixture was diluted with ethylacetate (50 mL), then washed with saturated aqueousammonium chloride solution (50 mL), saturated sodiumhydrogen carbonate solution (50 mL) and distilled water(50 mL) in that order, and dried over anhydrous sodiumsulfate. After filtration and concentration, the productwas purified by column chromatography, thereby obtainingCompound 243 (281 mg, 85%). EI-MS m / z : [M+H]+954.54,[M / 2+H]+478.04.Preparation of Compound 244Compound 243 (281 mg, 0.15 mmol) was dissolved indichloromethane (6 mL), thentetrakis(triphenylphosphine)palladium(0) (17 mg, 0.01mmol) and pyrrolidine (0.1 mL, 1.18 mmol) were added, andthe mixture was stirred at room temperature for 1 hourunder a nitrogen atmosphere. After concentration underreduced pressure, the product was purified by columnchromatography, thereby obtaining Compound 244 (28 mg).EI-MS m / z : [M+H]+852.57, [M / 2+H]+427.06.<Example 87> Preparation of Compound 245Compound 245 was synthesized from Compound 239 andCompound 40 in a similar manner to the synthesis ofCompound 244. EI-MS m / z : [M+OH]+1138.69, [M+H]+1116.70,[M / 2+H]+559.15.<Example 88> Preparation of Compound 248Preparation of Compound 246Compound 239 (137 mg, 0.30 mmol) was dissolved inN,N-dimethylformamide (2.5 mL), and then N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uroniumhexafluorophosphate (HBTU, 175 mg, 0.46 mmol) anddiisopropylethylamine
[116] (0.1 mL, 0.61 mmol) weregradually added at 0°C under a nitrogen atmosphere. Asolution of Compound 44 (160 mg, 0.36 mmol) in N,Ndimethylformamide(1 mL) was added to the reactionsolution, and the mixture was stirred at room temperaturefor 1.5 hours. Saturated aqueous ammonium chloridesolution (10 mL) was added to the reaction mixture,followed by extraction with ethyl acetate (20 mL x 3),washing with saturated sodium hydrogen carbonate solution(10 mL) and distilled water (10 mL), and then drying overanhydrous sodium sulfate. After filtration andconcentration, the product was purified by columnchromatography, thereby obtaining Compound 246 (210 mg,79%). 1H-NMR (400 MHz, CDCl3) δ 8.89 (br s, 0.5H), 8.02(m, 0.5H), 7.73 (br s, 0.5H), 7.32-7.27 (m, 1H), 7.25-7.22 (m, 2H), 7.05 (br s, 1H), 6.81 (m, 1.5H), 6.66 (br s,0.5H), 6.39 (br s, 0.5H), 5.97 (br, 0.5H), 5.75 (br s,0.5H), 5.57 (m, 1H), 5.37 (m, 0.5H), 5.13 (m, 3H), 4.67(m, 1H), 4.43 (m, 1H), 4.30 (m, 1H), 4.13 (m, 2H), 3.92-3.90 (m, 7H), 3.69-3.62 (m, 3H), 3.36 (m, 4H), 2.88 (s,3H), 2.70 (m, 1H), 2.50 (m, 2H), 2.21 (m, 2H), 1.72 (m,2H), 1.46 (s, 9H), EI-MS m / z : [M+H]+861.49Preparation of Compound 247Compound 246 (140 mg, 0.16 mmol) was diluted withdichloromethane (1.6 mL), then trifluoroacetic acid (0.4mL) was added at 0°C under a nitrogen atmosphere, and themixture was stirred for 1 hour. The reaction mixture wasconcentrated under nitrogen gas, thereby obtainingCompound 247 (123 mg). EI-MS m / z : [M+H]+761.56,[M / 2+H]+381.5Preparation of Compound 248Compound 247 (123 mg, 0.16 mmol) was dissolved indichloromethane (2 mL), thentetrakis(triphenylphosphine)palladium(0) (3.5 mg, 0.003mmol) and pyrrolidine (0.06 mL, 0.81 mmol) were added at0°C under a nitrogen atmosphere, and the mixture wasstirred at room temperature for 1 hour. The reactionmixture was concentrated under nitrogen gas, purified byHPLC, and freeze-dried, thereby obtaining Compound 248(20.3 mg, 38%). EI-MS m / z : [M+H]+659.55, [M / 2+H]+330.45<Example 89> Preparation of Compound 250Preparation of Compound 249Compound 239 (215 mg, 0.439 mmol) was dissolved inN,N-dimethylformamide (5 mL), then Compound 230 (180 mg,0.337 mmol), N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 189 mg, 0.498 mmol)and diisopropylethylamine
[117] (0.29 mL, 1.68 mmol) weresequentially added at 0°C under a nitrogen atmosphere,and the mixture was stirred at room temperature for 12hours. After addition of ethyl acetate (50 mL), thereaction mixture was washed with saturated aqueousammonium chloride solution (50 mL), saturated aqueoussodium hydrogen carbonate solution (50 mL) and distilledwater (50 mL). The collected organic layers were driedover anhydrous sodium sulfate, filtered and thenconcentrated. The product was purified by columnchromatography, thereby obtaining Compound 249 (233 mg,77%). EI-MS m / z : [M+H]+897.59, 1 / 2[M+H]+440.35.Preparation of Compound 250Compound 249 (233 mg, 0.126 mmol) was dissolved indichloromethane (3 mL),tetrakis(triphenylphosphine)palladium(0) (6.0 mg,0.005mmol) and pyrrolidine (0.021 mL, 1.298 mmol) wereadded under a nitrogen atmosphere, and then the mixturewas stirred at room temperature for 3 hours. The reactionmixture was concentrated, purified by HPLC, and freezedried,thereby obtaining Compound 250 as a white solid(24 mg). EI-MS m / z : [M+H]+795.50, [M / 2+H]+398.34.<Example 90> Preparation of Compound 251Compound 251 was synthesized from Compound 239 andCompound 234 in a similar manner to the synthesis ofCompound 242. 1H-NMR (400 MHz, DMSO-d6) δ 9.87 (m, 3H),7.94 (t, J =5.6 Hz, 1H), 7.20 (m, 2H), 7.15 (s, 2H), 7.03(m, 1H), 6.84 (dd, J =11.2 Hz, 1.2 Hz, 2H), 6.57 (s,0.5H), 6.34 (s, 1H), 6.10 (s, 0.5H), 5.08 (m, 1H), 4.94(m, 1H), 4.50-4.44 (m, 2H), 4.24-4.18 (m, 1H), 4.13-4.11(m, 2H), 4.03-3.95 (m, 2H), 3.86-3.77 (m, 10H), 3.70-3.65(m, 4H), 3.45 (m, 2H), 2.42 (m, 2H), 2.05 (m, 2H), 1.61(m, 2H), EI-MS m / z : [M+H]+768.32, [M / 2+H]+384.97.<Example 91> Preparation of Compound 255Preparation of Compound 253Compound 252 (1.0 g, 2.36 mmol, Compound 252 wasprepared by the method described in Korean PatentPublication No. 10-2020-0084802) and Compound 1 (735 mg,3.54 mmol) were dissolved in N,N-dimethylformamide (20mL), then potassium carbonate (654 mg, 4.73 mmol) andsodium iodide (177 mg, 1.18 mmol) were added, and themixture was stirred at 90°C for 2 hours under a nitrogenatmosphere. The reaction mixture was diluted with ethylacetate (300 mL), washed with distilled water (2 x 100mL), and then dried over anhydrous sodium sulfate. Afterfiltration and concentration under reduced pressure, theproduct was purified by column chromatography, therebyobtaining Compound 253 (1.12 g, 86%). 1H-NMR(400 MHz,CDCl3) δ 7.70 (s, 1H), 6.78 (s, 1H), 5.91-5.88 (m, 1H),5.53 (s, 1H), 5.33 (d, 1H), 5.25 (d, 1H), 4.65 (br s, 1H),4.61 (d, 2H), 4.15 (t, 2H), 3.93 (s, 3H), 2.82-2.75 (m,1H), 2.61-2.57 (m, 3H), 2.23-2.20 (m, 2H), 1.62 (s, 3H),0.90 (s, 9H), 0.10 (s, 6H).Preparation of Compound 254Compound 253 (2.4 g, 20.0 mmol) was dissolved inethyl acetate (20 mL) and ethanol (20 mL), then zinc dust(5.7 g, 87.4 mmol) was added at 0°C, and formic acid (3.3mL, 87.4 mmol) was added. After stirring at roomtemperature for 2 hours, the reaction mixture was dilutedwith ethyl acetate (30 mL) and filtered through Celite,and ethyl acetate (70 mL) was added. The organic layerwas washed with saturated aqueous sodium hydrogencarbonate solution (2 x 100 mL) and brine (50 mL) in thatorder, and then dried over anhydrous sodium sulfate.Filtration, concentration under reduced pressure, andpurification by column chromatography were performed,thereby obtaining Compound 254 (2.2 g, 97%). EI-MS m / z :[M+H]+519.38.Preparation of Compound 255Compound 254 (2.2 g, 4.24 mmol) was dissolved in drytetrahydrofuran (50 mL), then triphosgene (452 mg, 1.53mmol) and triethylamine (2.4 mL, 16.9 mmol) were added at0°C, and Compound 6 (3.4 g, 4.66 mmol) was added. Afterstirring at room temperature for 3 hours, the reactionmixture was diluted with ethyl acetate (200 mL), washedwith distilled water (150 mL), and then dried overanhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 255 (3.2 g, 60%). EI-MS m / z : [M+H]+1275.53,[M / 2+H]+638.53.<Example 92> Preparation of Compound 258Preparation of Compound 256Compound 255 (3.2 g, 2.51 mmol) was dissolved intetrahydrofuran / distilled water (10 mL / 10 mL), aceticacid (10 mL) was added at 0°C, and the mixture wasstirred at room temperature for 17 hours. The reactionmixture was diluted with ethyl acetate (100 mL), washedwith distilled water (50 mL) and saturated sodiumhydrogen carbonate solution (2 x 100 mL), and then driedover anhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 256 (2.6 g, 89%). EI-MS m / z : [M+H]+1161.45,[(M-BOC) / 2+H]+531.47.Preparation of Compound 257Compound 256 (2.0 g, 1.72 mmol) was dissolved indichloromethane (50 mL), Dess-Martin periodinane (876 mg,2.0 mmol) was added, and the mixture was stirred at roomtemperature for 2 hours under a nitrogen atmosphere. Thereaction mixture was diluted with dichloromethane (200mL), washed with saturated aqueous sodium hydrogencarbonate solution (150 mL) and aqueous sodiumthiosulfate solution (100 mL), and then dried overanhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 257 (1.4 g, 71%). EI-MS m / z : [M+H]+1159.40,[(M-BOC) / 2+H]+530.46.Preparation of Compound 258Compound 257 (200 mg, 0.17 mmol) was dissolved inN,N-dimethylformamide (2 mL), thentetrakis(triphenylphosphine)palladium(0) (60 mg, 0.05mmol) and sodium 2-ethylhexanoate (91 mg, 0.61 mmol) wereadded, and the mixture was stirred at room temperaturefor 19 hours under a nitrogen atmosphere. The reactionmixture was diluted with ethyl acetate (50 mL), washedwith saturated aqueous ammonium chloride solution (50 mL)and distilled water (50 mL), and then dried overanhydrous sodium sulfate. Filtration and concentrationunder reduced pressure were performed, thereby obtainingCompound 258 (196 mg).EI-MS m / z : [M+H]+1119.37,[M / 2+H]+510.44.<Example 93> Preparation of Compound 259Compound 259 was synthesized from Compound 258 andCompound 26 in a similar manner to the synthesis ofCompound 29. EI-MS m / z : [M+H]+1180.48, [M / 2+H]+591.67.<Example 94> Preparation of Compound 264Preparation of Compound 261Compound 260 (4.6 g, 6.45 mmol, Compound 260 wasprepared by the method described in ACS. Med. Chem. 2016,7, 11, 983-987) was dissolved inethanol / toluene / distilled water (10 mL / 20 mL / 10 mL), andthen 4-methoxyphenylboronic acid (1.27 g, 8.39 mmol),sodium carbonate (2.0 g, 19.36 mmol), andtetrakis(triphenylphosphine)palladium(0) (745 mg, 0.65mmol) were added at room temperature under a nitrogenatmosphere. After the reaction solution was stirred at85°C for 1 hour, the reaction mixture was diluted withethyl acetate (100 mL), and the organic layer was washedwith brine (100 mL) and distilled water (100 mL). Thecollected organic layers were dried over anhydrous sodiumsulfate, filtered and then concentrated under reducedpressure. The obtained compound was dissolved in N,Ndimethylformamide / distilled water (50 mL / 1.0 mL), sodiumacetate (688 mg, 8.38 mmol) was added, and then themixture was stirred at room temperature for 1 hour undera nitrogen atmosphere. The reaction mixture was dilutedwith ethyl acetate (200 mL) and washed with distilledwater (2 x 100 mL), and then the organic layer was driedover anhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 261 (2.75 g, 83%). 1H-NMR(400 MHz, CDCl3) δ 7.81(s, 1H), 7.14 (d, 2H), 6.85 (s, 1H), 6.80 (d, 2H), 6.15(s, 1H), 6.05 (br s, 1H), 4.79 (br s, 1H), 4.00 (s, 3H),3.78 (s, 3H), 3.18 (br, 1H), 3.02-2.98 (m, 1H), 0.90 (s,9H), 0.10 (s, 6H).Preparation of Compound 262Compound 261 (3.7 g, 7.19 mmol) and Compound 1 (2.2g, 10.78 mmol) were dissolved in acetone / N,Ndimethylformamide(40 mL / 10 mL), then potassium carbonate(2.0 mg, 14.4 mmol) and sodium iodide (538 mg, 3.59 mmol)were added, and the mixture was stirred for 19 hoursunder a nitrogen atmosphere while being heated underreflux. The reaction mixture was concentrated, thendiluted with ethyl acetate (300 mL), washed withdistilled water (2 x 100 mL), and then dried overanhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 262 (4.2 g, 91%). 1H-NMR(400 MHz, CDCl3) δ 7.73(s, 1H), 7.13 (d, 2H), 6.82 (s, 1H), 6.80 (d, 2H), 6.13(s, 1H), 5.97-5.90 (m, 1H), 5.33 (d, 1H), 5.25 (d, 1H),4.79 (brs, 1H), 4.62 (d, 2H), 4.18 (t, 2H), 3.95 (s, 3H),3.78 (s, 3H), 3.18 (br , 1H), 3.02-2.98 (m, 1H), 2.61 (t,2H), 2.27-2.20 (m, 2H), 0.90 (s, 9H), 0.10 (s, 6H).Preparation of Compound 263Compound 262 (2.0 g, 3.12 mmol) was dissolved inethyl acetate (20 mL) and ethanol (30 mL), then zinc dust(5.1 g, 78.0 mmol) was added at 0°C, and formic acid (2.9mL, 78.03 mmol) was added. After stirring at roomtemperature for 3 hours, the reaction mixture was dilutedwith ethyl acetate (30 mL) and filtered through Celite,and ethyl acetate (70 mL) was added. The organic layerwas washed with saturated aqueous sodium hydrogencarbonate solution (2 x 100 mL) and brine (50 mL) in thatorder, and then dried over anhydrous sodium sulfate.Filtration, concentration under reduced pressure, andpurification by column chromatography were performed,thereby obtaining Compound 263 (1.9 g, 96%). EI-MS m / z :[M+H]+612.83.Preparation of Compound 264Compound 263 (1.9 g, 3.08 mmol) was dissolved in drytetrahydrofuran (20 mL), then triphosgene (328 mg, 1.11mmol) and triethylamine (1.7 mL, 12.33 mmol) were addedat 0°C, and Compound 6 (2.5 g, 3.39 mmol) was added.After stirring at room temperature for 17 hours, thereaction mixture was diluted with ethyl acetate (200 mL),washed with distilled water (150 mL), and then dried overanhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 264 (2.9 g, 70%). EI-MS m / z : [M+H]+1368.79,[(M-BOC) / 2+H]+634.80.<Example 95> Preparation of Compound 267Preparation of Compound 265Compound 264 (2.9 g, 2.15 mmol) was dissolved intetrahydrofuran / distilled water (5 mL / 5 mL), acetic acid(5 mL) was added at 0°C, and then the mixture was stirredat room temperature for 17 hours. The reaction mixturewas diluted with ethyl acetate (100 mL), washed withdistilled water (50 mL) and saturated sodium hydrogencarbonate solution (2 x 100 mL), and then dried overanhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 265 (2.2 g, 81%). EI-MS m / z : [M+H]+1254.45,[(M-BOC) / 2+H]+577.73.Preparation of Compound 266Compound 265 (507 mg, 0.40 mmol) was dissolved indichloromethane (8 mL), then Dess-Martin periodinane (206mg, 0.49 mmol) was added, and the mixture was stirred atroom temperature for 1.5 hours under a nitrogenatmosphere. The reaction mixture was diluted withdichloromethane (200 mL), washed with saturated aqueoussodium hydrogen carbonate solution (150 mL) and aqueoussodium thiosulfate solution (100 mL), and then dried overanhydrous sodium sulfate. After filtration andconcentration under reduced pressure, the product waspurified by column chromatography, thereby obtainingCompound 266 (483 mg, 48%). EI-MS m / z : [M+H]+1252.34,[(M-BOC) / 2+H]+576.42.Preparation of Compound 267Compound 266 (300 mg, 0.24 mmol) was dissolved inN,N-dimethylformamide (6 mL), thentetrakis(triphenylphosphine)palladium(0) (14 mg, 0.01mmol) and pyrrolidine (0.04 mL, 0.48 mmol) were added,and the mixture was stirred at room temperature for 19hours under a nitrogen atmosphere. The reaction mixturewas diluted with ethyl acetate (50 mL), washed withsaturated aqueous ammonium chloride solution (50 mL) anddistilled water (50 mL), and then dried over anhydroussodium sulfate. After filtration and concentration underreduced pressure, the product was purified by columnchromatography, thereby obtaining Compound 267 (232 mg,80%). EI-MS m / z : [M+H]+1211.80, [(M-BOC) / 2+H]+556.42.<Example 96> Preparation of Compound 268Compound 268 was synthesized from Compound 267 andCompound 26 in a similar manner to the synthesis ofCompound 29. EI-MS m / z : [M+H]+1272.65, [M / 2+H]+637.12.<Example 97> Preparation of ADCExample 97-1. Method for preparing ADCADCs were prepared through the following two steps,and commonly used isoprenoids LCB14-0511, 0512 and 0606were prepared by the method described in Korean PatentApplication Laid-Open No. 10-2014-0035393. The structuralformulas of LCB14-0511, 0512 and 0606 are as follows.Step 1: Preparation of prenylated antibodyFor the prenylation reaction of the antibody in thepresent invention, a reaction mixture of a buffersolution {50 mM tris hydrochloride (Tris-HCl, pH 7.4), 5mM magnesium chloride (MgCl2), 10 μM zinc chloride (ZnCl2),0.250 mM dithiothreitol (DTT)} containing 24 μM antibody,200 nM FTase and 0.144 mM or 0.250 mM isoprenoid (LCB14-0511, 0512 or 0606) was used. After completion of thereaction, the prenylated antibody was desalted using aG25 Sepharose column (AKTA purifier, GE healthcare)equilibrated with PBS buffer.Step 2: Drug-conjugation reactionIn order to prepare ADCs using oxime bindingreaction, a reaction mixture was prepared by mixing 100mM sodium acetate (NaOAc) buffer (pH 5.2), 10% dimethylsulfoxide (DMSO), 24 μM prenylated antibody and 240 μMlinker-drug together, and gently stirred at 30°C. After 2hours or 24 hours of reaction, excess low molecularweight compounds were removed using a G25 Sepharosecolumn, and protein fractions were collected andconcentrated.In order to prepare ADCs using copper-free clickbinding reaction, a reaction mixture was prepared bymixing PBS buffer (pH 7.4), 1% dimethyl sulfoxide (DMSO),10 μM prenylation antibody and 100 μM linker-drugtogether, and reacted at 25°C for 6 hours, then excesslow molecular weight compounds were removed using a G25Sepharose column, and protein fractions were collectedand concentrated.In order to prepare ADCs using a click bindingreaction using copper, a reaction mixture
[118] was preparedby mixing 20 μM prenylation antibody, 200 μM linker-drug,10% dimethyl sulfoxide (DMSO), 1 mM copper sulfatepentahydrate, 2 mM (BimC4A)3 (Sigma-Aldrich), 10 mMsodium ascorbate and 10 mM aminoguanidine hydrochloridetogether, reacted at 25°C for 3 hours, then treated with20 mM EDTA, and reacted for 30 minutes. After completionof the reaction, excess low molecular weight compoundswere removed using a G25 Sepharose column, and proteinfractions were collected and concentrated.Example 97-2. Preparation of ADC using antibody HER2ADCs were prepared using the linker-drug prepared inExamples including Examples 23 and 29 above and antibodyHER2. The antibody HER2 was prenylated by step 1 of themethod disclosed in Example 97-1, and then ADCs wereprepared by using the oxime binding reaction and copperfreeclick binding reaction or click binding reactionusing copper in step 2 of the method disclosed in Example97-1. At this time, the compounds used and the ADCsprepared are as presented in Table 1 below. (Table 1.List of ADCs prepared)[Table 1]ADC number Compound numberADC1 23ADC2 29ADC3 35ADC4 38ADC5 41ADC6 45ADC7 54ADC8 57ADC9 61ADC10 65ADC11 68ADC12 76ADC13 85ADC14 88ADC15 94ADC16 100ADC17 110ADC18 118ADC19 129ADC20 139ADC21 148ADC22 158ADC23 163ADC24 168ADC25 173ADC26 177ADC27 190ADC28 194ADC29 204ADC30 211Comparative Example 1 231(Example 81)Comparative Example 2(Example 83)235<Example 98> In vitro cytotoxicity evaluationThe cell proliferation inhibitory activity of theADCs prepared in Example 91 against cancer cells wasmeasured. For this purpose, commercially available cancercell lines (SK-BR3, JIMT-1, and MDA-MB-468 cell lines)were used. Each cancer cell line was inoculated into a96-well plate by 1500 to 5000 cells per well, incubatedfor 24 hours, and then serially treated with the dilutedADC samples. After 144 hours, the number of viable cellswas quantified by SRB assay. The results of cytotoxicityagainst cancer cells are presented in Table 2. (Table 2.Comparison of cytotoxicity of ADC samples in antigenexpressingcancer cell lines)[Table 2]ADC numberIC50(pM)SK-BR3 JIMT-1ADC1 13.6 52.8ADC2 22.5 74.4ADC3 13.5 30.7ADC4 22.4 307.0ADC5 29.2 285.3ADC6 11.5 79.9ADC7 31.1 406.2ADC8 31.6 NDADC9 85.1 NDADC10 13.9 115.1ADC11 29.2 NDADC12 43.3 NDADC13 63.3 NDADC14 27.9 224.1ADC15 33.5 NDADC16 33.2 NDADC17 12.0 83.1ADC18 10.9 57.0ADC19 44.5 65.8ADC21 150.7 NDADC22 94.9 NDADC23 71.5 NDADC24 44.0 NDADC25 513.5 NDADC26 121.7 NDADC27 20.8 270.0ADC28 50.9 NDADC30 18.6 108.5Comparative Example 1(Example 81)19.1 188.5Comparative Example 2(Example 83)8.6 55.8* ND : Not determined.It was confirmed that ADCs 1 to 7, 10, 14, 17 to 19,27, and 30 exhibited cytotoxicity similar or superior tothat of Comparative Example 1 or Comparative Example 2 inthe antigen-overexpressed cancer cell lines. Among others,ADC2 exhibited cytotoxicity superior to that ofComparative Example 1 and similar to that of ComparativeExample 2.The cytotoxicity was evaluated in the MDA-MB-468cell line, which does not express an antigen, by treatingthe cell line with ADCs at a high concentration. (Table 3.Comparison of cytotoxicity of ADC samples in cancer celllines not expressing antigens)[Table 3]ADC numberIC50(nM)MDA-MB-468ADC2 238.9Comparative Example 2(Example 83)57.3In the MDA-MB-468 cancer cell line in which anantigen was not expressed, ADC2 exhibited cytotoxicityweaker than that of Comparative Example 2 by four timesor more.From the results above, it can be seen that ADC2according to the present invention has a much widertherapeutic window since the efficacy of ADC2 in antigenexpressingcell lines is similar to that of ComparativeExamples and ADC2 exhibits weak toxicity in cells that donot express antigens.<Example 99> Rat preliminary toxicity evaluationThe ADCs prepared in Example 91 were administeredintravenously to 8-week-old SD rats once, and the weightchanges and death were observed for 70 days. The lethaldose and maximum tolerable dose (MTD) are summarized asfollows based on the death according to each ADC and dose.(Table 4. Comparison of toxicity of ADC samples in SDrats)[Table 4]MTD Lethal doseADC2 9 mg / kg 12 mg / kgComparativeExample 1NA 2 mg / kgComparativeExample 2NA 4 mg / kg(* NA : not available (MTD cannot be confirmed since alldied at the experimental dose)It was confirmed that the lethal dose of ADC2according to the present invention in the rat toxicitytest was significantly higher than those of ComparativeExamples 1 and 2.From the results above, it can be seen that ADC2according to the present invention exhibits relativelyweak toxicity and excellent safety since the lethal doseof ADC2 in SD rats is significantly higher than those ofComparative Examples 1 and 2.[Industrial Applicability]The present invention has application in thepharmaceutical industry related to the treatment ofdiseases, including the treatment of proliferativedisease.
Claims
1. A pyrrolobenzodiazepine derivative represented by Chemical Formula I, or a pharmaceutically acceptable salt or solvate of the derivative: P-(B)a-(B')b-D (I) where, P is represented by the following Chemical Formula II, where P is bonded or not bonded to Linker I; (II) where, a dotted line indicates arbitrary presence of a double bond between C1 and C2 or C2 and C3 and arbitrary presence of a double bond between N10 and C11; Q1 is selected from the group consisting of H, OH, O, CH2, CN, Rm, ORm, CH-Rm', C(Rm')2, O-SO2-Rm, CO2Rm, CORm, halo and dihalo, where Rm' is selected from the group consisting of Rm, CO2Rm, CORm, CHO, CO2H, and halo, where Rm is selected from the group consisting of substituted or unsubstituted C1-12 alkyl, substituted or unsubstituted C2-12 alkenyl, substituted or unsubstituted C2-12 alkynyl, substituted or unsubstituted C5-20 aryl, substituted or unsubstituted C5-20 heteroaryl, substituted or unsubstituted C3-6 cycloalkyl, substituted or unsubstituted 3- to 7-membered heterocyclyl, substituted or unsubstituted 3- to 7-membered heterocycloalkyl, and substituted or unsubstituted 5- to 7-membered heteroaryl, wherein, when substituted, respective hydrogen atoms of C1-12 alkyl, C1-12 alkoxy, C2-12 alkenyl, C2-12 alkynyl, C5- 20 aryl, C5-20 heteroaryl, C3-6 cycloalkyl, 3- to 7-membered heterocyclyl, 3- to 7-membered heterocycloalkyl, or 5- to 7-membered heteroaryl are each independently substituted with any one or more selected from the group consisting of C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C5-20 aryl, C5-20 heteroaryl, C3-6 cycloalkyl, 3- to 7-membered heterocyclyl, 3- to 7-membered heterocycloalkyl, and 5- to 7-membered heteroaryl; Q2, Q3, Q5, and Q7 are each independently selected from the group consisting of -H, -Rm, -OH, -ORm, -SH, -SRm, -NH2, -NHRm, -NRmRm', -NO2, and halo, where Rm and Rm' are as defined above; Q4 is selected from the group consisting of -H, -Rm, -OH, -ORm, -SH, -SRm, -NH2, -NHRm, -NRmRm', -NO2, halo, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted C2- 6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 cycloalkyl, substituted or unsubstituted 3- to 7-membered heterocycloalkyl, substituted or unsubstituted C5-12 aryl, substituted or unsubstituted 5- to 7-membered heteroaryl, -CN, -NCO, -ORn, -OC(=O)Rn, -OC(=O)NRnRn', -OS(=O)Rn, -OS(=O)2Rn, -SRn, - S(=O)Rn, -S(=O)2Rn, -S(=O)NRnRn', -S(=O)2NRnRn', -OS(=O)NRnRn', -OS(=O)2NRnRn', -NRnRn', -NRnC(=O)Ro, -NRnC(=O)ORo, - NRnC(=O)NRoRo', -NRnS(=O)Ro, -NRnS(=O)2Ro, -NRnS(=O)NRoRo', - NRnS(=O)2NRoRo', -C(=O)Rn, -C(=O)ORn and -C(=O)NRnRn', wherein, when substituted, one or more hydrogen atoms may be each independently substituted with C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C5-10 aryl, 5- to 7-membered heteroaryl, -ORp, -OC(=O)Rp, -OC(=O)NRpRp', -OS(=O)Rp, -OS(=O)2Rp, -SRp, -S(=O)Rp, -S(=O)2Rp, - S(=O)NRpRp', -S(=O)2NRpRp', -OS(=O)NRpRp', -OS(=O)2NRpRp', - NRpRp', -NRpC(=O)Rq, -NRpC(=O)ORq, -NRpC(=O)NRqRq', - NRpS(=O)Rq, -NRpS(=O)2Rq, -NRpS(=O)NRqRq', -NRpS(=O)2NRqRq', - C(=O)Rp, -C(=O)ORp or -C(=O)NRpRp, where, Rn, Rn', Ro, Ro', Rp, Rp', Rq and Rq' are each independently selected from the group consisting of hydrogen, C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, C3-13 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-10 aryl, and 5- to 7-membered heteroaryl; X is a moiety bonded to Linker I, and is absent when not bonded to Linker I, Y is selected from the group consisting of -O-, -S-, and -NH-; and Q6 is absent, or is a substituted or unsubstituted and saturated or unsaturated C3-12 hydrocarbon chain, B and B' are each independently a bond, -O-, -NH-, - S-, -C(=O)-, -S(=O)-, -O-(CH2)n-, -(CH2)n-, -(CH2)n(C=O)-, -(CH2)n(C=O)NH-, -C6-10 arylene-, -O-(-C6-10 arylene)-, - (CH2)n-C6-10 arylene-, 5- to 20-membered heteroarylene containing a heteroatom independently selected from N, O or S, -O-(5- to 20-membered heteroarylene containing a heteroatom independently selected from N, O or S)- or - (CH2CH2O)n-, where n is each independently an integer of 1 or more and 10 or less, and a and b are each independently an integer of 0 or 1, and D is represented by the following Chemical Formula III, (III) where, means a site bonded to P, B or B', A1 and A2 are each independently a bond, -NH-, -O-, -C(=O)-, -C(=O)NH-, -NHC(=O)-, C6-10 arylene or 6- to 10- membered heteroarylene containing a heteroatom independently selected from N, O or S; A-1 and A-2 are each independently selected from 5- to 20-membered heterocycloalkylene, 5- to 20-membered heterocycloalkenylene, or 5- to 20-membered heteroarylene, in which one or more ring atoms are heteroatoms independently selected from N, O or S, Z1, Z2, Z3, Z1', Z2' and Z3' are each independently C, N or S, R1 and R1' are each independently C1-10 heteroalkyl in which one or more atoms include heteroatoms independently selected from N, O or S, C1-10 alkyl, -(CH2)mOH, -(CH2)mNH2, -(CH2)mNHCH3, hydrogen, halo, or -C(=O)OH, m is an integer from 0 to 10, B1 and B2 are each independently a bond, -NH-, -O-, -C(=O)-, or -S-, a1 and a2 are each independently an integer from 0 to 2; wherein a1 + a2 is an integer of 2 or less, E1 is a bond, -NH-, -C(=O)-, -C(=O)O-, -O-, -S-, - OCH2-, C1-20 alkylene, or -((CH2)p(CH2E11))q-, and e1 is an integer from 0 to 10; E2 is a bond, C1-20 alkylene, or -((CH2)p(CH2E11))q-, and e2 is an integer from 0 to 20, where E11 is a bond, O, or S, p is an integer from 0 to 10, and q is an integer from 1 to 20; and F1 is hydrogen, -OH, -OCH3, -SH, -SCH3, , , or , where, F11, F12, F13, F14, F15, F16, F17, and F18 are each independently C, N, O or S, a dotted line means a double bond or a single bond, F21, F22 and F22' are each independently selected from -H, -NH2, -CH3, -(CH2)rCH3, -(CH2)rOH, -(CH2)rNH2, - F33(CH2)rCH3, -F33(CH2)rOH, -F33(CH2)rNH2, or Linker II, where F33 is selected from -O-, -S-, -CH2-, -C(=O)-, -NH-, - C(NH2)- or -C(=NH)-, and F21' is selected from =CH2, =NH, =F33'(CH2)rCH3, =F33'(CH2)rOH, or =F33'(CH2)rNH2, where F33' is selected from =N-, =CH-, =C(OH)- or =C(NH2)- and r is an integer from 0 to 10; wherein, Linker I and Linker II are represented by the following Chemical Formula IV, and are each independently selected, (IV) where, G is a glucuronic acid) moiety or ; where Rc is hydrogen or a carboxyl protecting group, each Rd is independently hydrogen or a hydroxyl protecting group; Ra and Rb are each independently hydrogen, C1-8 alkyl or C3-8 cycloalkyl; W is -C(=O)-, -C(=O)NR'-, -C(=O)O-, -S(=O)2NR'-, - P(=O)R"NR'-, -S(=O)NR'- or -P(=O)2NR'-, and C, S or P is directly bonded to a phenyl ring, where R' and R" are each independently hydrogen, C1-8 alkyl, C3-8-membered cycloalkyl, C1-8 alkoxy, C1-8 alkylthio, mono- or di- C1-8 alkylamino, 3- to 20-membered heteroaryl or a compound of C6-20-membered aryl; T is independently C1-8 alkyl, halogen, cyano or nitro; s is an integer from 0 to 3; L is one or more units selected from the group consisting of a connection unit and a branching unit, or a combination of these units, wherein the connection unit connects W and Rz, W and a branching unit, or a branching unit and another branching unit, wherein the branching unit connects a connection unit and W or a connection unit and another connection unit, the connection unit is , , , , - (CH2CH2V)t-, -(CH2)t(V(CH2)u)v-, or a combination thereof; where L1 is a single bond or C2-30 alkenyl, R11 is H or C1-10 alkyl, and L2 is C2-30 alkenyl; where t is an integer from 0 to 10, u is an integer from 0 to 12, v is an integer from 1 to 20, V is a single bond, -O-, or -S-, the branching unit is selected from the group consisting of C2-100 alkenyl, a hydrophilic amino acid, - C(=O)-, -C(=O)NRv-, -C(=O)O-, -(CH2)n1-NHC(=O)-(CH2)n2-, - (CH2)n3-C(=O)NH-(CH2)n4-, -(CH2)n1-NHC(=O)-(CH2)n2-C(=O)-, - (CH2)n3-C(=O)NH-(CH2)n4-C(=O)-, -S(=O)2NRv-, -P(=O)RwNRv-, - S(=O)NRv-, and -P(=O)2NRv-, wherein, when the branching unit is C2-100 alkenyl, a carbon atom of the alkenyl may be substituted with one or more heteroatoms selected from the group consisting of N, O and S, and the alkenyl may be further substituted with one or more C1-20 alkyl, where Rv and Rw are each independently H, C1-8 alkyl, C3-8 cycloalkyl, C1-8 alkoxy, C1-8 alkylthio, mono- or di- C1-8 alkylamino, C3-20 heteroaryl or C5-20 aryl, n1, n2, n3 and n4 are each independently an integer from 0 to 10, and Rz is -O-NH2, -NH2, N3, substituted or unsubstituted C1-12 alkyl, C1-12 alkynyl, C1-3 alkoxy, substituted or unsubstituted 3- to 20-membered heteroaryl, 3- to 20- membered heterocyclyl, substituted or unsubstituted C5-20 aryl, or , where Rz' is N or C, wherein, when substituted, one or more hydrogen atoms are each independently substituted with OH, =O, halo, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, oxy, carboxy, C1-6 alkoxycarbonyl, C1-6 alkylcarbonyl, formyl, C3-8 aryl, C5-12 aryloxy, C5-12 arylcarbonyl or C3-6 heteroaryl.
2. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein the dotted line indicates presence of a double bond between C2 and C3.
3. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein Q1 is selected from the group consisting of substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C5-7 aryl and substituted or unsubstituted C3-6 heteroaryl.
4. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein Q2, Q3, Q5, and Q7 are each independently -H or -OH.
5. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein Q4 is methoxy, ethoxy or butoxy.
6. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein Y is -O-.
7. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein Q6 is a substituted or unsubstituted and saturated or unsaturated C3-8 hydrocarbon chain.
8. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein G is , where Rc is hydrogen or a carboxyl protecting group, and each Rd is independently hydrogen or a hydroxyl protecting group.
9. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein Rc is hydrogen and each Rd is hydrogen.
10. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein W is -C(=O)-, -C(=O)NR'- or -C(=O)O-.
11. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein W is -C(=O)NR'-, where C(=O) is bonded to a phenyl ring and NR' is bonded to L.
12. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein G is , and W is -C(O)NR'-, where C(O) is bonded to a phenyl ring and NR' is bonded to L, and Rc and Rd are hydrogen.
13. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein the branching unit is selected from the group consisting of C2-8 alkenyl, a hydrophilic amino acid, -C(O)-, -C(O)NRv-, -C(O)O-, -(CH2)n1-NHC(=O)-(CH2)n2-, - (CH2)n3-C(O)NH-(CH2)n4-, -(CH2)n1-NHC(O)-(CH2)n2-C(O)-, and - (CH2)n3-C(O)NH-(CH2)n4-C(O)-, wherein, when the branching unit is C2-8 alkenyl, a carbon atom of the alkenyl may be substituted with one or more heteroatoms selected from the group consisting of N, O and S, and the alkenyl may be further substituted with one or more C1-20 alkyl, where Rv is H, C1-8 alkyl, C3-8 cycloalkyl, C1-8 alkoxy, C1-8 alkylthio, mono- or di- C1-8 alkylamino, C3-20 heteroaryl or C5-20 aryl, and n1, n2, n3 and n4 are each independently an integer from 0 to 5.
14. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein the connection unit is -(CH2)t(V(CH2)u)v-, where t is an integer from 0 to 8, u is an integer from 0 to 12, v is an integer from 1 to 10, and V is a single bond or -O-.
15. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein the connection unit is -(CH2)t(V(CH2)u)v-, where t is an integer of 2, u is an integer of 2, v is an integer of 2, and V is -O-.
16. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein the connection unit includes , , or , where L1 is a single bond or C2-8 alkenyl, R11 is H or C1-6 alkyl, and L2 is C2-8 alkenyl.
17. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein Rz is -O-NH2, -NH2, N3, -OCH3, -OCH2CH3, - O(CH2)2CH3, or .
18. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein at least one or more of B or B' are -C(=O)-.
19. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein A1 and A2 are each independently -C(=O)- or -NH-.
20. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein at least one or more of Z1, Z2, Z3, Z1', Z2', or Z3' are N.
21. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein A-1 and A-2 are selected from , , or , where a dotted line means a double bond or a single bond, Za is Z1 or Z1', Zb is Z2 or Z2', Zc is Z3 or Z3', Z1, Z2, Z3, Z1', Z2' and Z3' are as defined above, and R1 or R1' is connected to Za.
22. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein A-1 and A-2 are each independently , or , where a dotted line means a double bond or a single bond, Za is Z1 or Z1', Zb is Z2 or Z2', Zc is Z3 or Z3', at least one or more of Z1, Z2, Z3, Z1', Z2' or Z3' are N or S, and R1 or R1' is connected to Za.
23. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein a1 and a2 are an integer of 1.
24. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein E1 is a bond, -NH- or -C(=O)-, and e1 is an integer from 1 to 5.
25. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein E2 is a bond, C1-5 alkylene, or - ((CH2)p(CH2E11))q-, when E2 is -((CH2)p(CH2E11))q-, E11 is O, p is an integer from 1 to 3, q is an integer from 1 to 15, and e2 is an integer from 1 to 5.
26. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein R1 and R1' are each independently hydrogen, C1-5 alkyl, (CH2)mOH or (CH2)mNH2, where m is an integer from 1 to 7.
27. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein F1 is -OH, -OCH3, -SH, -SCH3, or , where F11 and F12 are each independently C or N, F21, F22 and F22' are each independently selected from H, -(CH2)rCH3, -(CH2)rOH, -(CH2)rNH2, -F33(CH2)rCH3, - F33(CH2)rOH, -F33(CH2)rNH2 or Linker II, where F33 is selected from --C(=O)-, -NH-, or -C(=NH)-, F21' is selected from =CH2, =NH, =F33'(CH2)rCH3, =F33'(CH2)rOH, =F33'(CH2)rNH2 or Linker II, where F33' is selected from =N-, =CH-, =C(OH)- or =C(NH2)-, and at least one or more of F21, F22 or F22' are -CH3.
28. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein the pyrrolobenzodiazepine derivative further comprises the following General Formula V: (V) where, moieties are each independently bonded to a first linker or hydrogen, wherein the first linker is Linker I or Linker II; and SL means a second linker, wherein the second linker is represented by the following Formula VI, L'-Rzz' (VI) where L' and Rzz' are the same as L and Rz in Chemical Formula (IV), respectively.
29. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 28, wherein the first linker contains at least one or more branching units, wherein the branching unit is selected from the group consisting of -C(O)-, -C(O)NRv-, - C(O)O-, -(CH2)n1-NHC(O)-(CH2)n2-, -(CH2)n3-C(O)NH-(CH2)n4-, - (CH2)n1-NHC(O)-(CH2)n2-C(O)-, -(CH2)n3-C(O)NH-(CH2)n4-C(O)-, -S(O)2NRv-, -P(O)RwNRv-, -S(O)NRv-, and -PO2NRv-, Rv and Rw are each independently H, C1-8 alkyl, C3-8 cycloalkyl, C1-8 alkoxy, C1-8 alkylthio, mono- or di- C1-8 alkylamino, C3-20 heteroaryl or C5-20 aryl, n1, n2, n3 and n4 are each independently an integer from 0 to 5.
30. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 28, wherein L' includes one or more branching units and connection units, wherein the branching unit is selected from the group consisting of C2-8 alkenyl, a hydrophilic amino acid, -C(O)-, and -C(O)O-, and the connection unit is -(CH2)t(V(CH2)u)v-, where t is an integer from 0 to 5, u is an integer of 2, v is an integer from 1 to 10, and V is -O-; and Rzz' is -O-NH2, -NH2, N3, -OCH3, or -OCH2CH3.
31. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein the pyrrolobenzodiazepine derivative represented by Chemical Formula I is selected from the group consisting of and .
32. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 1, wherein the pyrrolobenzodiazepine derivative represented by Chemical Formula I is selected from the group consisting of , , and .
33. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 28, wherein the pyrrolobenzodiazepine derivative is .
34. A pyrrolobenzodiazepine derivative represented by Chemical Formula VII, or a pharmaceutically acceptable salt or solvate of the derivative: P'-B'-D' (VII) where, P' is the same as P described above; B' is Ba'-Bb'-Bc', where Ba' is -O-, -NH-, -S-, -C(=O)-, -S(=O)-, - (CH2)n'(C=O)-, -(CH2)n'-, C6-10 arylene, 5 to 20-membered heteroarylene containing a heteroatom independently selected from N, O or S, or -((CH2)n'B1)m'B2-, where B1 and B2 are each CH2, NH, O, or S, Bb' is a bond, C5-20 arylene, C5-20 cycloalkylene, or 5- to 20-membered heterocycloalkylene, 5- to 20-membered heterocycloalkenylene, or 5- to 20-membered heteroarylene, in which one or more ring atoms are heteroatoms independently selected from N, O or S, and Bc' is a bond, -O-, -NH-, -S-, -C(=O)-, -S(=O)-, - CH2(C=O)-, -(CH2)n'- or -(CH2CH2O)n'-, where n' and m' are each independently an integer from 1 to 10, and D' is the same as D described above.
35. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 34, wherein Ba' is a bond, -(CH2)n'- or -(CH2)n'B2-, where B2 is O and n' is an integer from 1 to 10.
36. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 34, wherein Bb' is a bond, , , , or , where the dotted line means a double bond or a single bond, and B1', B2' and B3' are each independently C, N, or S.
37. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 34, wherein Bc' is a bond, -C(=O)-, -NH- or -(CH2CH2O)n-, where n is an integer from 1 to 10.
38. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 34, wherein D' is the same as D, and a1 + a2 is an integer from 1 to 10 except for 2.
39. The pyrrolobenzodiazepine derivative or a pharmaceutically acceptable salt or solvate of the derivative according to claim 34, wherein the pyrrolobenzodiazepine derivative represented by Chemical Formula VII is selected from the group consisting of and .
40. A pyrrolobenzodiazepine derivative-ligand conjugate comprising the pyrrolobenzodiazepine derivative according to any one of claims 1 to 33, or a pharmaceutically acceptable salt or solvate of the derivative-ligand conjugate.
41. The pyrrolobenzodiazepine derivative-ligand conjugate or a pharmaceutically acceptable salt or solvate of the derivative-ligand conjugate according to claim 40, wherein the ligand is an antibody.
42. The pyrrolobenzodiazepine derivative-ligand conjugate or a pharmaceutically acceptable salt or solvate of the derivative-ligand conjugate according to claim 41, wherein the antibody has one or more amino acid motifs that may be recognized by an isoprenoid transferase.
43. The pyrrolobenzodiazepine derivative-ligand conjugate or a pharmaceutically acceptable salt or solvate of the derivative-ligand conjugate according to claim 42, wherein the isoprenoid transferase is FTase (farnesyl protein transferase) or GGTase (geranylgeranyl transferase).
44. The pyrrolobenzodiazepine derivative-ligand conjugate or a pharmaceutically acceptable salt or solvate of the derivative-ligand conjugate according to claim 42, wherein the amino acid motif is CYYX, XXCC, XCXC or CXX, where C is cysteine, Y is an aliphatic amino acid, and X is an amino acid that determines substrate specificity of an isoprenoid transferase.
45. A pharmaceutical composition for prevention or treatment of proliferative disease comprising the pyrrolobenzodiazepine derivative-ligand conjugate according to claim 40 or a pharmaceutically acceptable salt or solvate of the derivative-ligand conjugate.
46. A pharmaceutical composition for prevention or treatment of proliferative disease comprising the pyrrolobenzodiazepine derivative-ligand conjugate according to claim 40 or a pharmaceutically acceptable salt or solvate of the derivative-ligand conjugate; and a pharmaceutically acceptable excipient.
47. A pharmaceutical composition for prevention or treatment of proliferative disease comprising the pyrrolobenzodiazepine derivative-ligand conjugate according to claim 40 or a pharmaceutically acceptable salt or solvate of the derivative-ligand conjugate; one or more therapeutic co-agents; and a pharmaceutically acceptable excipient.
48. A method for preventing or treating proliferative disease, the method comprising administering a pyrrolobenzodiazepine derivative-ligand conjugate comprising the pyrrolobenzodiazepine derivative according to any one of claims 1 to 33, or a pharmaceutically acceptable salt or solvate of the derivative-ligand conjugate to an individual.
49. Use of a pyrrolobenzodiazepine derivative-ligand conjugate comprising the pyrrolobenzodiazepine derivative according to any one of claims 1 to 33, or a pharmaceutically acceptable salt or solvate of the derivative-ligand conjugate in a pharmaceutical composition for prevention or treatment of proliferative disease.
